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Inflammation of the ileoanal pouch, 'pouchitis', is a common complication of
restorative proctocolectomy mainly observed in ulcerative colitis. Its incidence has
been estimated up to 45% in some series, although there is no universal agreement
between clinicians of its definition. The difficulty lies in that histopathological changes
do not parallel the observed symptoms in all cases. Thus when defining pouchitis
emphasis may be placed in either histology or symptoms. The aetiopathogenesis also
is still largely unknown. This thesis explores the hypothesis that inflammation in
ileoanal pouches has similarities to inflammatory bowel disease (IBD). Therefore
methods of investigation of gut inflammation used in IBD should be readily
applicable. One such method is whole gut lavage. During whole gut lavage the
patient consumes a polyethylene glycol electrolyte solution until clear fluid is passed.
The first clear fluid specimen passed -gut perfusate- is collected for analysis.
The pouch patients recruited in this study were first analysed clinically. Their
assessment included endoscopy and pouch biopsy. The pouch patients' assessment
showed an association between the inflammation of the ileoanal pouch and the
extraintestinal manifestations. However, there was no such relation to backwash
ileitis with ileoanal pouch inflammation. A clinical algorithm based on patients clinical
features was devised to facilitate the appreciation of inflammatory events.
The whole gut lavage study performed in pouch patients showed that there is
gut protein loss in ileoanal pouches similar to that in IBD. This protein loss relates to
disease activity and may be used as an objective indicator of disease activity in
ileoanal pouches. The protein loss is evident in the first few months of pouch
function and may settle at a later stage.
The whole gut lavage method allowed measurements of haemoglobin in the
lavage specimen. This whole gut lavage haemoglobin also coincides with the protein
loss. The bleeding however did not relate to the protein loss in all cases.
IX
Cytokine activity in the form of raised IL-1(3 and IL-8 in the whole gut lavage
seems to accompany the gut protein loss. Luminal neutrophilia measured by whole
gut lavage neutrophil granulocyte elastase relates to the IL-8 levels. This observation
was initially described in whole gut lavage studies in ulcerative colitis. Luminal
neutrophilia was apparent in some cases of high protein loss at a level much higher
than noticed in ileostomy patients. Luminal neutrophilia again has been previously
shown to be a feature of active ulcerative colitis or active Crohn's colitis but not of
active small bowel Crohn's disease.
In an attempt to analyse possible chemotactic activity of the luminal contents,
the method of neutrophil polarisation assay was evaluated and applied to whole gut
lavage samples. The assay is based on the observation that when a culture medium is
devoid of chemotactatic factors, neutrophils remain spherical; with addition of
chemoattractants, neutrophils acquire a polarised morphology. The use of this assay
in gut fluid was the first ever attempt to use this assay in the gut. It was found that
certain modifications of the lavage processing had to be made for the assay to work.
It was apparent that even normal control subjects had a variable percentage of
polarisation. In pouch patients the percentage of polarisation noticed was independent
both from the disease activity parameters but also from the luminal or mucosal
neutrophilia. This indicated that the luminal chemotaxis phenomenon as pictured by
the assay was multifactorial. Chemotactic and antichemotactic factors acting together
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The operation of restorative proctocolectomy has been a major advance in
the surgical management of patients requiring total colectomy. During the
operation, a pouch of ileum is constructed and stitched to the anal muscles. Thus,
a permanent spout ileostomy is avoided, and most patients with an ileoanal pouch
have an acceptable degree of faecal continence.
This new surgical technique has been intensely audited, and it has become
apparent that some pouch patients develop an intermittent or chronic syndrome
with features of inflammation; this is generally described as pouchitis.
The current definition of pouchitis incorporates clinical, endoscopic and
histological parameters. Pouchitis is mainly observed in patients who underwent
colectomy for ulcerative colitis. The working hypothesis that is emerging from a
number of research studies is that pouchitis represents a renaissance of
inflammatory bowel disease in a susceptible individual.
Parallel to the emerging body of knowledge about pouchitis, there have
been synchronous developments in the diagnosis and studies of pathogenesis of
inflammatory bowel disease. In particular, gut immune events are best studied
with material collected directly from the gut-biopsies and secretions- rather than
by tests on blood. For example, by using fluid obtained by a new technique of
whole gut irrigation, various tests of inflammation allow the investigator
accurately to categorize and describe patient groups in inflammatory bowel
disease.
The initial and general aim of the work I have undertaken has been to test
the hypothesis of pouchitis as a form of inflammatory bowel disease, by using the
whole gut lavage methodology and techniques. I have therefore studied a large
series of pouch patients, firstly by documenting clinical and endoscopic features,
operative, past medical, family and drug history; calculating the conventional
pouch disease activity index (PDAI); subdividing the pouches into normal or
inflamed groups, according to whole gut lavage fluid (WGLF) parameters; then
by examining the correlation and inconsistencies within these data.
If the hypothesis that pouchitis is a form of inflammatory bowel disease is
true, then the disease activity of pouchitis may be accurately assessed by gut
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lavage methods in a similar fashion to what is known to happen in the
inflammatory bowel diseases. Ultimately, I hoped to develop gut lavage as an
objective and relatively non-invasive test for assessing pouch patients.
1 then compared the results in patients with pouches and patients with
ileostomies. The reservoir created in pouch patients is rapidly colonized with
faecal flora, as it adapts to its new added function of a capacitance organ. My
hypothesis therefore was that there will be differences in the gut lavage parameters
of the two groups, because of the role of bacterial flora as triggers of gut immune
reactions.
Previous investigations of gut flora in pouches have mainly been directed
towards analysis of the microbial taxonomy, the corresponding metabolite changes
of luminal contents and the morphology of the gut mucosa. Since this flora is not
only a source of antigens, but also of peptides which are chemotactic to
leucocytes, analysis of the chemotactic effect of the luminal contents would be of
great interest. I therefore developed a method for measuring chemotactic activity
based on neutrophil polarization. This method was used to explore chemotactic
activity of gut fluids from control subjects, from patients with active and inactive






B. INFLAMMATORY BOWEL DISEASE
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2.A. THE ILEOANAL POUCH
2.A.L Indications-Complications-Function
2.A.I.I. Introduction
One of the major advancements in the management of diseases requiring
total colectomy has been the introduction of restorative proctocolectomy. The
first series with a description of an ileoanal pouch come from Sir Alan Parks, St.
Marks Hospital in London (Parks & Nicholls, 1978). Since then, few
modifications of the surgical technique have appeared, with the description of the
'J' pouch by Professor Utsunomiya (Utsunomiya et al, 1980) and the 'W' pouch
by Nicholls (Nicholls & Lubowski, 1987). Myers, Rothenberger and Goldberg
give an analytical description of the evolution of surgical thought for anal
preservation and the techniques that were used (Myers et al, 1993). The earlier
development of the Kock's continent reservoir is worth mentioning. This
continent ileostomy may be considered as the immediate step towards the creation
of the ileoanal pouch. Many of the problems and complications of this design
were common in the ileoanal pouches. This made Kock's pouches a valuable
guide and a model for comparison, especially at the early days of the ileoanal
pouches (Myers et al, 1993).
2.A.I.2. Indications
The indications for restorative proctocolectomy, amongst other surgical
options available, are mainly Ulcerative colitis (UC) and Familial Adenomatous
Polyposis (FAP) Coli (Mortensen, 1992). The Cleveland Clinic group reviewed
1005 patients who had restorative proctocolectomy over a period of 10 years.
This showed that 85% of patients had a preoperative histopathologic diagnosis of
UC, 8% Indeterminate Colitis (IC), 6% FAP (Fazio et al, 1995). About 1%
underwent operations for other diagnoses: stage 2 (TNM classification) colon and
rectal cancer, multiple cavernous haemangiomata of the colon and rectum and
Hirschsprung's disease. There have been reports of use of the pouch operation
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for functional bowel disorders, that is intractable slow transit constipation,
when the ileorectal anastomosis was considered 'unsuccessful' (Hosie et al,
1990). However, a later report from the same group admitted poor results of this
surgical treatment. Four out of eight patients in which they attempted the
procedure required pouch excision. This was thought to be due to continuing
feeling of incomplete evacuation and abdominal bloating. The procedure was
therefore abandoned (Keighley et al, 1993).
2.A.I.3. Contraindications
Old age does not seem to be a contraindication. Many operations have by
now been performed on patients above the 70 years' threshold. There was no
particular difference in the adverse events when compared to the younger
population of pouch patients (Mortensen, 1993). Since there is a decrease of the
resting and squeeze pressure with increasing age (McHugh & Diamant, 1987),
special care should take place upon the selection of this group. The Edinburgh
experience has been that the procedure should be contraindicated only when the
preoperative sphincter function is severely compromised (Bartolo & Duthie,
1993).
Crohn's Disease (CD) is considered to be a contraindication, but recently
there has been debate about the validity of this statement. Equally there is debate
on the role of restorative proctocolectomy in cases of indeterminate colitis. The
histological characterisation of the resected colon in the latter may be difficult.
The following sections 2.A. 1.5 and 2.A. 1.6 discuss these controversies.
2.A.I.4. Complications
2.A. 1.4.1. Morbidity & Mortality
In the large reported series the complication rate of ileoanal pouch surgery
has been considerable. Fazio from Cleveland Clinic reports an overall morbidity
of 63% and mortality of 1% in 1005 patients, with septic complications on 7% of
patients and reoperation rate of 24% (Fazio et al, 1995).
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The morbidity reported by Mayo Clinic is approximately 50% (Grotz &
Pemberton, 1993), while the Birmingham group reported an overall morbidity of
41% in 168 restorative proctocolectomies (Keighley et al, 1993). The early
experience in St. Marks Hospital, before 1985, showed a morbidity of 45% and a
mortality of 2% (Setti-Carraro et al, 1994).
It has been observed that the rate of specific complications for the
procedure decreases with increase in expertise (Keighley et al, 1993). This may
account to a reduction of morbidity to 30% in the most recent Mayo Clinic series
(Grotz & Pemberton, 1993). Complications observed may be divided in early and
late onset (described in the following sections 2.A. 1.4.2 & 2. A. 1.4.3).
2.A. 1.4.2. Early Postoperative Complications
2.A.1.4.2.1. Pouch Specific
Pelvic infection, as an early complication, happened in 5% of patients with
UC in the Mayo Clinic (Grotz & Pemberton, 1993). Abdominal sepsis was
noticed in 6% early post operatively and this had a grave consequence as 41% of
those required pouch excision eventually (Pemberton, 1993). Small bowel
obstruction occurred in 13%, with 5% requiring surgical intervention (Pemberton,
1993).
Other immediate complications are pouch infarction with an expected rate
of 0.1% - 3% (Fazio et al, 1995; Keighley et al, 1993), bleeding into the pouch
3%- 4% (Setti-Carraro et al, 1994; Fazio et al, 1995), and fistula formation
0.9%-1.2% (Setti-Carraro et al, 1994; Fazio et al, 1995).
2.A.I.4.2.2. General Complications
General complications of chest infection, deep vein thrombosis, myocardial
infarction, wound infection, urinary tract infections are encountered in almost 24%
of patients (Setti-Carraro et al, 1994). Ileostomy closure has also its own
morbidity; 9% of small bowel obstruction and 1% anastomotic leakage
(Pemberton, 1993).
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2.A. 1.4.3. Late Postoperative Complications
2.A. 1.4.3.1. Anastomotic Stricture
A common problem post-operatively, is anastomotic stricture at the pouch
anal anastomosis. The incidence of this web stenosis in most cases is higher at a
later stage amounting to about 5-15% of patients (Pemberton, 1993; Fazio et al,
1995; Keighley et al, 1993). Risk factors for this complication have been singled
out as the use of small diameter stapling gun, the occurrence of anastomotic
disruption with resultant pelvic sepsis and the use of defunctioning ileostomy
(Lewis et al, 1994).
2.A. 1.4.3.2 Fistula Formation
Late complications include pouch-vagina fistula formation in 7% of female
cases, as seen at a collective review of 325 women from 25 centres (Wexner et al,
1989). The overall reported incidence in the Cleveland Clinic is lower at 4%. The
same authors estimate the pouch-cutaneous fistula incidence overall in 8% of the
cases (Fazio et al, 1995).
2.A.1.4.3.3. Intestinal Obstruction
Intestinal obstruction continues to be a problem at the late period as well,
with an estimated overall occurrence of 18%-25% (Keighley et al, 1993; Fazio et
al, 1995), requiring reoperation in approximately 7%.
2.A.I.4.3.4. Malignancy
Malignancy has been observed in two cases so far (Stern et al, 1990; Puthu
et al, 1992). Although the occurrence of the cancer on residual islands of rectal
mucosa could not be excluded, a recent histomorphological survey found low
grade dysplasia in 3 patients, who belonged to the group with permanent, near
total villous atrophy, after severe pouchitis (Veress et al, 1995). One of those
cases from this Swedish group had DNA aneuploidy at a biopsy from the centre of
a pouch, and an adjacent biopsy showed low grade dysplasia (Lofberg et al,
1991).
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2.A.I.4.3.5. The Long Efferent Limb & Other Late Complications
Late complications include intestinal malabsorption, urinary abnormalities,
sexual dysfunction, superior mesenteric syndrome, adrenal insufficiency,
perforation from either blunt trauma or injury to the blood supply (Santos &
Thompson, 1993).
The incidence of a specific complication, the pouch obstruction due to a
long efferent limb of an 'S' pouch, has almost disappeared after modification of
the surgical technique and the advent of corrective procedures (Pemberton,
1993).
2.A.I.5. Crohn's Disease & The Ileoanal Pouch
Crohn's Disease can affect any part of the Gastrointestinal tract (Clark &
Kumar 1994). Accordingly there is the theoretical risk that patients may develop
inflammation in their pouch, if they were to have restorative proctocolectomy.
Therefore there was a great reluctance over the years to offer this operation to
patients with Crohn's Colitis. On certain occasions however, clinicians were faced
with the problem that after the restoration with a pouch, the preoperative
diagnosis of UC had to be reviewed. This was due to either the histological
appearance of the colectomy specimen or to the later emergence of clinical signs
reminiscent of CD.
A retrospective study of 272 patients who had restorative proctocolectomy
for what thought to be UC at the time, found nine patients who could be labelled
as CD. Five of them had the diagnosis made from the excised rectum on a three
stage procedure. No mention was made to any features of diversion colitis in the
resected specimens. The rest of the patients had their diagnosis changed because
of the development of complications reminiscent of CD. Only three patients out
of the nine had their pouch excised and histologically proven to have CD. The
rest of the patients continued with their pouch and considerable morbidity. The
authors reinforced the idea that pouch surgery has to be avoided on patients with
preoperative diagnosis of CD (Deutsch et al, 1991).
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The same concern was expressed in a later study, which was prospective in
design with a single surgeon and pathologist participating. The differences
between the complication rates of UC and CD patients did not reach statistical
significance, though a 'trend' of higher percentages of pelvic sepsis, fistulas and
ileoanal stenosis was observed in CD. They concluded that, when there are
histological features suggestive of CD there is a higher complication rate. The
medium term functional results though, may be acceptable if the pouch can be
retained (Grobler et al, 1993).
The same observation was made also by the St. Marks Hospital group; the
reported failure rate of 12% was due to suspected CD and perianal/pelvic sepsis
(Setti-Carraro et al, 1994). Another report (Hyman et al, 1991) revealed that
only one out of nine patients with preoperative diagnosis suggestive of CD had a
functioning pouch amongst a group of 362 pouch procedures.
Recent reports suggest that in a selected group of Crohn's colitis, with no
features of perianal or small bowel disease, restoration with a pouch may be
recommended, with comparable function at five years follow up and a failure rate
of 6% (Panis et al, 1996). The number of patients with CD included in the study
is small (31 patients), but the follow up is reasonably long (5 years mean). The
morbidity is considerable, having had 3 patients with pouch perineal fistulas and
one with pouch vaginal fistula. Further prospective studies from other centres will
be needed to address the same problem for an agreement to be reached.
2.A.I.6. Ileoanal Pouch & Indeterminate Colitis
The controversy of whether it is advisable to perform the operation on
grounds of Indeterminate Colitis (IC) still continues. Reports from Mayo Clinic
(Mclntyre et al, 1995) showed that the failure rate is higher in the IC group versus
the UC patients (19% vs. 8%). This was in agreement with an earlier report from
Vancouver, which reported a success rate of 95% for UC and 81% for IC
(Atkinson et al, 1994). Another study has implicated IC with perineal
complications and a greater risk of pouch loss (Koltun et al, 1991). Previously, a
report from the same group in Mayo Clinic did not find any significant differences
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in function, complication rate or incidence of pouchitis in these patients (Pezim et
al, 1989). Admittedly though, the total number of patients' records examined in
the first study was about half of those reported in the second study (514 vs. 1,232
patients). The numbers of indeterminate colitis patients were 25 vs. 71.
2.A.I.7. Functional Aspects Of Ileoanal Pouches
2,A. 1.7.1. Introduction
The debate on surgical techniques to improve the function (i.e. storage
capacity, defecation characteristics, etc.) without compromise to the 'curative'
potential of the operation has been outstanding. The main areas that have been
analysed were the pouch design, the type of anastomosis (hand-sewn or stapled),
the height of the anastomosis, the advisability of mucosectomy, the use of
medication. Several studies compared the functional outcome and the effect of the
above parameters.
2.A. 1.7.2. Frequency Of Evacuation & Continence
The reported frequency of evacuation on the literature varies from 4-6 per
day with a range of 1-20 (Fazio et al, 1995; Setti Carraro et al, 1994). Nocturnal
frequency has been reported as 1.811.8 (Pena et al, 1992). In large series,
seepage during the night may happen to 29% of the patients, while 10% complain
of spotting during the day (Fazio et al, 1995). In the same series, 44% of patients
needed to change their diet (Fazio et al, 1995). Other series have reported minor
incontinence rates as high as 65% during the night and 12% during the day,
requiring a night pad in 61% (Pena et al, 1992).
2.A. 1.7.3. Physiological Assessment Of The Anal Musculature
It has repeatedly been observed, that the resting anal pressure is decreased
by over 50% post-operatively, and recovers gradually but incompletely (anal
resting pressure=63 cmH20 at 18 months). Equally, the internal anal sphincter
(IAS) electromyographic (EMG) activity greatly reduces post-operatively (pre¬
operative IAS EMG=0.51 Hz; post-operative IAS EMG=0.31 Hz at 18 months),
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to recover only partly (Farouk et al, 1994). The functional length of the anal canal
is significantly lower, mainly when the pouch-anal anastomosis is a low one (Deen
et al, 1995). Anal endosonography reveals a reduction of the IAS thickness, with
gaps and tapering (Silvis et al, 1995). Whether this is due to direct trauma, or to
denervation, as some investigators have proposed, needs to be conclusively
resolved. Abnormal EMG registrations of the external anal sphincter (EAS) after
restorative proctocolectomy have been recorded (Emblem et al, 1989). However,
the EAS voluntary contraction - 'squeeze' is well preserved and stress
incontinence is an uncommon feature in these patients. It is so believed that,
despite the above mentioned EMG abnormalities, no major damage is exhibited
(Hulten et al, 1993).
2.A.I.7.4. The Anorectal Angle
Videoproctographic assessment of pouches has shown that the anorectal
angle was not different between the various designs, at rest, during pelvic floor
contraction or attempted defaecation. Its position and movement also were not
different. The only parameter that influenced emptying, was the presence of an
anal stricture (Kmiot et al, 1990).
2.A.I.7.5. Ileoanal Pouch: Volume, Compliance & Evacuation
Other determinants of pouch function are the volume of the pouch and the
percentage of complete evacuation achieved (Nicholls, 1993; Schmidt et al, 1996;
Stryker et al, 1986). The 'W' configuration (Figure 2.1) is thought to convey the
higher volumes, as compared to the 'J' pouch (Figure 2.1). If the actual length of
bowel is kept the same, then probably the volume achieved by the pouch depends
on the availability of pelvic space (Bartolo & Duthie, 1993; Phillips, 1991).
Consequently, the maximal filling pressure in one study was similar, although the
'W' pouches tolerated significantly higher filling pressures before urgency
occurred (Farouk et al, 1994).
The compliance of both designs is normally comparable (Bartolo &
Duthie, 1993). The evacuation of both designs is probably analogous, but worse
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approximately 70% vs. 90%) than in the normal rectum (Heppell et al, 1987). An
interesting finding has been that, in 'J' pouches, the compliance of the pouch was
higher at the lowest pressure interval (0-20 cmH20). In pressures that are close to
the threshold volume, high pressure waves are generated, which may be an
important physiological parameter as compared to the normal rectum and its
ability to adapt in increases of pressure (Hulten et al, 1993).
The evacuation of the 'S' pouch (Figure 2.1) is often hampered by the
incidence of a long afferent limb (de Silva et al, 1991), and 40% require the use of
a catheter to defaecate (Nicholls & Pezim, 1985).
2.A.I.7.6. The Sensation Of The Neo-Rectum
The sensation of neo-rectal filling and urge to defecate, as compared to the
healthy rectum is probably quite different. Most patients referred to a feeling of
suprapubic pressure, or borborygmi or diffuse abdominal discomfort or a feeling
of deep pressure sensation in the pelvis. This measured volume of feeling was
related to the functional score of the patient, but not to the sensory threshold for
the urge to defaecate (Oresland et al, 1990). Others have not seen that the actual
volume required for sensation in a pouch is higher than in the normal rectum
(Keighley et al, 1988).
All of the above observations may indicate that storage, evacuation and
sensory function of the pouch are influenced by mechanisms other than those of a
normal rectum. The pouch has lost all sensory and motor connections to the
pelvic pathways, with frequent, almost universal abolishment of the rectoanal
inhibition reflex (Hulten et al, 1993). In spite of this the functional results in most
of the patients are remarkably good.
2.A. 1.7.7. Poor Functional Results In Ileoanal Pouches
Patients with poor functional outcome seem to have similar 24 hour stool
output, according to one study (Groom et al, 1994). The radiological size of the
pouch seemed to be equal, but the maximum tolerated volume was 290 ml,
compared to 475 ml of the 'good' functional outcome group. They also seemed
to have a greater number of migrating motor complexes (10 vs. 3) of the proximal
15
small bowel, although very few of these ever seemed to pass into the pouch
(Groom et al, 1994). Other investigators have observed that patients with poor
function tend to have rhythmic activity as the predominant motility pattern in their
pouch, although there was considerable overlap (Levitt et al, 1992; 1994).
Incontinent patients when examined with ambulatory methodology are
often noticed to have lower resting pressure in the anal canal, more prolonged anal
canal relaxation, higher amplitude high-pressure waves and a non-responsive anal
canal (Ferrara et al, 1994). They also seem to have rapid filling of their pouch,
which in turn provokes high amplitude propulsive pressure waves (Stryker et al,
1986). The episodes of high pressure pouch waves, which often overwhelm the
anal sphincter pressures, are most common during sleep (Farouk et al, 1994).
Another study using microtransducers pre- and post-operatively to record
anorectal manometry, found that patients with a resting pressure of 100 cmH20 or
greater than this pre-operatively, had significantly higher pressures at 12 months
post-operatively. Patients with 5 or fewer bowel movements per 24 hours, had
significantly higher resting anal tone. Patients who could defer defaecation for 1
hour had also higher resting anal tone (65 vs. 45 cmH20) compared with the rest
(Lindquist, 1990). Another study however, has observed that pre-operative anal
manometry failed to predict clinical functional outcome in ileoanal pouches
(Morgado et al, 1994). When ileostomy is constructed (before ileostomy closure),
a low anal resting pressure was seen to be associated with nocturnal incontinence,
whereas low pouch compliance may infer increased nocturnal frequency (Scott et
al, 1989).
2.A. 1.7.8. Use Of Anti-Diarrhoeal Medication
The use of Loperamide has been shown to increase resting anal pressure
by approximately 20%, without affecting the squeeze pressure, the pouch volume
or contractility (Hallgren et al, 1994). The anticholinergic drugs seem on the
other hand to damp pouch motility, increase pouch volume and raise luminal
pressures for feeling and urge (Hallgren et al, 1991). Oral Calcium supplements in
one study have been shown to reduce bowel frequency in pouches compared to
placebo or before treatment, while at the same time they reduced cell proliferation
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(Barsoum et al, 1992). In the Minnesota study, 43% of patients required
continuous anti diarrhoea medication (Pena et al, 1992). Fazio reports that 62%
of his patients required the occasional or regular anti-diarrhoeal medications
(Fazio et al, 1995).
2.A.I.7.9. Pouch-Anal Anastomosis - Stapling & Mucosectomy
It is believed that patients with higher pouch-anal anastomosis have better
functional results, (Lewis et al, 1994) according to the Leeds group studies.
However the magnitude of these differences has not been reproduced by other
investigators (Hulten et al, 1993), leading to the hypothesis that the actual level of
anastomosis in Leeds is even higher from what it is supposed to be, i.e. it is rather
pouch-rectal (Bartolo & Duthie, 1993). This may also be the reason, why other
investigators hardly ever observe any intact rectoanal inhibitory reflexes post
operatively (Lindquist, 1990). If these reflexes do reappear, then the distension
pressure required to elicit the response is much higher (Oresland et al, 1990).
Williams et al, have shown that stapled anastomosis are superior to the
hand sewn ones, but still they also convey significant sphincter impairment
(Williams et al, 1989). Seow-Choen from St. Marks Hospital on the other hand,
has seen no difference in the functional outcome comparing stapled to hand sewn
anastomoses with and without mucosectomy (Seow-Choen et al, 1991).
2.A.1.7.10. Pouch Function & Patients'Age
Another significant parameter of function may be related to the age of the
subject. Older patients in one study had worse sphincter function compared to the
younger group, but both results were within the reference range for that
laboratory. The maximal tolerable pre- and post-operative pouch filling pressures,
were significantly improved in both groups, indicating the advantage conferred
upon the excision of a diseased non-compliant rectum (Bartolo & Duthie, 1993).
This finding may explain why older patients seem to have comparable clinical
functional results (Keighley et al, 1993). The Leeds group study also reflects
preservation of the sensory and anal reflex function in the older age group, with
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slightly inferior clinical results, which were not statistically significant (Lewis et
al, 1993).
2.A.1.7.11. Pouch Function In The FAP Group
Patients who had the pouch constructed for FAP have fewer bowel
movements per 24 hours and also less night time faecal spotting (Dozois et al.,
1989). In this study from Mayo Clinic 97 FAP patients were compared to 758 UC
patients. It is noticeable that the overall pouch specific operative complication
rate (e.g. small bowel obstruction) was similar for both groups, except for pelvic
sepsis, which was higher in the UC group (6% vs. 0%).
2.A.1.7.12. Pouch Functional Score
A functional score has been described incorporating most of the above
clinical parameters). The score ranges from 0-15. Patients with overall good
function will score 0 points, and those with poor function will score a maximum of
15 points (Table 2.1).
In this particular study (Oresland et al, 1989), parameters such as
frequency of evacuation and soiling showed gradual improvement with time up to
two years post-operatively, while others observed no improvement after few
months (Gionchetti et al, 1995). Multivariate and step wise analyses of the above
parameters have indicated that the most influential parameters are pelvic sepsis or
fistula formation as well as endoanal mucosectomy (Keighley et al, 1976);
other recognised parameters are maximal pouch volume and compliance (Oresland
et al, 1990).
2.A.1.7.13. Sexual Function & Pregnancy
Male sexual function is generally preserved (94%), with only few cases
experiencing retrograde ejaculation, decreased libido, impotence or dyspareunia
(Damgaard et al 1995). In another study 8% reported improvement of their sex
life, while another 8% noticed decrease of their sexual activity (Pena et al, 1992).
In a review of twenty-one female patients with hystero-salpingography, 2 patients
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Table 2.1. The functional score according to Oresland (1989). Score ranges from 0-
15. Patients with overall good function will score 0 points, and those with poor
function will score a maximum of 15 points.
Functional Parameters Score 0 Score 1 Score 2
No of bowel movements daytime <4 5 >6
No of bowel movements at night 0 >l/week >2/night
urgency * no yes
evacuation difficulties** no yes
soiling or seepage daytime no >l/week
soiling or seepage at night no >l/week
perianal soreness no occ. permanent
protective pad day time no >l/week
protective pad at night no >l/week
dietary restiction*** no yes
medication **** no yes
Social handicap***** no yes
* URGENCY inability to defer evacuation >30 min
** EVACUATION DIFFICULTIES :>15 min spent in toilet on any occasion
during the week
*** DIETARY RESTRICTION : avoid certain items that affect pouch function
**** MEDICATION : continuous or occasional
***** SOCIAL HANDICAP :Not able to resume full time occupation or participate
in social life
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had bilateral occlusion of the fallopian tubes, 9 had unilateral, while 10 patients
had tubes adhering at the bottom of the lesser pelvis (Oresland et al, 1994). In a
questionnaire study from Lahey clinic with a 53% response rate, 15% reported
dyspareunia, 7% faecal incontinence during intercourse, 31% menstrual problems
with infertility observed in 18 patients out of 206. Fifteen patients developed
pelvic cysts, 11 requiring surgery (Counihan et al, 1994). Pregnancy and
childbirth were well tolerated in women with an ileoanal pouch, with a low
complication rate but a higher Caesarean section rate than a historical control of
women with ileostomy or Kock pouch (Juhasz et al, 1995). In the same database
from the Mayo Clinic it is noticeable that from 577 women, 43 succeeded in
pregnancy and delivery; 79% of the deliveries were vaginal.
2.A.1.7.14. Overall Patient Satisfaction
The post-operative patient satisfaction is high despite patients never really
achieving near normal function. In the Cleveland Clinic series, 93% of patients
report excellent quality of life (Fazio et al, 1995). This may be due to an
improvement of the ability to work uninterrupted with a dramatic increase from
12% pre-operatively in the UC patients to 96% post-operatively (Damgaard et al,
1995). Others (Weinryb et al, 1995), compared quality of life in the same patient
after ileostomy or pouch using the Psychosocial Adjustment to Illness Scale in its
self report version. Restoration of bowel continuity did not yield much further
improvement, as long as the initial disease was cured (Weinryb et al, 1995). In
another study UC patients required at least 12 months to restore their body
composition to normal (Christie & Hill, 1990).
2.A.I.8. Ileoanal Pouches:
Haematological & Clinical Chemistry Aspects
Pre-operatively patients with UC not infrequently are anaemic; this is
mainly due to blood loss from the gut. Post-operatively one may expect that this
problem will cease. However, in a review of 83 patients 12 months post¬
operatively, 4% had low values of haemoglobin compared to 22% pre-
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operatively. Decreased serum iron was observed in 10% compared to 58% in
the acutely ill pre-operative group. Two patients with pouch developed iron
deficiency anaemia 2.5 years and 5 years later. Factors responsible may be
dietary, impaired iron absorption, increased requirements or blood loss. Although
the aetiology for iron deficiency is not further analysed, it does however appear
that regular assessment of the full blood count in ileoanal pouch patients may be
necessary (M'Koma, 1994).
In the same study, at 36 months 11% of the patients had low serum B!2,
while other studies have observed a variable absorption rate for B[2 varying from
36% to 87% (Bayat et al, 1994). The Schilling test was decreased in 36%. The
main factor influencing BJ2 absorption is the length of terminal ileum retained.
The abnormal growth of the bacterial flora possibly associated with changes in the
intrinsic factor, the ileal receptor for the intrinsic factor-Bi2 complex, bacteria
utilising vitamin Bi2, and decreased transit time due to anatomic constraints, might
interfere with vitamin B12 absorption (M'Koma, 1994). Folates were normal
throughout the functional period.
A study on the electrolyte balance in pouches, showed that although serum
electrolytes are not disturbed either in the presence of ileostomy or pouch, the
ileostomy caused chronic dehydration which was compensated for by activation of
the renin-aldosterone axis. The electrolyte balance becomes closer to normal after
ileostomy closure following ileoanal anastomosis (Okamoto et al, 1995).
Flowever, another study found that serum chloride was lower in ileoanal pouches




One of the complications that emerged after the first pouch was
constructed was pouchitis. Under this term patients themselves refer to a
condition that is quite similar to their previous inflammatory bowel disease, with
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often bloody diarrhoea, abdominal pain, malaise and occasionally fever. Often this
picture is accompanied by the re-emerge or de novo (12% in Mayo Clinic studies)
appearance of extraintestinal manifestations (Mignon et al, 1995; Mortensen &
Madden, 1993).
Kock first realised that the continent ileostomies are prone to inflammatory
changes ("pouch-ileitis"); the same phenomenon was later discovered to hold true
for ileoanal pouches (Fozard & Pemberton, 1992; McLeod et al, 1986). The first
systemic approach to describe and define this phenomenon come from the St.
Marks Hospital (Moskowitz et al, 1986).
2.A.2.2. Definition
The definition of pouchitis went through multiple stages. Initially many
clinicians, including the Mayo Clinic attendants, were inclined to diagnose
pouchitis on clinical grounds only (Fozard & Pemberton, 1992). The problem of
this approach is that it may not differentiate between different pouch pathologies,
i.e. diarrhoea due to anastomotic stricture or long efferent limb in an 'S' pouch
(Mortensen & Madden, 1993).
Subsequent work by Moskowitz, Shepherd and Nicholls standardised the
syndrome as diarrhoea above six times, endoscopic findings of inflammation with
a score above 4 (on a scale 0-6), and acute inflammation histopathological criteria
with a score above 4 (Moskowitz et al, 1986). This triad of clinical, endoscopic
and histological parameters is referred commonly as the Moskowitz criteria (Table
2.2) for diagnosis of pouchitis.
Shepherd and colleagues systematically analysed the biopsy characteristics
of ileoanal pouches (Table 2.3) and categorised the acute and chronic
inflammatory changes observed in ileoanal pouches (Shepherd et al, 1987). He
also noticed other chronic changes in the pouch mucosa of pyloric metaplasia and
changes reminiscent of mucosal prolapse. This approach however depends on
good sampling, and since the endoscopic changes in pouches are often patchy,
there might be a considerable sampling error (Madden et al, 1990). Furthermore,
there are few severely inflamed histologically pouches, which cause minimal
symptoms (Madden et al, 1990),
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Table 2.2. The Moskowitz criteria for diagnosis of pouchitis (1986)
Diarrhoea above 6 per day
Endoscopic findings
loss of vascular pattern,
granularity score one for each one present,







moderate + crypt abscess score 2
severe + crypt abscess score 3
Ulceration /low power field
<25% score 1
>25%- <50% score 2
>50% score 3
total score>4 required for diagnosis
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Mild + patchy infiltrate surface 1
Moderate + crypt abscess 2







Chronic inflammatory cell infiltration
None 0





Minor abnormality architecture 1
Partial 2
Subtotal 3




Usual postoperative stool frequency 0
1-2 stools/day> postoperative usual I
3 or more stools/day > postoperative usual 2
Rectal bleeding
None or rare 0
Present daily 1

















Moderate + crypt abscess 2
Severe + crypt abscess 3
Ulceration /power field
< 25% 1
25 to 50% 2
> 50% 3
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The Moskowitz criteria were also criticised by the Mayo Clinic group as
being rather strict and not sensitive, and consequently a Pouchitis Disease Activity
Index (PDA!) score was proposed (Sandborn et al, 1994). This index again
includes clinical, endoscopic and histological parameters (Table 2.4), with a worst
possible score of 18; 'pouchitis' is defined with an additive score of 7 or above.
The obvious advantage of this scoring system is that it works as a continuum and
not as a binary scoring system. On the other hand, its actual evaluation as a
scoring system was based on comparison of data on 20 pouch patients only
(Sandborn et al, 1994). No large scale prospective studies have been described
upto now that used this index but one (Boerr et al, 1995). At this study 33
patients with ileoanal pouch were characterised clinically, endoscopically, and
histologically, with subsequent calculation of the PDAI. All these parameters
were individually correlated to the faecal ai-antitrypsin. It was evident from the
figures that the PDAI provided neater correlation. In another study, faecal ai-
antitrypsin clearance, as a marker of protein loss, was abnormal in few pouch
patients (Fiorentini et al, 1987); one may therefore hypothesise that the PDAI may
be describing the same phenomenon as gut protein loss in the pouch.
As the experience grew, it became apparent that other patients may suffer
only one or two self limiting episodes of diarrhoea and ill health, but upto 17% of
patients may get a continuous state of ill health with waxing and waning episodes
of disease (Fozard & Pemberton, 1992).
2.A.2.2. Pouchitis In FAP
The main parameter that influences the appearance of the syndrome of
pouchitis is the original diagnosis for which the colectomy was performed (Fozard
& Pemberton, 1992). Up to now very few cases of pouchitis have been described
globally in the FAP group of patients. In his 9 year review of results on 168
restorative proctocolectomies, Keighley described 3 out of 26 FAP pouch
patients who were diagnosed clinically and endoscopically to have pouchitis. All
had single episodes of pouchitis (Keighley et al, 1993).
One of these patients was fully investigated with histological confirmation
of the diagnosis. He had an abnormal indium-labelled granulocyte scan and
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increased radioactivity in a 4 day faecal collection. Following metronidazole
treatment for a month both clinical, endoscopic, histological and radionuclear
parameters returned to normal (Kmiot et al, 1990).
Fazio from the Cleveland Clinic group observed pouchitis in 5 out of 62
FAP patients over a period of 10 years. No information though is given as to how
the diagnosis was made and whether these patients had single or multiple episodes
of pouchitis (Fazio et al, 1995).
Pouchitis was described in 6% of 63 FAP patients over a period of 40
months follow up, data obtained from the Mayo Clinic Database. The diagnosis
was based only on clinical symptoms and response to antibiotic treatment, since
the follow up was done over the telephone (Lohmuller et al, 1990).
2.A.2.3. Pouchitis In UC: Incidence & Prevalence
Pouchitis is relatively common in UC, in contrast to familial adenomatous
polyposis coli, accounting for upto 30% of the patients in one report (Fozard &
Pemberton, 1992). This incidence rises with time after pouch creation. The
actual figures of prevalence and incidence of pouchitis differ between centres,
according to the criteria used for definition, the vigor of the follow up and also the
length of follow up (Sandborn, 1994).
Recent reports from the Mayo Clinic suggest a cumulative risk of
developing pouchitis in the 1st, 5th and 10th year as 15%, 36% and 46%
respectively (Sandborn, 1994). A review of results on 1005 patients by the
Cleveland clinic group suggested this to be 1% as an early complication, and
22.5% as a late complication (Fazio et al, 1995). The Birmingham group
mentions an incidence of 18% (Keighley et al, 1993), while the St. Marks Hospital
group refers to 45% had at least one episode of pouchitis, out of 66 patients
reviewed post-operatively (Setti-Carraro et al, 1994).
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2.A.2.4. Risk Factors In Pouchitis
Extraintestinal manifestations, pre- or post-operatively, seem to be more
prominent amongst the patients who develop pouchitis (Lohmuller et al, 1990).
Patients reported pyoderma gangrenosum, erythema nodosum, polyarthritis,
ankylosing spondylitis, sacroileitis, uveitis, episcleritis. Patients with sclerosing
cholangitis are at an even higher risk according to a later report from the same
Mayo Clinic group (Penna et al, 1996). The figure given for pouchitis in
sclerosing cholangitis is 63% as compared to an overall 32% incidence during a 12
year retrospective study of 1097 patients.
The presence of perinuclear antineutrophil cytoplasmic antibodies
(pANCAs), identify the group of pouchitis patients who seem to have continuous
symptoms (Sandborn et al, 1995). An earlier study from Birmingham, showed
that pANCAs persist in the sera for two years after restorative proctocolectomy.
From the 39 pouch patients who were recruited, five had pANCAs in their serum
and all five were patients with previous episodes of pouchitis (Patel et al, 1994).
A recent report from Oxford has revealed that smokers have fewer
episodes of pouchitis, a finding in common with UC (Merrett et al, 1996). There
was no association of smoking with other adverse outcomes of pouch surgery.
The presence of backwash ileitis in the resection specimen was examined
in association with pouchitis (Gustavsson et al, 1987). In a retrospective study, it
was revealed that pouchitis developed only in two of 15 patients with backwash
ileitis and in 18 of 116 patients without ileitis. In total 20 patients had pouchitis
for the two year study period. An association of pouchitis with the extent of the
disease has been described; pouchitis being more common in pancolitis. However,
no referral to different treatment patterns has been made (Mikkola et al, 1995);
furthermore, this observation has not been confirmed by other studies
(Samarasekera et al, 1995).
Repeated efforts in an attempt to correlate pouchitis with a missed
diagnosis of CD have not been proved fruitful (Subramani et al, 1993). There has
been a report that relates pouchitis to the pouch design, pouchitis being more
common in 'J' pouches (Hewett et al, 1995).
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2.A.2.5. Aetiology Of Pouchitis
2.A.2.5.I. Introduction & Histological Appraisal
The aetiology of the syndrome is unknown. It has been observed that a
number of pouch patients manifest some inflammatory changes at endoscopy, at
least in some parts of their pouches. Biopsies from pouches from different areas
may vary, but invariably in 87% of the patients some elements of chronic
inflammation are present, while acute inflammation may appear in 30%
(Moskowitz et al, 1986). Biopsies from the posterior aspects of the pouch tend to
show more inflammatory changes. This may be the result of a more prolonged
contact of faeces with the bowel mucosa posteriorly (Shepherd et al, 1993).
Apel et al (1994), in a prospective study, looked at the early morphological
changes of the histological picture in pouches from their creation onwards. They
reported that soon after creation, pouches are infiltrated by neutrophils and
eosinophils, with a mild degree of villous atrophy and Paneth's cell hyperplasia.
These features remain fairly stable after six months, except for a greater degree of
mononuclear infiltration, a progressive increase in the degree of eosinophilic
inflammation and a new higher level of crypt epithelial kinetics. The partial
transition to colonic mucin phenotype remains also stable.
The chronic inflammatory infiltrate that is observed in most of the pouches
consists of lymphocytes, plasma cells, eosinophils and histiocytes (Meuwissen et
al, 1989). Moskowitz has observed that the histological grading of acute
inflammation is related to the sigmoidoscopic features of inflammation as well as
to the frequency of defaecation; the histological inflammation could not be
correlated either to the pouch design or to the percentage of evacuation
(Moskowitz et al, 1986).
2.A.2.5.2. Partial Colonic Metaplasia
The above described elements of chronic inflammation are commonly
accompanied by varying degree of villous atrophy, at times giving a picture of
partial colonic metaplasia (Mortensen & Madden, 1993).
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The composition of mucus may also change in pouches, in some, attaining
more colonic type sulphomucin (Corfield et al, 1992).
However, other investigators showed that the ileal glycoprotein synthesis,
assessed by a glucosamine synthetase assay, does not differ in pouches, inflamed
or not (Winslet et al, 1993). On the other hand, changes in goblet and columnar
cells have been observed in pouches with acquirement of some colonic
characteristics (Campbell et al, 1994).
In some pouches the changes of chronic inflammation attain great severity;
this is known as the 'group C' (Setti Carraro and Nicholls, 1994), who invariably
get chronic pouchitis. A similar study in Sweden, has shown that patients with
chronic pouchitis have subtotal or total villous atrophy and some of them also
display low grade dysplasia (Veress et al, 1995). Subsequently, advice for
surveillance of this particular group has been issued (Shepherd, 1995).
2.A.2.5.3. Bacterial Ecology In Ileoanal Pouches & Pouchitis
Over the years, there have been considerable efforts to associate pouchitis
with some bacterial species resulting in an intense debate. Nicholls originally
described that pouches with histological inflammation had higher aerobic counts
(Nicholls et al, 1981). This was confirmed later at another study (Ruseler-van-
Emdben et al, 1994), which showed a decreased ratio of anaerobes to aerobes,
less bifidobacteria and anaerobic lactobacilli and more Clostridium perfringens in
pouchitis. Others have seen no differences in faecal bacterial counts between
pouchitis or non-pouchitis patients (Kmiot et al, 1993).
Ileoanal pouches were compared with ileostomies; pouches seem to have a
greater ratio of anaerobes with more bacteroides and bifidobacteria (Nasmyth et
al, 1989; Luukkonen et al, 1988) or of facultative aerobes (McLeod et al, 1994).
Bacteroides were also implicated with the advent of villous atrophy (Nasmyth et
al, 1989). One study reported that in pouchitis there was no increase in carriage
of adhesive Escherichia coli, which is in disagreement with observations in UC
(Lobo et al, 1993).
No one particular micro-organism has been implicated in the pathogenesis
of pouchitis. Routine faecal cultures in clinical practice do not yield any
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recognised intestinal pathogen (Nasmyth & Williams, 1993). In spite of that,
metronidazole, an antianaerobic antibiotic, seems to control pouchitis, at least
during an acute attack. However, the use of metronidazole in chronic unremitting
pouchitis does not seem to influence the histological or the endoscopic appearance
of the pouch, only partly reducing the diarrhoea (Madden et al, 1994).
Metronidazole has been reported to have an effect on cell mediated immunity
(Mortensen & Madden, 1993).
Onderdonk and McLeod in an electron microscopy study have
demonstrated that 47% of pouch mucosa biopsies have intramural bacteria, mainly
facultative aerobes, as compared to 14% in ileostomies (McLeod et al, 1994).
Intramural bacteria increase, though not significantly, in pouchitis.
If a particular micro-organism cannot be held responsible for pouchitis,
then there may be two possibilities. One hypothesis is that in pouchitis, the
disturbed bacterial ecological system produces a bacterial metabolite that causes
direct mucosal injury; or alternatively a bacterial antigen comes in close conduct
with the mucosa and triggers inflammation.
2.A.2.5.4. Pouchitis & The Short Chain Fatty Acids Theory
Short Chain Fatty Acids (SCFA), a product of anaerobic bacterial
fermentation of dietary fiber, are thought to be trophic for the colonic mucosa, and
probably for the ileal mucosa as well (Mortensen & Madden, 1993).
It is also known that SCFA stimulate terminal ileal motility, when
introduced into the lumen. In pouches, however, there seemed to be an inverse
relation of the total SCFA concentration per day and the stools per day (Ambroze
et al, 1993). This may relate to the current finding of lower SCFA concentration
in pouchitis (Sagar et al, 1995; Clausen et al, 1992). Sandborn from Mayo Clinic
has reported such differences only in a subgroup of sclerosing cholangitis patients
with pouchitis (Sandborn et al, 1995; Sandborn et al, 1993).
The SCFA level and composition may be influenced not only by the
bacterial taxonomy (Macfarlane et al, 1992), but also by the availability of
fermentable saccharides (Clausen et al, 1992) and by the pH of the environment
(Ruseler-van-Emdben et al, 1994). It has been shown that pouch effluent is
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more alkaline in pouchitis; in alkaline conditions more mucin can be degraded,
with a possible adverse effect on pouch mucosa integrity ((Ruseler-van-Emdben et
al, 1994). Furthermore, the percentage of pouch evacuation may be important in
determining the levels of SCFA (Nasmyth et al, 1989; Sagar et al, 1992).
SCFA have been disappointing in controlling inflammation, reducing only
cell proliferation in UC pouches when utilised as a therapeutic manipulation for
treatment of pouchitis (Tonelli et al, 1995; de Silva et al, 1989); in another study
SCFA were only partly successful (Cutler, 1992).
2.A.2.5.5. The Bile Acid Theory
The situation with bile acid absorption is equally obscure. Hill and Owen
have observed lower levels of conjugated bile acids in pouchitis (Shepherd et al,
1989), but their method has been criticised for not standardising the diet or the
period post creation of pouch. Others have observed no such differences
(Sandborn et al, 1995). Nasmyth showed that the bacterial metabolism of primary
conjugated bile acids was higher in pouches than in ileostomy (Nasmyth et al,
1989). Salemans showed that the reabsorption of conjugated bile acids was
impaired in pouches (Salemans et al, 1993). In spite of these differences, studies
have concluded that the construction of a pouch facilitates restoration of a near
normal bile acid profile (Kelly et al, 1993). Distinct patients, however, have
impaired bile acid absorption and may be at risk of increased bile acid loss (Hosie
et al, 1993).
Utilisation of jejunum as neorectum in dogs after total colectomy has
shown that if the terminal ileum is spared from contact with faecal fluids, the bile
acid absorption is totally normal (Juhasz et al, 1995).
2.A.2.5.6. The Ischaemic Theory Of Pouchitis
Another theory to elucidate pouchitis has been based on the observation of
reduced blood flow in pouchitis, measured by laser Doppler flowmetry (Hosie et
al, 1989). However, the histological findings of pouchitis do not resemble
ischaemia, furthermore overt ischaemia of pouches presents itself early and in a
dramatic fashion (Mortensen & Madden, 1993).
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2.A.2.5.7. Pouchitis As A Form Of Inflammatory Bowel Disease -
The Immunological Theory
Pouchitis may be considered as reappearance of inflammatory bowel
disease (IBD) (Banerjee, 1994). This hypothesis has been based on the many
common elements in the natural history, pathology, response to treatment and
evidence from the complications (Banerjee, 1994)
Studies of mucosal biopsies in pouchitis have shown increased levels of
cytokines IL-1J3, EL-6, IL-8 with undetectable TNFa in one study (Gionchetti et
al, 1994), and increased TNFa in another (Patel et al, 1995). There were no
differences in the cytokine gene polymorphism examined in patients with pouchitis
(Roussomoustakaki et al, 1995). Similar findings of raised levels of IL-ip, IL-6,
IL-8 in IBD were demonstrated in colonic biopsies of involved and non-involved
IBD mucosa (Nassif et al, 1996).
Leukotriene LTB4 is increased in pouchitis along with prostaglandin PGE2
(Gertner et al, 1994). Platelet Activator Factor (PAF) - acether and its metabolite
lyso-PAF were also increased in stools from pouchitis patients, when compared
with normal pouches (Chaussade et al, 1990). The role of PAF and the
eicosanoids is well described in IBD, with phospholipase-A2 having a central
pivotal role (Nassif et al, 1996).
The RFD9+ macrophages (epithelioid and tingible body macrophages),
that are found in active IBD and not in infective colitis, are commonly seen in
pouchitis (de Silva et al, 1991; Gionchetti et al, 1992).
The intra-epithelial lymphocyte count is paradoxically low, similar to the
one in colon and it does not increase even in pouchitis (de Silva et al, 1991). The
CD4:CD8 ratio of T cells is not significantly different in pouchitis compared with
normal pouches (de Silva et al, 1991).
The mucosal permeability in pouches is increased, a finding described in
IBD (Koltun et al, 1993). The lympho-plasmacellular infiltrate in pouchitis is
characterised by an abundance of IgA and IgG bearing cells, with few IgM cells,
while IgE could not be detected (Meuwissen et al, 1989).
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2.A.2.5.8. The Axonal Necrosis Theory
Electron microscopy studies showed that a fair number of pouchitis
biopsies appear to have axonal necrosis, in a similar way as in CD; replicate
biopsies taken are also positive for bacteria, mainly facultative aerobic and
intramural. At the same study an association of axonal necrosis and mast cell and
eosinophil secretion was noted. All these findings are irrespective of the original
diagnosis of UC or FAP (Dvorak et al, 1993).
2.A.2.6. The "Objective" Assessment Of Pouchitis
Two methods have been described for objective assessment of pouchitis:
the measurement of faecal a-1-antitrypsin (Boerr et al, 1995) and the mIn-labeled
autologous granulocyte scan with faecal collections for four days (Kmiot et al,
1993).
The authors for the a-1-antitrypsin test reported sensitivity and specificity
of 80% and 97% respectively. However, the PDAI was used for comparison,
which is yet to be formally evaluated. On the other hand, this study clearly
demonstrated that gut protein loss, seen in IBD, is also observed in pouchitis
(Boerr et al, 1995).
The diagnosis of pouchitis in the 11'in-labeled autologous granulocyte
scan and faecal collection study is obscure. Although clinical, histological and
endoscopic parameters were studied, it seemed that the diagnosis of pouchitis was
based solely on endoscopy. In spite of this weakness the authors calculated a
70% sensitivity and 100% specificity for the four hours scan. The four days
faecal collection had an increased sensitivity of 90% and a specificity of 88%. An
important observation may be made from this study: neutrophilia in pouchitis is
concentrated in the mucosa as in IBD. Neutrophils do migrate into the gut lumen
at a later stage and present themselves in the faecal collections (Kmiot et al,
1993).
34
2.A.2.7. Treatment Of Pouchitis
The treatment of pouchitis has explored the utilisation of antibiotics.
Apart from metronidazole, antibiotics such as Ciprofloxacillin, Augmentin,
Vibramycin have been used (Mortensen & Madden, 1993). Some patients
however may require long term treatment so there is always the fear of the
resultant drug toxicity. Metronidazole has been successfully utilised in a study as
a local irrigation with very low blood levels (Nygaard et al, 1994). It has been
suggested that patients, who do not respond to metronidazole, belong to the IC
group and not to UC group (Rauhet al, 1991).
Systemic or local steroids have been used as well as 5-aminosalicylates (5-
ASA) derivatives (Mortensen & Madden, 1993). Budesonide suppositories have
been effective in spite of relapses when discontinued (Belluzzi et al, 1992).
Butyrate suppositories have been tried with moderate success, while
glutamine substitution was more promising (Cutler, 1992). The theory behind
these approaches was that both SCFAs and glutamine are considered to be trophic
for the pouch mucosa. Other investigators found no improvement with SCFA
enemas (Tonelli et al, 1995).
Ten out of twelve patients with pouchitis in one study did improve with
the use of Bismuth carbomer enemas (Gionchetti et al, 1995).
Cyclosporin enema in one patient with unremitting pouchitis improved the
clinical and endoscopic parameters of the disease (Winter et al, 1993).
Allopurinol, a xanthine oxidase competitive inhibitor that curtails free
radical production, has been used successfully in a study to terminate episode of
acute pouchitis, or prevent pouchitis from recurring in 50% of the cases (Levin et
al, 1992).
A trial of octreotide in two patients with unremitting diarrhoea (but not
pouchitis), did not show any improvement (Sagar et al, 1994).
2.A.2.8. The Prognosis Of Pouchitis
The prognosis of pouchitis depends on the pattern of presentation. 39% of
all pouchitis patients present with self limited disease that confers no problems as
it responds promptly to antibiotics (Sandborn, 1994). The remaining 61% of the
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pouchitis patients may experience more than one episode of inflammation. Only
patients with chronic or continuous pouchitis have major morbidity. This group
consists of 15% of all pouchitis patients. Pouch failures and excisions in these
circumstances are up to 40% of these patients, which translates to a total of 2%
excision rate due to pouchitis out of all pouch cases (Sandborn, 1994).
There is a hidden danger of dysplasia in some of the pouches that requires
surveillance for the future. It is possible that a few of these patients will require
excision eventually; the follow up period extends to the end of the second decade
after the introduction of this type of surgery (Sandborn, 1994).
2.B. INFLAMMATORY BOWEL DISEASE
2.B.L Inflammatory Bowel Disease Assessment
2.B.1.L Introduction
The two main forms of non-specific inflammatory bowel disease
recognised are Crohn's disease and ulcerative colitis. Crohn's disease can affect
any part of the gastrointestinal tract, while UC affects only the large bowel
(Kumar 1994). Hence the attraction of the surgical treatment in UC, which offers
permanent cure to the patient. Furthermore, with the creation of an ileoanal
pouch, this cure is achieved avoiding a permanent ileostomy, which has an obvious
psychological advantage.
It has been recognised however, that there is certain overlap between CD
and UC not only in the clinical features but also in the histological characteristics
and radiological findings. Approximately 10% of the colitis cases cannot be
categorised with certainty to one or the other of the inflammatory bowel diseases.
Accordingly they are referred to as indeterminate colitis (IC), until the actual
natural history of the disease manifests the true underlying pathology (Kumar,
1994).
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The clinical presentation in CD includes diarrhoea, abdominal pain and
weight loss; in Crohn's colitis the diarrhoea may be bloody. In UC diarrhoea is
often bloody with mucous, while the abdominal pain is more like discomfort with
tenesmus. Both inflammatory bowel diseases may be accompanied by
constitutional symptoms of malaise lethargy and anorexia, but Crohn's patients
may also complain of nausea, vomiting and low grade fever. Extraintestinal
manifestations may be present in either of the two diseases. In CD the
development of complications like stricture, abscess and fistula formation, may
pose real management dilemmas. Often it is difficult to identify, whether a
particular symptom is due to the disease process of gut inflammation or to the
emergence of these complications. Furthermore, medical treatment may change
the presentation of the disease by introducing its own side effects. Nutritional,
social and psychological factors further add to the puzzle of the disease morbidity
and complex presentation (Kumar, 1994).
2.B.I.2. Disease Activity Indexes In IBD
The accurate assessment of the therapeutic manipulations made necessary
the introduction of methods destined to measure the degree of inflammation
associated with the disease, so meaningful comparisons between the various
therapeutic options may be possible. It was evident, however that patients who
had clinically inactive disease may have features of inflammation in their gut, as
measured by granulocyte excretion (Saverymuttu 1986). Alternatively, systemic
indices of inflammation like the erythrocyte sedimentation rate and serum C-
reactive protein concentration do not always reflect the gut related immune
processes.
In UC, Truelove and Witts devised a simple classification of the severity of
colitis: severe disease was defined as the passage of six or more stools per day
with blood, accompanied by fever, tachycardia, anaemia, or rapid ESR (Keighley
1993 a).
Another useful index for assessment of disease activity in UC was devised
by Powell-Tuck during a prospective study to compare two different regimes of
steroid treatment (Powel-Tuck et al, 1978). This index includes parameters like
37
general health (score 0-3), abdominal pain (score 0-2), bowel frequency (score 1
or 2), stool consistency (score 0-2), blood in stool (score 0-2), anorexia, nausea,
abdominal tenderness (score 0-3), eye inflammation, arthralgia, oral ulceration,
related skin lesions (score 0-2), temperature (score 0-2), and sigmoidoscopy
(score 0-2). It is obvious that this index has many similarities with Crohn's
Disease Activity Index (CDAI).
The CDAI was devised by gastroenterologists from 13 institutions as a
method to monitor the progress of CD after collecting data from 187 patient visits
(Best et al, 1976). The dependent variable used for each patient visit was the
physician's over-all evaluation of "how the patient was doing". This variable was
then related to 18 independent variables, which could be readily available at each
visit. With a multiple regression with stepwise deletion, 8 variables were identified
as independent parameters. Each of them was rounded in such a way to give
simple figures for calculation of the CDAI. In practice, the patient records in a
card, for seven days prior to his/her consultation, the number of liquid or very
soft stool, the presence of abdominal pain, and his general well being. The rest of
the parameters are filled in by the physician: presence or absence of six
complications (arthritis, iritis, skin complications, anal fissure, fistulae, fever), use
of anti diarrhoeal medication, presence of abdominal mass, value of haematocrit
and the body weight. A value of CDAI above 150, was agreed to signify active
disease.
Over the years other disease activity indexes were improvised in an
attempt for simplicity and to minimise the bias of the subjective symptoms
incorporated in the CDAI. Notable examples are the OMGE disease index from
the World Organisation of Gastroenterology and the International Organisation
for the study of Inflammatory Bowel Disease (IOIBD). Harvey and Bradshaw
(1980) created a CDAI modification that is widely used in Britain (Keighley,
1993b).
An endoscopic index was also devised which included the severity of
ulceration, extent of disease, presence of stenosis with or without ulceration
(Mary & Modigliani, 1989). Furthermore, a whole range of parameters was
proposed: erythrocyte sedimentation rate, the C-reactive protein , orosomucoid,
38
faecal ar antitrypsin or its clearance, faecal "'indium excretion. More recently,
other parameters were described: assessment of microalbuminuria (Mahmud et al,
1996), DNA flowcytometric evaluation of cell cycle distribution of rectal biopsy
specimen for UC (Bortoluzzi et al, 1995), Doppler sonography of superior
mesenteric artery flow (Van Oostayen et al, 1997), serum thrombomodulin in UC
(Boehme et al, 1997), leukocyte adhesiveness/aggregation test (Arber et al, 1995),
urine levels of soluble TNF receptors p55 and p75 (Hadziselimovic et al, 1995).
The question, however that emerges is what is the biological
phenomenon, if any, that CDAI and the other similar clinical activity indexes
measure. These indices are certainly a reflection of the overall clinical impression
of the physician of "how well the patient is doing". De Dombal though, made a
disquieting point that there is considerable interobserver variation in calculating
the various indices used for the disease activity between clinicians. (De Dombal &
Softtley, 1987).
Saverymuttu originally found a high correlation of the faecal excretion of
'"indium labelled leukocytes and the CDAI (r=0.78, p<0.001; Saverymuttu et al,
1983). In later studies, however, he admitted that patients in clinical remission as
judged by a CDAI less than 150, may have significantly higher excretion of faecal
"'indium compared to control group of irritable bowel syndrome (Saverymuttu,
1986). Instead the endoscopic and histological scores correlated well with the
"'indium scans (Saverymuttu et al, 1986). Similar results were observed with
the use of the 99mTc-HMPAO labelled autologous granulocytes (Sciarretta et al,
1993).
The relations between clinical activity, endoscopic severity and biological
parameters in CD were assessed in 121 consecutive patients with colonic or
ileocolonic disease. Stepwise linear regression identified the C-reactive protein as
predictive of the clinical index (CDAI), and, successively a2- globulin, erythrocyte
sedimentation rate, faecal a 1-antitrypsin and serum orosomucoid as predictive of
the endoscopic index. However, both predictions were poor, indicating that
clinical activity in CD is virtually independent of the severity of the mucosal
lesions and biological activity (Cellier et al, 1994).
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Protein losing enteropathy is a measure of extent or severity of CD
(Chadwick & Camilleri, 1990); recently this was substantiated in a prospective
study using 51CrCl3 labelled proteins and measuring their faecal excretion
(Nordgren et al, 1990). Studies also with the whole gut lavage fluid methodology
have shown that the CDAI is closely related to this protein losing enteropathy
(see following section 2.B.1.3).
The Pouchitis Disease Activity Index (PDAI) is another example of the
creation of an index in an attempt to objectively measure disease activity in a
unique inflammatory disease process of the gut i.e. pouchitis. It is obvious that it
also has a heavy bias from the stool frequency and urgency, which may be due to
other pouch pathologies. The endoscopic and histopathological aspect of the
PDAI may be biased from sampling error. It is not influenced by haematocrit; it
does not take into account anti-diarrhoeal medication; and it ignores largely the
extraintestinal manifestations.
2.B.I.3. Whole Gut Lavage Fluid -
Assessment Of Disease Activity In IBD
The limitations of all these indexes were a trigger for intense research in an
attempt to identify a practical and objective method to assess disease activity in
inflammatory bowel disease that will be clinically relevant, reproducible and well
tolerated. This work led to the Whole Gut Lavage Fluid (WGLF) methodology.
In this section, I will introduce the way the WGLF methodology was developed in
our Gastrointestinal Laboratory and explain how it was used to assess various
aspects of inflammation, injury and bleeding in the gut.
Whole gut lavage with a polyethylene glycol electrolyte solution is
extensively used in clinical practice for bowel preparation prior to surgery or
colonoscopy. It has also been utilised as a form of treatment for various
poisoning states (Jawary et al, 1992). It is well tolerated. Only one serious
adverse event has been reported in relation to the WGLF method; a child
developed acute pulmonary oedema during a whole gut irrigation via a nasogastric
tube. From the description however, it is not entirely convincing that the
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pulmonary oedema was not due to aspiration of the stomach contents (Paap &
Ehrich, 1993).
Gaspari et al, (1988) described a method of utilising the gut lavage to
detect immunoglobulins in 12 human volunteers. The main problem they faced
was that the human intestinal secretions contained an abundance of proteases.
With the addition of various protease inhibitors this problem was overcome.
O'Mahony et al, (1990) showed that lavage specimens which were
faecally contaminated contained negligible quantities of immunoglobulins. On the
other hand, once the specimens became clear a steady state was reached, with
little variation in immunoglobulin content between serial specimens and with a
uniform dilution (around 20%) of the ingested polyethylene glycol (O'Mahony et
al, 1990). ELISA techniques were used in the measurements of total IgA, IgM
and IgG in WGLF in healthy controls, in coeliac disease and in CD patients. A
striking difference noticed was that the IgG content of the WGLF of patients with
active CD was at least 10 times higher than the concentration in the normal group
(O'Mahony et al, 1990).
Prompted by this finding, another study was conducted where the IgG in
the WGLF of a larger group of IBD patients with active or inactive disease was
compared with controls. "Disease activity" was assessed by an independent
clinician on review of current symptoms and signs; radiological, endoscopic and
histopathological features; haematological and biochemical indices: ESR, platelet
count, C-reactive protein, plasma protein, and albumin. This time, it was noticed
that active IBD was characterised by significantly higher levels of IgG both
compared to inactive disease and the controls (O'Mahony et al, 1991).
Furthermore, the albumin measured in the WGLF of these patients seemed to
mirror the IgG levels (r= 0.68, p<0.0001). This finding signified that the IgG
measured in the WGLF was probably plasma derived, in spite of the known
phenomenon of high levels of IgG secretory plasma cells in the lamina propria in
IBD patients (O'Mahony et al, 1991).
It was evident, from the above studies, that disease activity in IBD may be
associated with protein loss as judged by the IgG content of the WGLF. A
prospective study of WGLF parameters was undertaken, where the disease
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activity was measured along with the CDAI or the Powel-Tuck (PTI) indices for
CD or UC respectively. During this study another protein, a-1-antitrypsin
(A1AT), was also assessed. It was shown that IgG in CD strongly correlated
with the CDAI (r=0.723, p<0.0001). A similar observation was true for IgG and
the PTI in UC (r=0.714, p<0.0001). The results for albumin and A1AT were
similar to those of IgG, but were less sensitive in detecting active disease
(Choudari et al, 1993). It was argued in this paper, that if the resultant increase of
concentration of the above proteins in the WGLF was merely due to bleeding,
then their concentration should mirror their plasma concentrations. This in fact is
not the case. It was also shown that albumin in unprocessed WGLF degrades
more rapidly than the other proteins, with a reduction in measured quantity of 10-
40% in one hour (Choudari et al, 1993). This study, therefore demonstrated that
measuring WGLF IgG was a new objective and accurate method to quantify
disease activity in IBD; it also showed that the disease activity as described by the
CDAI and the PTI is analogous to the gut protein loss that happens in
inflammation of the bowel.
Ground work on the validity of the method was performed; polyethylene
glycol, residual protease activity, IgA, IgM, IgG, albumin, A1AT and titres of
IgA antibody to Salmonella typhi LPS were similar in five sequentially collected
WGLF specimens (Ferguson et al, 1995). This was also an indication that the
system established when the patient was drinking the polyethylene glycol and at
the point of the production of the clear specimen was at a steady state i.e. the fluid
obtained was a gut perfusate. Sixty-three immunologically normal patients and
254 with various gastrointestinal symptoms were tested and reference levels were
established for WGLF IgG, albumin, and A1AT. The normal ranges given were
1-10 pg/ml for IgG; 1-26 pg/ml for albumin; 1-19 pig/ml for A1AT (Brydon et al,
1993). The gut protein loss as defined by the WGLF was consistent, in the
majority of patients, with the clinical picture (one lymphangiectasia, seven
colorectal cancers, one gut lymphoma, one perforated diverticulitis, one pouchitis
and one lymphocytic colitis). The level of IgG in WGLF, when used in IBD
patients, could accurately define active and inactive disease, in a similar way as in
the prospective study mentioned above.
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2.B.I.4. Gastrointestinal Blood Loss In WGLF
Another area of investigation was occult gastrointestinal bleeding. To
quantify the severity of this phenomenon, WGLF haemoglobin was examined.
This was found to be higher in patients with colorectal cancer, severe diverticular
disease and rectal varices. Seven out of sixteen patients with IBD and four
patients with iron deficiency anaemia of gastrointestinal origin had raised WGLF
haemoglobin (Brydon & Ferguson, 1992). In parallel to that, subjects with
healthy gastrointestinal tracts had WGLF haemoglobin concentration measured:
range of 0.5-5.1 pg/ml. A comprehensive analysis of iron deficiency anaemia
referrals, with clinical, endoscopic and WGLF haemoglobin methodology, showed
that occult gastrointestinal bleeding sufficient to cause anaemia was evident in
only 19% of the cases, the rest having a plethora of other potential causes for their
iron deficiency, suggesting that most of the gastrointestinal lesions detected in
them were probably coincidental (Ferguson et al, 1996).
2.B.I.5. Pro-Inflammatory Cytokines In WGLF
Lymphocytes and macrophages synthesise and secrete a number of potent
pro-inflammatory mediators. Interleukins IL-la and IL-ip are of particular
interest, since human T-cell activation is promoted by IL-1 presence. IL-1 also
promotes B-cell activation, while the best known IL-1 activities are fever and
stimulation of acute phase protein synthesis. In IBD, Mahida et al (1989) studied
IL-ip release from isolated intestinal lamina propria mononuclear phagocytes and
observed enhanced spontaneous and LPS induced secretion from monocytes.
Others described raised levels of IL-ip in mucosa of endoscopic biopsies,
correlating with disease activity (Brynskov et al, 1992).
Other cytokines, including TNFa and IL-6 have also been studied. These
were associated with the immune process in IBD (Isaacs et al, 1992). The
interleukin IL-8 is a potent chemoatractor and activator of neutrophils, which can
cause much of the mucosal destruction during migration from the endothelium
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into the gut lumen. Raab et al (1993) measured IL-8 in rectal perfusates in IBD
patients and found that levels of this cytokine correlated well with the
myeloperoxidase activity that was simultaneously assessed.
The work performed on the cytokine profile in WGLF in various entities
was of considerable interest. Bioassays were found to be not suitable for the
WGLF, but instead enzyme linked immunosorbent assays (ELISA) and radio
immunoassay (RIA) techniques could readily be applied. Whole gut lavage was
performed in a mixed group of patients who received elemental diet E028.
WGLF was obtained before and after elemental diet. The clinical responders to
this form of treatment manifested a reduction of the WGLF levels of soluble IL-2
receptor, which is a marker of T-cell activation. In these patients however, the
serum sIL-2R did not change (Ferguson et al, 1994). Studies on TNF in IBD,
measured in WGLF, showed that TNF was detectable in both CD and UC. This
correlated more closely to disease distribution (colonic) than to disease activity
(Ferguson & Mwantembe, 1995). Studies on IL-ip and IL-8 of the WGLF
showed that these proinflammatory cytokines are higher in active IBD (Ghosh,
1995). Cytokine work in cystic fibrosis children showed that a subgroup with
distal intestinal obstruction syndrome treated with Nutrizym 22, had a very
abnormal cytokine profile in their WGLF, with an added elevation of the WGLF
albumin (Croft et al, 1995).
2.B.I.6. Neutrophil Migration In IBD & The WGLF
Neutrophil polymorphs are a prominent feature of the intestinal
inflammatory infiltrate in IBD. Amplification of this neutrophil response is largely
due to activated phagocytes in situ releasing the potent neutrophil chemoattractant
leucotriene B4 (Lobos et al, 1987).
Several studies over the years have been described to assess the
chemotaxis of neutrophils in IBD. These are presented in the next section (see
section 2.B.2). In vivo, Saverymuttu showed that peripheral blood leukocytes,
labelled with 111 Indium, injected in IBD patients quickly accumulate in the
inflamed intestine (Saverymuttu et al, 1985a; 1985b). Furthermore, these
leukocytes within a few days appear in the faeces. Accordingly a 4-day faecal
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collection for measurement of11'indium excretion was introduced. This combined
method of labelled leukocyte scintigraphy and faecal collection was used in clinical
practice for assessment of the disease extent, the disease activity, for screening for
IBD and the detection of complications of IBD (Giaffer 1996).
Another radioisotope was later used, Technetium-99m hexamethyl
propylene amine oxime (99m Tc HMPAO). The advantage of this scan is that it
gives superior quality images, the radioisotope is readily available and the
technique does not require the time consuming granulocyte separation. The
radiation dose involved is low. The only disadvantage is that it cannot be used for
faecal excretion studies since it has a short half life and has a biliary excretion
(Giaffer, 1996). The introduction of the "mTC-HMPAO labelling along with the
single photon emission computerised tomography (SPECT) allowed visualisation
of the entire bowel separate from overlying structures (Weldon et al, 1996).
It was evident, from these scintigraphic studies, that there is a
phenomenon of neutrophil migration to the gut lumen in IBD. It is feasible to
hypothesise that these "luminal" neutrophils that have migrated through
endothelium and epithelium, have characteristics very similar to the exudative
neutrophils: enhanced microbicidal activity, expression of CDllb, CD16 and the
FMLP receptor (Yee et al, 1994).
Animal studies on FMLP, a potent granulocyte activator that is produced
by bacteria resident in the colon and ileum, have shown that mucosal permeability
is increased by FMLP in the distal 10 cm of the terminal ileum. Furthermore, this
increase is prevented by rendering the animal neutropenic. Activated neutrophils
release both oxidants and proteases; the latter can be rapidly inactivated by
antiproteases normally found in extracellular fluid (e.g. al-antitrypsin).
However, neutrophil derived oxidants are believed to alter the
protease/antiprotease balance by inactivating antiproteases. Thus, neutrophil
derived oxidants and proteases work in concert to mediate the increase in mucosal
permeability elicited by FMLP (Crissinger et al, 1990).
Two observations relevant to the issue of the importance of luminal
neutrophilia is the observation of an enterohepatic circulation for FMLP in
experimental colitis in rats (Hobson et al, 1988) and of immunoreactive bacterial
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chemotactic peptides in man (Roberts et al, 1990). Furthermore, increased
neutrophil receptors for FMLP were discovered in patients with CD (Anton et al,
1989). Tt is noticeable that oxidised and reduced forms of FMLP can be detected
in bulk environmental organic dust samples (Siegel et al, 1994).
Cytology of the WGLF was performed in an attempt to investigate
neutrophil migration into the gut lumen (Handy et al, 1995). It was shown that
luminal neutrophilia characterised active UC and active colonic CD, but not active
small bowel CD, or inactive disease. This was in agreement with earlier work on
faecal Indium111 excretion experiments (Crama-Bohbouth et al, 1989). This work
was expanded to the utilisation of neutrophil granulocyte elastase measurement in
WGLF, with similar results, since the cytology methodology proved to be rather
laborious (Handy et al, 1996).
2.B.I.6. Other Uses Of WGLF Methodology In IBD
The method has now been established as acceptable for routine clinical
practice in the objective assessment of IBD disease activity and blood loss. The
research took on various directions. Levels of IgA antibodies to bacteroides
fragilis LPS were measured in CD and found to be higher (Poxton et al, 1995).
The total IgA in WGLF was also assessed in smokers as compared to UC patients
and found to be lower (Srivastava et al, 1991). The WGLF IgA antibodies to
Klebsiella pneumoniae were studied in normal controls, patients with CD and
patients with ankylosing spondylitis and found to be similar in spite of the apparent
differences in serum IgA between the normal group and the other two groups with
high IgA (O'Mahony et al, 1992).
Other substances have been measured in WGLF, which although they
appear to have no direct impact on the immediate research in IBD, may in the
future enlighten aspects of the pathological mechanisms involved. Ghosh showed
that Insulin-like growth factor-1 and TGF-(3 in WGLF can be utilised as markers
of intestinal fibrosis (Ghosh et al, 1997). Measurement of the cytokine RANTES
or of the eosinophil cationic protein can assess eosinophil activity in various
pathologies in the gut (Handy et al, 1995).
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The advantages of adopting the WGLF methodology to study the
immunity of the gut in IBD are clearly considerable. This can be reinforced by
two more observations. First observation; when faecal extracts of
immunoglobulins, albumin, A1AT and isotype specific antibodies were compared
with the estimated daily output (the amount known to be produced from the gut
with WGLF assays) the recovery rate was extremely variable (Ferguson et al,
1995). This finding demonstrated that probably saline faecal extracts do not
represent the true status of the gut humoral system and that they better be looked
upon with caution. Second observation; when the CDAI was compared with
various clinical subgroups of patients, some discrepancies could be identified.
Firstly patients with clinically inactive IBD, but with fibrous small bowel strictures
would have high CDAI score but a normal IgG in the WGLF. This was due to the
overemphasis given by the CDAI to the clinical aspects of disease. Consequently
the CDAI was also raised in psychologically disturbed patients, for whom the
Clinicians' assessment was of inactive disease. In these cases the WGLF IgG was
again low. Thirdly in children, the CDAI had no relation whatsoever to the
activity of the disease as assessed by the Clinician. The WGLF IgG, however
could fairly accurately characterise them. Fourthly, the CDAI in ileostomy
patients did not correlate with any of the parameters studied. The IgG though,




The interest in chemotaxis (directional movement) or chemokinesis
(random movement) of leukocytes in IBD has been based on the assumption that
neutrophils are one of the main components in acute inflammation. Thus, their
excessive aggregation in IBD gut mucosa should follow a possible abnormality in
their function.
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One of the most influential studies in this field was the work of Segal and
Loewi (1976). They observed that leukocytes from CD patients exhibited
decreased chemotaxis to their own sera in skin window chambers. This may be
explained, either by defective chemotaxis of neutrophils or by the appearance of
anti-chemotactic agents into the sera. Many other investigators have reproduced
this finding and attempted to explain its occurrence. Since the methodology used
by individual investigators differed both in the particular assays used and in the
various chemoattractants utilised, a considerable variation of outcome and
resulting opinion has risen.
2.B.2.2. Chemotaxis In IBD
Neutrophils from UC patients showed decreased chemotaxis to casein in
vitro, while their spontaneous motility, or chemokinesis, in active disease was
enhanced (Binder & Riis, 1977). One UC patient was reported, who had
abnormal chemotaxis, thought to stem from the presence of a serum inhibitor in
the form of IgA (Patrone et al, 1978). Corticosteroids and sulphasalazine reduced
chemotaxis, a phenomenon which was irrespective to response to treatment
(Hermanowicz et al, 1985; Rhodes et al, 1981). Other investigators however
found no difference in vitro chemotaxis whether spontaneous or casein stimulated
in Boyden chambers in either UC or CD (Wandall, 1985). This finding was
supported also by Elmgreen, who again did not find any difference in chemotaxis,
when the chemoattractant was casein. Instead he observed reduced chemotaxis to
the complement fraction C5a both in UC and CD patients, who had no treatment
for at least three months (Elmgreen, 1984). In another study in CD, he showed
that the in vitro activation of the complement cascade produced in the alternative
pathway a defective C5a with under utilisation of C3 (Elmgreen et al, 1983). On
the other hand, a reduction of chemotaxis was found in active disease in UC when
compared with inactive UC. This was not accompanied by changes in motility of
neutrophils at the skin window chamber experiments (Elmgreen & Binder, 1982).
The skin window chamber chemotaxis is reduced in CD, but in the in vitro
experiment no differences were noted. Furthermore, the patients' sera could not
modify the chemotaxis effect (Morain et al, 1981). Rhodes and Jewell however,
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demonstrated the presence of a substance in serum of active CD patients, which
was similar to the 7S y-globulin, and could be precipitated by the 40% ammonium
sulphate. This substance was a serum inhibitor of chemotaxis (Rhodes et al,
1982).
In another study, Rhodes and Jewell found no decrease in vitro chemotaxis
or chemokinesis in either UC or CD, as far as the neutrophils were concerned, but
noticed a slight increase of the monocyte chemotaxis in UC (Rhodes & Jewell,
1983). Other investigators found similar increase of monocyte chemotaxis in UC,
but this did not show statistical significance. On the other hand, increased
chemokinesis was demonstrated in both UC and CD cases (Whorwell et al,
1981).
When the agarose method for chemotaxis was employed, there was a
reduction in chemotaxis, in vitro, which on this occasion was related to disease
activity (Belsheim et al, 1984). Others observed that, whereas all UC patients had
originally low chemotaxis compared to the normal controls, when these patients
were studied during the active phase of their disease their corresponding
chemotaxis increased (Hermanowicz & Nawarska, 1981). The opposite was
observed in CD patients. Active CD presented lower chemotaxis and inactive
disease higher (Belsheim et al, 1981). Lennard-Jones team showed similar
reduction in chemotaxis in UC and CD; but in active UC the immunofluoresence
after incubation of normal neutrophils and sera from UC was analogous to the
impaired cell migration (Kirk et al, 1983).
These discrepancies in the results may be due to the different methodology
and assays used by each investigator. However, Wandal managed to clarify some
of these problems by introducing an extra parameter, which was missing in the
previous presentations, i.e. the time scale of the biological phenomena observed.
The skin window chamber test performed in UC showed no difference at the first
12 hours, but 24 and 48 hours later revealed lower total number of neutrophils
present and lesser rate of migration (Wandall & Binder, 1982). This mobilisation
was dependent on the total count of neutrophils in the blood of the patient. The in
vitro chemotaxis was reduced. In CD, there was a lag phase initially and then
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again the migration was reduced, while the chemotactic response to casein was
not affected (Wandall & Binder, 1982).
In the following years the interest moved towards the importance of
arachidonic acid derivatives and their effects in chemotaxis.
Serum from UC patients, who have been given fish oil supplements
(MaxEPA) was found to be less chemotactic, while the neutrophil LTB4 content
was reduced at the same time (McCall et al, 1989). Nielsen experimented in the
Boyden chamber with neutrophils from UC and CD patients compared to controls
using different concentration of casein, FMLP, C5a, LTB4 and its metabolites, and
5-HETE and its metabolites. The chemotaxis was reduced in both diseases at the
suboptimal concentrations of LTB4 and 5-HETE, while the peak response of
casein, FMLP, LTB4 and 5-HETE of IBD neutrophils were similar to normals.
The peak response to C5a was reduced in IBD. The LTB4 appeared to be 100
times more potent chemotactic factor than 5-HETE (Nielsen & Elmgreen, 1987).
These findings with the FMLP chemotaxis were not observed on filter assays in
neutrophils from CD patients, whereas in other series, these neutrophils from CD
patients were found to exhibit increased chemotaxis. Similar increase in
chemotaxis was also seen for those neutrophils when Candida albicans was used
as the chemoattractant (Curran & Keighley, 1991).
An observation was made in two patients with Crohn's like colitis and
glycogen storage disease lb. These patients had decreased neutrophil chemotaxis
in vitro to FMLP, zymosan-activated serum and Escherichia coli bacteria derived
factor. This raised the hypothesis, whether the chemotaxis abnormality was the
linking factor between the colitis and the glycogen storage disease (Couper et al,
1991).
In a large scale experiment, Hermanowicz compared in vitro neutrophil
chemotaxis between controls and UC patients using either complement derivatives
or a mononuclear derived chemotactic factor (MDCF). The chemotaxis to
complement derivatives was again defective, whereas no problem was observed
with the MDCF (Hermanowicz & Nawarska, 1986).
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2.B.2.3. Chemotaxis In IBD & The Bowel Wall
The main problem with all these studies is that they address chemotaxis in
neutrophils as part of the systemic immune phenomenon and do not consider the
interactions of the neutrophils and the gut mucosa as a whole.
Lobos et al (1987) studied colonic biopsies from 3 normal controls and 9
IBD patients after they had been homogenised and showed an increase in
chemotaxis of human neutrophils for the IBD samples in a Boyden chamber.
Further analysis of the homogenates showed that chemotaxis was mostly due to a
lipid extractable substance, which with the help of reverse phase high pressure
liquid chromatography could be coeluted with LTB4. The amount of chemotactic
activity correlated well with the concentration of leucotriene B4 measured by UV
absorbance.
Kazi et al (1995), exposed normal neutrophils to rectal dialysates from
control subjects, and from patients with active and inactive UC. He then
measured reactive Oxygen species (ROS) production with chemiluminescence.
He discovered that active UC dialysates significantly increased the production of
ROS. When he stimulated the neutrophils with either FMLP or phorbol myristate
acetate (PMA), dialysates from the control group would mostly inhibit this
stimulation. In contrast, 44% of rectal dialysates from active UC could actually
potentiate the effect ofFMLP, but only 13% in the control samples could do so.
It is possible that the neutrophil as it passes through the mucosa to reach
the lumen requires the influence of separate mechanisms at each stage. This
hypothesis may be substantiated by the following observations. The first is that
neutrophils in crypt abscesses in IBD seem to contain ELAM-1. At the same time
ELAM-1 is mainly seen at the areas of the mucosa where inflammation was
present, while VCAM-1 was uniformly distributed (Koizumi et al, 1992). The
second observation is that bleeding (tissue injury as judged by faecal excretion of
chromium-51 labelled red cells) correlates with intestinal inflammation (measured
simultaneously by faecal excretion of11'indium labelled leukocytes)
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in UC and not in CD. This may indicate that the possible chemoattractant in UC is









This chapter describes the patients recruited for the study and the
methodology followed. This includes patients who underwent restorative
proctocolectomy for ulcerative colitis, indeterminate colitis, familial adenomatous
polyposis coli and other reasons which will be discussed in the following sections.
Patients characteristics are described. Details of patients who underwent
restorative proctocolectomy within six months of the study will be given in a
separate group 'early group'. The patients and methodology of the ileostomy
patients recruited will be presented at the end of this chapter.
3.A.2. Patient Recruitment
Seventy-four consecutive patients who were attending the General
Surgical Department in the Western General (12 patients) and the Royal Infirmary
of Edinburgh (62 patients) between October 1994 and March 1996 were
recruited for the study. They all had previous restorative proctocolectomy.
Five patients were excluded from the study: 1 patient was not able to
attend due to employment difficulties; 1 patient did not participate due to
travelling long distance to Edinburgh; and 3 simply refused to participate in the
study.
Seventy patients out of the 74 recruited were attending for follow up in the
Surgical Outpatient Clinic. Four, were inpatients: 1 in the Western General
Hospital and 3 in the Edinburgh Royal Infirmary.
From the 74 patients recruited, 3 had the procedure repeated twice. These
were patients with 'pouchitis' on different treatment regimes each time. Only the
1st patient-episode was used in our later analysis of results.
Three patients did not have the study completed according to the protocol.
They were excluded from further analysis. As it will be explained in detail at the
next section (see section 3.B), the protocol included the whole gut lavage, the
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patient questionnaire, pouchoscopy and biopsy. Biopsy was omitted in 1 patient
because of the high prothrombin time and the risk of bleeding, and in 2 other
patients due to patients' intolerance. Therefore, 71 patients' results were finally
included in the analysis.
Between 1/1/1991-31/12/95, from the data available for the Royal
Infirmary, 95 patients had restorative proctocolectomy under Mr DCC Bartolo.
The period of the study, in which recruitment took place for the Royal Infirmary,
was February 1995 till February 1996. From this cohort of 95 patients, 62
consecutive patients eventually did have the whole gut lavage study (65%). It
was not possible to recruit 35% of patients. The reason for this was that their
outpatient appointments were outwith the study period; alternatively a number of
patients resided outside the Lothian Region and opted for follow up in their local
Hospital.
Between 1/1/1991-31/12/95, from the data available for the Western
General Hospital, 22 patients had restorative proctocolectomy under Mr DW
Hamer-Hodges. The period of study in which recruitment took place for the
Western General Hospital was February 1995 till February 1996. February 1995
till February 1996 From this cohort of 22 patients, 12 consecutive patients
eventually did have the whole gut lavage study (55%). It was not possible to
recruit 45% of patients. The reason for this was that their outpatient
appointments were outwith the study period; alternatively a number of patients
resided outside the Lothian Region and opted for follow up in their local Hospital.
3.A.3. Patients' Characteristics
Patients' age ranged from 18.2 to 76 years (median: 41.7 years). The
male to female ratio was 40:31. The period of time between the study and the
creation of pouch ranged from 1.1 to 83.7 months postoperatively (median: 26.9;
95%CI: 22.8, 31.1 months). For those patients who had a covering ileostomy,
this time was calculated from the time they had their ileostomy closed.
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3.A.4. The Patient Groups
3.A.4.I. 'Ulcerative Colitis Group' & 'Early Group'
Sixty-one patients had restorative proctocolectomy for Ulcerative Colitis
(UC). The clinical characteristics of the UC patients will be analysed in detail in
chapter IV. The male to female ratio was 36:25. Patients' age ranged from 18.2
to 74.6 years (median: 41.9 years). The period of time between the study and the
creation of pouch ranged from 1.1 to 83.7 months postoperatively (median: 26.6
months; 95%CI: 22.5, 32.0).
Analysis of the data of these patients showed that patients who had pouch
constructed less than six months from the day of the study, had some distinct
clinical characteristics (see chapter IV). This may be related to the fact that these
patients underwent major surgery in the non-distant past from the study.
Furthermore, the prospective histological study from Apel et al (1994) indicated
that a period of six months is required for the histological changes in the pouch
mucosa to stabilise. Consequently, a subgroup of UC patients, called 'early
group' in our study, was formed and analysed separately. Five patients
constituted this group (see chapter IV). The male to female ratio was 4:1,
Patients' age ranged from 23 to 35 years (median: 36.3 years). The period of time
between the study and the creation of pouch ranged from 1.0 to 5.8 months
postoperatively (median: 3.4 months).
The remaining fifty-six patients, who had pouch constructed in greater
than six months from the date of the study, constituted the 'Ulcerative Colitis
group'. This group concluded the main body of our study (see chapter IV). The
male to female ratio was 32:24. Patients' age ranged from 18.2 to 74.6 years
(median: 42.8 years). The period of time between the study and the creation of
pouch ranged from 6.5 to 83.7 months postoperatively (median: 28.9; 95%CI:
24.4, 34.7).
3.A.4.2. 'Indeterminate Colitis Group'
Indeterminate colitis (IC) patients may have some different clinical
characteristics concerning their pouch (see chapter II; Mclntyre et al, 1995;
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Koltun et al, 1994). It was therefore, considered appropriate to study this cohort
of patients separately from the main body of UC patients. Five of 71 patients
had their pouch constructed for what it could have been characterised as IC in the
colectomy specimen. Four of them had emergency surgery: 3 for toxic megacolon
and 1 for diverticular abscess. One of the patients with toxic megacolon
developed diversion colitis in the deliinctioned rectum, before the pouch
construction. Only 1 patient had routine surgery, restoration and colectomy done
as one procedure. No patient has been operated for Crohn's Colitis.
In this group, the male to female ratio was 1:4. Patients' age ranged from
35.7 to 61.0 years (median: 43.7 years). The period of time between the study
and the creation of pouch ranged from 7.4 to 39.0 months postoperatively
(median: 26.5 months).
3.A.4.3. 'Non Inflammatory Bowel Disease Group'
Five of 71 patients had their pouch constructed for reasons other than UC:
2 patients had pouch for multiple synchronous cancers of the colon; 1 patient had
the operation for Familial Adenomatous Polyposis Coli; 1 patient had restorative
proctocolectomy for intractable constipation with previously failed ileorectal
anastomosis. The male to female ratio was 3:2. Patients'age ranged from 23.2
to 76.8 years (median: 48.2 years). The period of time between the study and the




The methods included tests already well established in the investigation of
ileoanal pouches and tests well described and established for the evaluation of
bowel disorders, i.e. the Whole Gut Lavage methodology. In the presentation of
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our methodology, the whole gut lavage process will first be described and then the
clinical procedures followed will be examined. The study of chemotactic potential
of the whole gut lavage fluid will be presented in chapter VIII.
3.B.2. 'Pilot' Study
To check the feasibility of the project, the medical and laboratory notes of
8 patients who previously had a whole gut lavage study of their pouch were
examined. During this retrospective study of the notes, the clinical problem of
each patient was considered in association with the Whole gut lavage results.
From these preliminary observations, it was evident that there were differences in
the whole gut lavage parameters that could be used to distinguish between the
various diagnostic groups.
3.B.3. Whole Gut Lavage
3.B.3.I. Introduction
Gut lavage with a polyethylene glycol (PEG) electrolyte solution has been
extensively used in clinical practice for bowel preparation prior to surgery,
colonoscopy and barium enema. When this particular methodology of performing
the gut lavage is adhered to, then the resultant whole gut lavage fluid (WGLF)
becomes a true gut perfusate (Ferguson et al, 1995). This is readily acceptable for
use in the study of mucosal immune events.
3.B.3.2. Formulation Of Lavage
The polyethylene lavage electrolyte solution, which was utilised, was
constituted by dissolving one sachet of Klean- Prep® (Forgone Ltd, Harefield,
Middx, UK) in 1 litre of tap water. Each sachet contained 59.00g of polyethylene
glycol 3350 USNF. PEG 3350 is a mixture of different sized molecules with a
mean molecular weight between 3200 and 3700. Other ingredients per sachet of
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Klean- Prep® include 5.685g of sodium sulphate anhydrous Ph Eur; 1.685g of
sodium bicarbonate Ph Eur; 1.465g of sodium chloride Ph Eur; 0.743g of
potassium chloride Ph Eur; 0.0494g of aspartame USNF.
The resultant solution can be used, if refrigerated, for up to 24 hours. The
initial content of fluid of 59 g/L PEG will reduce to 47.5 g/L at the end of the
processing phase.
3.B.3.3. The Protocol Of Whole Gut Lavage
The patient fasts overnight, and then consumes the PEG solution at a
steady rate. The rate of consumption is kept to 1 litre per hour adhering to the
protocol, supervised by an experienced research nurse (Choudari et al, 1993).
Nausea and vomiting associated with mild abdominal distension are
common side effects to this procedure. These may be counteracted by transient
delay of the lavage process, or the administration of Metoclopropamide.
Occasionally an orogastric tube is required. Care may be needed for the
maintenance of adequate environment temperature control, since the fluid is
administered chilled for palatability. This will prevent the hypothetical risk of
inducing hypothermia to the patient due to the large intake of chilled fluid.
After the passage of fluid stools, it has been shown that the concentration
of immunoglobulins in the WGLF remains stable over time (Ferguson et al, 1995).
Thus having achieved a steady state and for convenience, the first clear specimen
obtained is processed immediately as described in the following section (see
3.3.A.4. WGLF Processing)
This protocol was approved by the Medicine Subcommittee of the
Lothian's Area Ethics Research Committee.
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3.B.3.4. Whole Gut Lavage Fluid Processing
3.B.3.4a Preparation & Timing
The need for immediate processing of the WGLF cannot be over¬
emphasised, since it has been shown that immunoglobulin and other proteins in the
lavage fluid degrade rapidly. Within two hours there is a variable loss (0-62%) of
immunoglobulin IgA activity as measured by an Enzyme linked immunosorbent
assay (ELISA) technique (Gaspari et al, 1988). Furthermore, inhibitors used in
the processing have been shown not to interfere with the ELISA assays which are
subsequently performed on WGLF (Croft, 1996a).
In order to ascertain that the processing was done on time, a continuous
monitoring of the timing of lavage handling took place. This also meant that,
whenever a whole gut lavage was performed in other departments apart from the
Gastrointestinal Laboratory at the Western General Hospital, the provision of
facilities for processing on site was mandatory.
3.B.3.4b. Processing Of WGLF & Handling
20 ml of the WGLF were obtained from each patient. 10 ml of those
were filtered through a glass filter (GAF/A, Whatman, Maidstone, UK). The
following reagents were then added to 5 ml of filtered and 5 ml of unfiltered
WGLF:
i. 0.5ml of Soya bean trypsin inhibitor in PBS (SBTI).
ii. 0.28ml of sodium ethylene diamine tetracetic acid in PBS (EDTA)
iii. 0.12 ml phenyl methyl sulphonyl fluoride in 95% ethanol (PMSF)
iv. 0.06 ml of sodium azide as a preservative
v. 0.3ml of new-born calf serum (2 minutes later).
Extra samples were stored of the filtered and the unfiltered WGLF without
the processing reagents, but with the addition of 0.03 ml of sodium azide in 1.5 ml
of fluid. All specimens, processed or not, were stored in aliquots at -70°C. If
immediate storing was not possible, the specimen was transported stored in dry
ice. After processing, the PEG content of the lavage fluid was reduced from
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59g/L to 47.5g/L. As a result, the fluid stored would be 78.5% PEG-electrolyte
solution and 21.5% gut secretions (Gaspari et al, 1988).
3.B.3.5. WGLF Assays
The assays that are performed on the WGLF are described in detail in
appendix I(see section 3.C). In brief, WGLF IgG is assayed by ELISA using
affinity-purified goat anti-human IgG (North East Laboratories). The WGLF
albumin and a 1-antitrypsin are analysed by immunoturbidimetry; anti-human
albumin was supplied by the Scottish Antibody Production Unit and anti-human
a 1-antitrypsin was obtained from the Protein Reference Unit.
Haemoglobin was assayed by the HemoQuant method using as a standard
a simulated lavage fluid with PEG solution and human haemoglobin.
The elastase activity was assayed by its amidolytic effect on the substrate
pyro Glu-Pro-Val-pNA. The cytokines IL-ip and IL-8 were assayed by ELISA
kits from Cistron Biotechnology and R&D Systems.
3.B.4. Whole Gut Lavage In Ileoanal Pouches
3.B.4.I. Introduction - The Protocol
The general principles of the Whole Gut Lavage were applied to the study
of the patients with an ileoanal pouch. The patients were first seen in the
outpatient department, except from the inpatients, where the procedure was
explained to them. Those who agreed were booked for the investigation on
another day.
Patients were asked to fast overnight, but were instructed to take their
medications as usual. When they arrived at the investigation suite in the morning,
the procedure was again explained to them. The following steps were then
followed :




d. Pouchoscopy & biopsy
The results of the tests were forwarded to the referring Surgeon.
3.B.4.2. The Place & Time Of The Study
The study took place in the investigation room, GI annexe of the
Gastrointestinal Laboratory at the Western General Hospital or ward 39 and the
attached endoscopy suite at the Centre of Liver and Digestive Disorders (CLDD)
at The Royal Infirmary of Edinburgh. The inpatients were studied in the
corresponding Surgical wards of the two Hospitals.
All of the outpatient whole gut lavages were performed in a morning
session; 65% of them whilst an outpatient list of colonoscopies was taking place.
Within the time limits of this morning session the pouch patients would have
received their bowel preparation which was followed by pouchoscopy.
The five inpatients had their whole gut lavage during the hours of the early
afternoon , having had an early breakfast.
3.B.4.3. Whole Gut Lavage Adverse Effects
None of the whole gut lavages performed on the 71 patients had to be
abandoned because of ill effects to the patients. There were no serious adverse
events noted during the test, apart from transient nausea and 2 cases of vomiting.
Four patients in total required an orogastric tube: 2 patients with vomiting and 2
patients who were intolerant to the taste of the Klean- Prep® .
3.B.4.4. Whole Gut Lavage Rate In Pouch Patients
The whole gut lavage rate is defined as the amount of consumption of
PEG solution per hour, till the patient produces a clear specimen. This clear
specimen has been validated as a gut perfusate (Ferguson et al, 1995); the lavage
rate on that study was 1 litre per hour.
Data on 67 pouch patients showed that the median consumption of Klean
Prep during the lavage was 1.45 litre (1Q range: 1.25-1.8). The time required for
completion of the lavage was 75 minutes (IQ range: 55-90). In the 67 pouch
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patients studied the rate was 1.2 litre/hour (IQ range: 0.96-1.5). The initial
diagnostic category did not affect the rate of the lavage.
There seemed to be no relation of the lavage rate to the current use of
antidiarrhoeal medication, or to the dose of antibiotics, e.g. metronidazole.
3.B.5. Patient Questionnaire
A structured clinical questionnaire was used to assess the patients' clinical
status at the time of their gut lavage. This questionnaire (see appendix III, section
3 .C) was subdivided in the following 3 separate entities:
3.B.5.I. Patient Component Of The Questionnaire
Information about the following were recorded:
a. patients demographic details(age, sex)
b. preoperative diagnosis and time when the diagnosis was first
established
c. past medical and surgical history
d. family history
e. medication prior to the colectomy
f. extraintestinal manifestations
3.B.5.2. Operation Component Of The Questionnaire
The following parameters were recorded:
a. date of the colectomy, date of the construction of the pouch and
the time of closure of the covering ileostomy, if performed
b. type of pouch: J,W, or S (information obtained from case notes)
c. type of anastomosis, performance of mucosectomy or not
d. postoperative complications (dehiscence, pelvic sepsis, peritonitis
anastomotic stricture, perineal sepsis, fistula, outlet obstruction,
intestinal obstruction sexual or micturition disturbances)
e. the immediate post-operative medical treatment
f. post-operative extra-intestinal manifestations, and lastly
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g. histology report of proctocolectomy reviewed, to check for:
i. stigmata of indeterminate colitis
ii. extend of the disease
iii. evidence of dysplasia or atypia and its degree
iv. state of the appendix in the resected specimen
3.B.5.3. 'Functional' Component Of The Questionnaire
A modification of Oresland Functional criteria was used to assess the
present function of the patients' pouch and their 'best ever' function (Oresland et
al 1989; see Table 2.1 chapter II). The following were recorded:
a. bowel function during the day and night
b. faecal urgency (inability to defer defaecation for 30 minutes)
c. evacuation difficulties (straining or spending >15 minutes at the
toilet at any point during the week)
d. faecal incontinence or spotting
e. usage of protective pad (day- or night-time)
f. dietary restrictions
g. medications
h. presence of perianal soreness
j. any social handicap
At the end, a functional score was compiled both for the present time and
the time of the pouch's 'best ever' function. A score was recorded from 0-15,
where 0=best and 15=worst 'functional' result
3.B.6. Haematology & Clinical Chemistry Results
The following parameters were recorded:
a. Full Blood Count
b. Erythrocyte Sedimentation rate (ESR)
c. C-reactive protein (CRP)
d. Serum Immunoglobulin plasma levels
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The specimens were assayed either in the Western General Hospital or the
Royal Infirmary of Edinburgh Haematology, Clinical Chemistry or Microbiology
laboratories and it was included in the routine follow up of these patients.
3.B.7. Pouchoscopy & Histology
Pouchoscopy rigid or flexible was performed. Pouchoscopies were
performed in the GI Annexe for the outpatients, or at the endoscopy suite at the
CLDD, or in ward 39 at the Royal Infirmary. Patients were positioned in the left
lateral position. Written or verbal consent was obtained in all cases. The presence
of oedema, granularity, friability, loss of vascular pattern, mucous exudate and
ulceration was noted. Multiple biopsies were taken from the most inflamed area
or, if no overt inflammation was obvious, from a representative part of the pouch ,
normally posteriorly at 10 cm from the anal verge. This area was chosen since
histological findings showed this area to have the maximal changes (Shepherd et
al, 1993). Patterson biopsy forceps were used, when performing rigid
pouchoscopy, and ordinary flexible sigmoidoscopy biopsy forceps were used
during flexible pouchoscopy. Rigid scopes were used in 37% of the cases. The
pouchoscopy score was not different between flexible or rigid pouchoscopy
(p>0.05, Mann-Whitney test). It was of particular interest to notice that the
bowel preparation and subsequently the views obtained were immaculate.
The histological specimens obtained were fixed in formalin, and then sent
to the histopathology service of both the Western General Hospital and the Royal
Infirmary. Information about the patient was given to the pathologists.
3.B.8. Pouchitis Disease Activity Indices
3.B.8.I. Introduction
Various scoring systems and criteria have been proposed over the years to
assess the 'disease activity' in pouches. In this study two of them were used: the
Pouchitis Disease Activity Index (PDAI); and the Moskowitz criteria. The rational
behind this approach was that each one of these indexes had its own advantages
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and problems, but studies comparing both of them are really very few. This is
particularly true for the newer one, the Pouchitis Disease Activity Index (PDAI),
which may still require more research.
3.B.8.2. Calculation Of The PDAI
This is a composite index devised by the Mayo Clinic group (Sandborn et
al 1994). The advantage of this index is that it forms a continuum from 0-18,
while a score>7 signifies pouchitis. PDAI has already been described in chapter
II (see Table 2.4).
The clinical features of the PDAI include stool frequency, bleeding,
urgency or abdominal cramps, and fever above 37.8 C. Noticeably it is not the
absolute frequency that matters, but the difference between the current frequency
and the usual post-op frequency. The latter is rather subjective and may impose
difficulties because of that. The clinician has to rely on patient's ability to note
this difference according to their psychology at the time.
The endoscopic criteria derive 1 point each by their presence. These
include oedema, granularity, friability, loss of vascular pattern, mucous exudate,
and ulceration.
The histological criteria make no effort to record any of the chronic
inflammatory changes or the villous atrophy that sometimes is seen in pouches.
Instead they only rely on the polymorphonuclear infiltration and the ulceration.
This is because, it has been shown that symptomatology correlates with acute
inflammatory features but not with chronic inflammation (Moskowitz et al, 1986).
The score varies from 0-3 and corresponds to the scoring of Moscowitz. By
definition, for scoring purposes the most inflamed area is recorded.
At the time of the gut lavage the clinical and endoscopic score would be
filled in. The histological score is filled in later based on the actual histological
report. The PDAI was calculated in advance to avoid any bias from knowing the
gut lavage parameters.
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3.B.8.3. The Moskowitz Criteria
The Moscowitz criteria define pouchitis based on clinical, endoscopic and
histological criteria. Pouchitis is characterised by diarrhoea exceeding 6 times a
day, endoscopic score greater than 4 on a scale similar to the PDAI and
histopathological features of neutrophilia and ulceration exceeding 4 on a
histological scale. This definition also adopts an 'all or none' approach, since the
patient has to fulfil all three criteria before pouchitis is held to be present. It is
very similar to the PDAI, but follows a binary concept and not that of a
continuum. For many investigators, it has become the 'gold standard' in
diagnosis of pouchitis (Moskowitz et al 1986).
3.B.9. Statistical Analysis & PC Software
The data on this thesis were stored using the Access version 2.0 (Microsoft),
whilst statistical analysis was performed using the Minitab for Windows version 10
(Minitab statistical software) and the Excel version 5.0 (Microsoft). Graphs were
produced using Prism version 1.03 (Graphpad). The word processing was
performed with Word for Windows version 6.0 (Microsoft), whilst the references
were prepared with the Reference Manager for Windows version 6.01 (Research
Information Systems).
Some data has been presented as percentages. For descriptive statistics, the
median with the interquartile range and the range is given. Comparisons between
parameters of different groups have used the non-parametric Mann-Whitney test.
The correlation between various parameters used the Pearson correlation
coefficient and statistical significance was achieved at p<0.05. At each chapter,
the specific statistical tests used are individually referred to as applied.
3.B.10. The IBD & Ileostomy Database
The Gastrointestinal Laboratory maintains a database on patients who had a
Whole Gut Lavage. Part of this database is the IBD database which includes
anatomical characteristics of the patients, their haematological parameters of
disease activity (haemoglobin, white cell count, platelet count, C- Reactive Protein
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and ESR), their lavage parameters and clinical appraisal of their disease. This
database includes also patients with ileostomies. These data are collected in a






In this chapter the clinical, endoscopic and histological characteristics of
the patients, studied by Whole Gut Lavage, are described. The majority of the
patients had previous restorative proctocolectomy for ulcerative colitis (UC). A
few patients underwent restorative proctocolectomy for causes other than
inflammatory bowel disease (see chapter III). The study of the clinical parameters
on these patients would allow a more accurate description of patients' health state
at the time of the gut lavage. This will also allow the study of possible
connections between the various clinical and laboratory parameters.
4.2. PATIENTS & METHODS
4.2.1a. Patients
Seventy-four consecutive patients attending the General Surgical
Departments of the Royal Infirmary and the Western General Hospital of
Edinburgh were recruited for study. Five patients were excluded as described in
chapter III (section 3.2.3.1). Three more patients had to be excluded from the
analysis, because the procedure followed did not comply fully with the protocol.
Consequently 71 patients were analyzed.
There were 40 male patients and 31 female. Age ranged from 18.2 to 76.4
years (median: 41.7 years). The period of time between the study and the creation
of pouch and restoration of intestinal continuity ranged from 1.1 to 83.7 months
post operatively (median: 26.9 months).
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4.2.1b. Patient Subgroups
Patients were subdivided according to the original diagnosis for which the
pouch was created. From the 71 patients, 61 patients had UC, 5 had
indeterminate colitis (IC), and 5 patients other diseases - refractory constipation,
familial adenomatous polyposis coli (FAP) or multiple synchronous cancers (see
chapter III: 'Non-IBD group', sections 3.A4.1, 3.A.4.2, 3.A.4.3).
In the early stages of the study another subdivision became apparent.
Several patients were identified who had recent pouch construction for UC. A cut
off point of six months was taken to separate this 'early' group, which
corresponded to the differences in the clinical profile observed for these patients.
This group numbered five patients.
The characteristics of these groups are described in Table 4.1. The 'non
IBD' group included 2 patients who had their colectomy for multiple synchronous
cancers, one patient with FAP, and two who had their colectomy for intractable
constipation, after failure of ileorectal anastomosis. The term 'median time post
pouch' is defined as the time between my study and patient's intestinal continuity
restoration after pouch surgery.
4.2.2a. Methods
Detailed analysis of the protocol followed is given in chapter III. In brief,
the patients attended for whole gut lavage study. During this time medical
history was obtained via a prestructured questionnaire (see chapter III, section
3.B.5). Blood tests were performed for full blood count, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), and serum immunoglobulins
(IgG, IgM, IgA). This was followed by pouchoscopy and biopsy as described
earlier (see chapter III, sections 3.B.6, 3.B.7, 3.B.8).
4.2.2b. Statistical Analysis
The statistical analysis of the results used the median values; 95%
confidence interval (CI) or range; the Pearson correlation coefficient and its p
value; the non-parametric Mann-Whitney U test for unpaired comparison of
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Table 4.1. Demographic details of the 71 patients with ileoanal pouch who
participated in the study. The pouch groups included: the 'UC group' - patients who
underwent restorative proctocolectomy for ulcerative colitis; the 'early group' -
patients who underwent restorative proctocolectomy for UC within the last 6 months;
the 'IC group' - patients who underwent restorative proctocolectomy for
indeterminate colitis; and the 'non IBD group' - patients underwent restorative
proctocolectomy for causes other than IBD. There were no significant differences in
gender or age between the four groups. No significant difference in the median time
post pouch was seen between the three groups - 'UC', 'non IBD', and IC.









4 1 36.3 (23.0-35.0) 3.4
IC group
(n = 5)
1 4 43.7 (35.7-61.0) 26.5
non IBD group
(n = 5)
3 2 48.2 (23.2-76.8) 25.6
The results are expressed as: median values (range).
Age is expressed in years.
Median time post pouch is expressed in months.
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observations; % with Yates correction with Odds Ratio (OR) or Relative Risk




Demographic characteristics are given in detail in Table 4.1.
4.3.A.2. Family History
Ten patients (16%) in the UC group had a family history of IBD. Eight of
these (13%) had first degree relatives with IBD. Nineteen patients had family
history of other diseases (see Table 4.2). Nine patients had a family history of
bowel, lung, cervical, liver and breast cancer. There was only one patient in IC
group with family history of IBD, but four patients had significant family history
(see Table 4.2). There was no family history of IBD in the 'non IBD' group.
There was no difference in the family history of IBD between UC and IC cases.
UC and IC patients had similar number of first degree relatives with IBD. There
was no difference in ischaemic heart disease (IHD) or cancer family history
between IBD and 'non IBD' patients.
4.3.A.3. Age At Presentation & Age At Colectomy
The age of presentation in the various groups is presented in Figure 4.1.
Seven patients (10.4%) with IBD were older than 50 years at presentation. In the
'non IBD' group the presentation age was variable. This may be explained by
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Table 4.2. The family history of the various pouch groups. The family history
includes first degree relatives with IBD and details of other family history.
Pouch groups FHx of IBD IBD in 1st degree relatives Other FHx
9 cancer
UC group 9 7 4 asthma
(n = 56) 2 diabetes
3 IHD
(17 patients)*
'early' group 1 1 1 IHD
(n - 5) (1 patient)*
1 cancer j
IC group 1 1 1 asthma




non IBD 0 0 1 Spina Bifida
group 1 IHD
(n = 5) (3 patients)*
'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis;
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months;
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
* overall number of patients with other family history.
FHx: family history.
74
the heterogeneity of the 'non IBD' group: 2 patients had severe constipation,
one had FAP, and the two older patients had multiple synchronous carcinomas.
The time between presentation and colectomy is presented in Figure 4.2.
This ranged from 1.0 month to 29.6 years (median: 6.9 years) in the UC patients.
In the IC patients, this ranged from 1.0 month to 19.5 years (median: 8.6 years).
4.3.A.4. Past Medical & Surgical History
Six patients had previous tonsillectomy in the UC group (10%) and one in
the 'non IBD' group. The incidence of appendicectomy in the UC group was
5%. Anal and pelvic surgery (hysterectomy or sterilization) was present in 5%
and 3% respectively of patients. Three patients had a history of urolithiasis (5%).
There were a variety of chest complaints, hypertension, IFID and psychotic
problems related to steroids in one case (see Table 4.3).
4.3.A.5. Medications Pre-Colectomy
The drug regimens followed immediately pre-colectomy in the UC group
are shown in Table 4.4. Preoperative treatment was unknown in three patients.
One patient was on no treatment except iron, due to drug intolerance. 17% of
patients were on high dose of systemic steroids (more than 30mg Prednisolone or
equivalent). All of these patients had pancolitis and all but two had emergency
operations. 41% of patients were on steroids and 5-aminosalicylates (ASA). This
group included a fair number of left colitis (35%) and only 54% required
emergency operations. 24% of patients were maintained only on 5-ASA.
Although 79% of these patients underwent elective surgery, 43% exhibited a
degree of dysplasia, including one case of Dukes C cancer. Finally, 14% of
patients were maintained on azathioprine. This included one patient who has
been on azathioprine alone, the rest being on combination of azathioprine and
steroids. 75% of patients underwent elective operations. 25% of this group had










UC UC 'early' IC non IBD
Figure 4.1. Patients' age at presentation of diagnosis of the various pouch groups:
'the 'UC group' - patients who underwent restorative proctocolectomy for ulcerative
colitis; the 'early group' - patients who underwent restorative proctocolectomy for
UC within the last 6 months; the 'IC group' - patients who underwent restorative
proctocolectomy for indeterminate colitis; and the 'non IBD group' - patients









UC UC 'early' IC non IBD
Figure 4.2. The period between presentation and colectomy in the various pouch
groups expressed in years.
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Table 4.3. The past medical history in the various pouch groups. The surgical,
medical and psychiatric history are presented separately.






























'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis;
'early group' - patients with restorative proctocolectomy for UC within the last 6 months: included in UC group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
The number of patients suffering from the given disease is presented in brackets(*)
PMHx: past medical history
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Table 4.4. Precolectomy treatment in the pouch groups. Patients were treated with
local or systemic steroid medication with or without 5-aminosalicylates. A number of

















'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis;
'early group' - patients with restorative proctocolectomy for UC within the last 6 months: included in UC group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;
'non E3D group' - patients underwent restorative proctocolectomy for causes other than D3D




The incidence of extraintestinal manifestations in the preoperative period
was 21.3%, whereas in the postoperative period was 11.4% (de novo 3.2%).
Sclerosing cholangitis was noted in 5% of the patients; eye problems such as
iridocyclitis or uveitis in 3% (2 patients). Joint pathology appeared more common
in 21%. There was one case of pyoderma gangrenosum and two of erythema
nodosum (5%). The patient with pyoderma gangrenosum and one of the patients
with the erythema nodosum continued to have the problem postoperatively. In
the IC group only one patient had previous history of polyarthralgia. See Table
4.5.
4.3.A.7. The Histology Of Resected Colon Specimens
The histological aspects in the 'non IBD' group confirmed the initial
diagnosis for which the colectomy was performed. There were two patients with
synchronous cancers, two patients were treated surgically for intractable
constipation and one patient with FAP. The histopathology in the UC and IC
groups is described below.
4.3.A.7a Histological Extent Of Disease
The extent of the disease was based on the histology report of the resected
specimen. In the UC group 22% of patients had left sided colitis. All IC patients
had pancolitis. See Table 4.6.
4.3.A.7b Backwash Ileitis
The incidence of backwash ileitis is shown in Table 4.7. The incidence in
the UC group was 17%. In the IC group only 1 patient was noted to have
backwash ileitis.
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Table 4.5. The extraintestinal manifestations in the various pouch groups. There
was no difference between UC & IC groups at the total number of EIM exhibited.









1 liver function abnormalities
'early' group
(n=5)





'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis;
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months;
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;
'non IBD group' - patients underwent restorative proctocolectomy for causes other than EBD




Table 4.6. The extent of disease is presented in the pouch groups*. There was no
significant difference in the extent of disease between the two groups.
Pouch groups Pancolitis Left sided colitis
UC group 47 13
(n=60)
IC group 5 0
(n=5)
Table 4.7. The presence of backwash ileitis in the UC and IC pouch groups*. There
was no significant difference between the two groups.
Pouch groups Backwash Ileitis Unknown
UC group 8 15
(n=60)
IC group 1 1
(n=5)
*'UC group' - patients who underwent restorative proctocolectomy lor ulcerative colitis;
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months;
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;
Record of extent of disease or presence of backwash ileitis was missing in one patient's histological report,
though other histological features were described.
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Table 4.8. The state of the appendix in the various pouch groups*.
Pouch groups Normal Inflamed Fibrotic Unknown
UC group (n=60) 5 14 14 28
IC group (n=5) 0 1 3 1
non IBD group (n=5) 2 0 0 3
Table 4.9. The presence of dysplasia, atypia and cancer in resected specimen in
various pouch groups*. There was no significant difference between the groups.
Pouch groups Dysplasia Atypia Ca colon Normal Unknown
UC group (n=60) 12 6 1 36 5
IC group (n=5) 0 1 0 3 1
: non IBD group (n=5) 1 0 2 2 0
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients with restorative proctocolectomy for UC within the last 6 months: included in UC
group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
Record of the state of appendix & presence of atypia was missing in one patient's histology report
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4.3.A.7c The Pathology Of The Appendix
The appendix in the resected specimen was frequently abnormal, showing
either inflammation, or fibrosis. This was also true for patients who had left sided
colitis. The state of the appendix was not described in some patients. The
occurrence of the various abnormalities relating to the pathology of the appendix
is given in Table 4.8.
4.3.A.7d Dysplasia In The Resected Specimens
Eighteen per cent of the resected specimens showed evidence of dysplasia.
The incidence for observed cancer was 1.5%.
4.3.A.8. The Operative Characteristics
The operations were performed at the Royal Infirmary of Edinburgh and
the Western General Hospital in Edinburgh. There were few patients who had
their initial colectomy elsewhere in Scotland but referred for restoration or
follow up in Edinburgh. The operations were performed by Messrs. Bartolo (57
patients), Hamer-Hodges (11 patients), Smith (1 patient) and Keenan (1 patient).
All the patients but one had their operation in NHS hospitals.
4.3.A.8a Number Of Emergency Or Urgent Operations
Forty-five per cent of the operations in the UC group were performed as
urgent (see Table 4.10). There was no higher complication rate of urgent
operations compared with elective procedures. As expected, fewer restorative
proctocolectomies were performed as one stage operations, when the colectomy
was urgent (x2= 8.6, p=0.003).
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Table 4.10. The number of urgent colectomies performed in each pouch group*.
There was no significant difference between the UC & IC groups.
Pouch group Number of Urgent Colectomies
UC group (n=61) 28
IC group (n=5) 4
non IBD group (n=5) 2
Table 4.11. The number of operations before restoration of continuity in the various
pouch groups*. There was no significant difference between the groups.
Pouch groups One stage Two stages Three stages
UC group (n=61) 30 26 (3 with IRA) 5
IC group (n=5) 1 4 (no IRA) 0
non IBD group (n=5) 2 3 (2 with IRA) 0
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients with restorative proctocolectomy for UC within the last 6 months: included in UC group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
IRA : ileorectal anastomosis
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Table 4.12. The distribution of'J', 'W' and 'S' pouch in the various pouch groups*.
The characteristics in the presenting disease were similar in both subgroups with 'J' or
'W' pouches, in the UC group.
Pouch groups 'J' pouch 'W' pouch 'S' pouch
UC group (n=61) 48 12 1
IC group (n=5) 5 0 0
non IBD group ( n=5) 4 1 0
Table 4.13. Number of complications in the various pouch groups. There was no
significant difference between the groups.
Pouch groups Co c, c2 c3 Ctotal C/patient
UC group (n=61) 29 21 9 2 32 (52%) 0.7
IC group (n=5) 1 2 2 0 4 (80%) 1.2
non IBD group (n=5) 2 2 1 0 3 (60%) 0.8
'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients with for UC within the last 6 months: included in UC group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
Complications: C; Co =no complications, Ci =1 complication, C2 =2 complications, C3=3 complications,
C4totai=total number of complications (percentage); C/patient: complication per patient
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Table 4.14. The various complications in the pouch groups*.






Complications (total) 47 6 4
Dehiscence anastomosis 5 0 0
Pelvic sepsis 1 0 0
Anastomotic stricture 9 1 0
Peritonitis 4 0 1
Perineal sepsis 1 0 o ;
Fistula 2 1 0
Outlet obstruction 2 0 0
Intestinal obstruction 9 1 0
Other 16 3 3
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients with restorative proctocolectomy for UC within the last 6 months: included in UC group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
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4.3.A.8b Operative Stages
Forty-nine per cent of the patients had their operation as one stage
procedure, in the UC group. As mentioned above, patients who underwent
emergency colectomies tended to have staged operations in order to create and
then close a covering ileostomy. Since the creation of an ileostomy may present
with complications of its own, patients who had staged operations had higher
postoperative complication rate (x2=8.292, p=0.004). See Table 4.11.
4.3.A.8c Pouch Design
The type of pouch constructed is given in Table 4.12. As seen most of the
pouches were of 'J' configuration, the 'W' being only 18% of the total. There
was only one 'S' pouch. All but one of the 'J' pouches was constructed by the
same surgeon, and all but one of the 'W' pouches was performed by another
surgeon. The suture material differed between 'J' and 'W' pouches, the 'J'
pouches were all stapled, and the 'W' were hand sewn with non absorbable suture
material (Neurolon™).
The pouch anal anastomosis in most of the cases in both 'J' and 'W'
groups were made by the use of the staple gun, slightly smaller diameter usually
for the 'W' pouches. In spite of this, the incidence of anastomotic stricture in the
UC group did not reach significance (p=0.051). Only two anastomoses were hand
sutured among the 71 patients. Equally only three mucosectomies of the anal cuff
were performed.
4.3.A.8d Postoperative Complications
The following Tables 4.13 and 4.14 describe the number and type of
complications noted in the various groups. For the 71 patients there were 5 cases
of anastomotic dehiscence, 1 case of pelvic sepsis, 10 cases of anastomotic
stricture, 5 cases of peritonitis, 1 case of perineal sepsis, 3 cases of fistulas, 2 cases
of outlet obstruction and 10 cases of intestinal obstaiction.
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Other complications included:
a) UC firoup: 2 pulmonary embolism, 3 wound infections, 1 incisional hernia, 2
chest infections, 1 acute psychosis, 3 persistent postoperative anaemia.
b) IC group: 1 dyspareunia, 1 suprapubic abscess (fistula related).
c) 'Non IBP' group: one bile leak from synchronous cholecystectomy.
Surgery was needed in 21 of the 71 total patients (re-operation rate: 29%
of the patients; 37% of their complications). In the UC group as mentioned
above, patients with staged operations were inclined to have more complications.
4.3.A.9. 'Functional' Characteristics
The 'functional' characteristics for each patient were recorded using a
questionnaire (see chapter III, appendix III). These were collated to produce a
functional score (Oresland et al, 1989).
4.3.A.9a Bowel Activity
Figures 4.3 and 4.4 show the bowel activity during the day and during the
night for the various groups. For the UC group, the bowel activity during the day
ranged from 2 to 15 (median: 6.0; 95%CI: 5.5, 6.5). The bowel activity during
the night ranged from 0 to 7 (median: 1.0; 95%CI: 1.0, 1.5).
4.3.A.9b Pouch Related Difficulties:
Urgency - Difficult Evacuation - Perianal Discomfort - Social Handicap
Table 4.15 summarizes the above mentioned aspects of function in all three
groups. Since the UC group is the largest, it serves as the principle reference.
UC Group
A. 15% (9 patients) exhibited urgency (15%). Patients were unable to withhold
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Figure 4.3. Daytime bowel activity in the various pouch groups: 'UC group' -
patients who underwent restorative proctocolectomy for ulcerative colitis; the 'early
group' - patients who underwent restorative proctocolectomy for UC within the last 6
months; the 'IC group' - patients who underwent restorative proctocolectomy for
indeterminate colitis; and the 'non IBD group' - patients who underwent restorative
proctocolectomy for causes other than UC. The transverse lines in the figure depict





















Figure 4.4. Night time bowel activity in the various pouch groups: 'UC group' -
patients who underwent restorative proctocolectomy for ulcerative colitis; the 'early
group' - patients who underwent restorative proctocolectomy for UC within the last 6
months; the 'IC group' - patients who underwent restorative proctocolectomy for
indeterminate colitis; and 'non IBD group' - patients underwent pouch surgery for
causes other than 1BD. The transverse lines in the figure represent the means of the
values observed. There was no significant difference between the groups.
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Table 4.15. Pouch related difficulties in the various pouch groups*.
Pouch groups UC group IC group non IBD group
(n=61) (n=5) (n=5)
Urgency 9 2 3
Evacuation difficulties 13 2 2
Perianal discomfort 34 2 3
Diet change 23 2 2
Social handicap 16 0 3
The apparent higher urgency in the non IBD group, due to small numbers, did not reach statistical significance
(with Yates correction). It resulted from the inclusion of two patients who had their operation for severe
constipation.
Table 4.16. Incontinence and pad use in the various pouch groups*. There was no
significant difference between the three groups.
Pouch groups Day soiling Night soiling Pad/day Pad/night
UC group (n=61) 12 14 6 10
IC group (n=5) 1 1 1 0
non IBD group (n=5) 0 0 0 0
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients with restorative proctocolectomy for UC within the last 6 months: included in UC group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non 1BD group' - patients underwent restorative proctocolectomy for causes other than IBD
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Table 4.17. The presence of bleeding per pouch as perceived by the patient in the
various pouch groups: 'the 'UC group' - patients who underwent restorative
proctocolectomy for ulcerative colitis; the 'IC group' - patients who underwent
restorative proctocolectomy for indeterminate colitis; and the 'non IBD group' -
patients underwent restorative proctocolectomy for causes other than IBD.
Pouch groups Bleeding per pouch
UC group* (n=61) 17
IC group (n=5) 0
non IBD group (n=5) 2
Table 4.18a. Drug use in the various pouch groups.
Pouch groups Codeine Loperamide Metronidazole Steroid
UC group* (n=61) 16 11 15 6 j
IC group (n=5) 1 0 1 0
non IBD group (n=5) 1 0 0 0
*
- the 'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
included in the UC group.
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*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients with restorative proctocolectomy for UC within the last 6 months: included in UC group
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non H3D group' - patients underwent restorative proctocolectomy for causes other than H3D
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B. 21% were recorded as having evacuation difficulties, i.e. straining at anytime
during the week, or a toilet 'session' lasting more than 15 minutes.
C. 56% complained of perianal discomfort.
D. 38% of patients admitted a change in diet after surgery.
E. 26% considered that the pouch function interfered with their activities and life
style.
4.3.A.9c Pouch Continence & Use Of Incontinence Pads
The patients were asked whether they experienced any episodes of faecal
incontinence for solid or liquid stool, or had troublesome soiling, either during the
day or at night (Table 4.16). In the UC group, the incidence of faecal incontinence
was 20% during the day and 23% during the night. 8% of the UC patients were
incontinent during both day and night. Only 10% and 16% of the patients would
rather wear a protective pad for the day or for the night as a permanent
precaution. Patients with daytime soiling require a day pad, but may not require a
night pad (x2=8.168, p=0.0004). On the contrary, patients who complain of night
soiling, require protective pads for both day and night (x2=8.168, p=0.004 and
X2=20.223, p=0.0001 respectively).
4.3.A.9d Bleeding Per Pouch
Seventeen (28%) UC patients reported some form of pouch bleeding. No
IC patients and only 2 in the 'non IBD' group complained of pouch bleeding (see
Table 4.17).
4.3.A.9e Medications
The most commonly used drugs were antidiarrhoeal such as codeine and
loperamide, and metronidazole. Only one patient was on Lomotil. Some patients
also used methylcellulose and steroids either local or systemic.
94
In the UC group, 26% were on codeine (Table 4.18a). In the same group,
18% were on loperamide. Only two patients were using both drugs.
Metronidazole was used in 25% of patients. The rest of the medications are
mentioned in the Tables 4.18a and 4.18b. Systemic steroid treatment was
reported in two cases: for treatment of florid postoperative extraintestinal
manifestation (pyoderma gangrenosum) in one case, and for active pouchitis in
another case. One patient used local steroids for treatment of pouchitis. One
patient in the 'early' group required systemic steroids for erythema nodosum. In
the same group, two patients used local steroids.
4.3.A.9f 'Functional' score
The 'functional' score used was an adaptation of the Oresland scoring
system (Oresland et al, 1989). Figure 4.5 shows the distribution of scoring
between the groups.
4.3.A.10. Haematological Parameters
4.3.A. 10a Blood Haemoglobin
The systemic haemoglobin values of the patients studied are presented in
Figure 4.6. The haemoglobin in the UC group ranged from 91.0 to 169.0 g/L
(median: 142.0; 95%CI: 136.0, 147.0). The haemoglobin in the 'early' group was
lower (median: 111.5g/L; p=0.034, ). Female patients had lower haemoglobin
compared to men in the UC group (p=0.00001).
4.3.A. 10b Total White Cell Count (WCC)
The systemic WCC in the UC group ranged from 9.1X109/L to
15.5X109/L (median: 7.0X109/L; 95%CI 6.1, 7.9). This was not statistically
different from the WCC in the 'early' group. See Figure 4.7.
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Figure 4.5. The Oresland functional criteria comparing the various pouch groups*.
The apparent higher score (i.e. worse function) of the non IBD subgroup is not
statistically significant compared to the rest of the groups.
*'UC group' - patients who underwent restorative proctocolectomy lor ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
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Figure 4.6. Estimation of blood haemoglobin (Hb) in pouch patients' groups*.
There was a statistically significant difference between the 'early' and the rest of the
UC group (p=0.034).
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis






















Figure 4.7. Estimation of systemic white cell count (WCC) in pouch patients'
groups*.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
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Figure 4.8. Estimations of systemic platelet (pit) counts in pouch patients' groups"
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis

















UC C 'early IC non IBD
Figure 4.9. Estimation of Erythrocyte Sedimentation Rate (ESR) in pouch patients'
groups*.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
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4.3.A. 10c The Platelet Count
The platelet counts of the groups examined are presented in Figure 4.8. In
the UC group the platelet count ranged from 137X109/L to 588X109/L (median:
278X109/L; 95%CI: 251, 308).
4.3.A.10d The Erythrocyte Sedimentation Rate (ESR)
The ESR measured in the UC group ranged from 1 to 85 mm/hr (median:
9 mm/hr; 95%CI: 6, 12). Female patients in the UC group had higher ESR
compared to males (p=0.0174). The ESR values for the UC patients, 'early', IC
and 'non IBD' groups are presented in Figure 4.9.
4.3.A.10e The C-Reactive Protein (CRP)
All groups, except for the 'early', had a median within the normal
reference range for the laboratory (CRP: 1.5 mg/dL). Maximum value recorded in
the UC group was 10.8 mg/dl. The CRP in the 'early' group was significantly
higher compared to the UC group (p=0.0343).
4.3.A.10f Combination Of Systemic Inflammatory Markers
In the UC group, one patient with long-standing 'active pouchitis' had all
four parameters high (WCC, Platelet count, ESR, CRP). Another patient with
'pouchitis' had all but the WCC raised. Three patients had high WCC and platelet
count: one patient had 'pouchitis', one pyoderma gangrenosum, and the third one
had a perianal abscess. Lastly, 6 patients with raised platelet count, 3 with raised
platelet count and ESR and one with raised WCC had normal clinical parameters.
One patient with raised ESR and CRP was on Metronidazole (200mg daily) and
ASA.
4.3.A.10g Serum Immunoglobulins
Figures 4.10, 4.11, 4.12 demonstrate the serum IgA, IgG and IgM of the
patients studied. The median values for the UC group were: IgA: 2.5 g/L
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Figure 4.10. Serum Immunoglobulin-A (IgA) in pouch patients'groups*.
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Figure 4.11. Serum Immunoglobulin-G (IgG) in pouch patients'groups*.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis;
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months;
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;









Serum IgM in pouch patients
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Figure 4.13. The endoscopic score in the various pouch groups*.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months;
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
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Table 4.19. Anal cuff inflammation at endoscopy and pouch anal anastomosis'
stenosis in the various pouch groups*. The apparent differences are not statistically
significant.









Table 4.20. The pouch biopsy neutrophilia and ulceration in the various pouch
groups*. There was no significant difference between the groups.
Pouch groups Mild neutrophilia Severe neutrophilia Ulceration
UC group (n=56) 27 12 12
'early' group (n=5) 1 2 2
IC group (n=5) 2 1 1
non IBD group (n=5) 1 1 0
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis;
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months;
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis;
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
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(95%CI: 2.3, 2.9); IgG: 12.3 g/L (95%CI: 11.3, 13.2); IgM 1.2g/L (95%CI: 1.0,
1.4). These values correlated with each other, best correlation seen between IgA
and IgG (r=0.40, p=0.0053).
4.3.A.11. Endoscopic Characteristics At Pouchoscopy
4.3.A.lla Endoscopic Score
The presence of inflammatory stigmata was noted during endoscopy, with
a severity score on a scale 1-6. Figure 4.13 shows the distribution of the scores in
the various groups. In the UC group the median score was 2 (95%CI: 1.5, 2.5).
4.3.A.llb Anal Cuff Inflammation & Pouch Anal Stenosis
The incidence of anal cuff inflammation is presented in Table 4.19. This
incidence in the UC group was 27%. The incidence of pouch anal stenosis was
16% in the UC group.
4.3.A.12. Pouch Biopsy Characteristics
The results described in the following sections refer to the most severely
affected pouch biopsies.
4.3.A.12a Biopsy Neutrophilia & Ulceration
Some degree of neutrophilia was present in 70% of the patients in the UC
group. The presence of ulceration was noted in 24% of UC patients. See Table
4.20.
4.3.A.12b Chronic Inflammation & Villous Atrophy
Chronic inflammation of pouch biopsies was present in 70% of the UC
cases (see Table 4.21). Villous atrophy was present in 28% of the UC patients
(see Table 4.21).
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Table 4.21. Chronic inflammation and villous atrophy in biopsies from the pouch
mucosa in the various pouch groups*. There was no significant difference between
the groups.










27 12 11 5
'early' group
(n=5)
2 1 2 0
IC group
(n=5)
4 1 1 0
non IBD group
(n=5)
4 0 1 0
Table 4.22. The number of previous episodes (none, one, several) of 'pouchitis like
symptoms' as perceived by the pouch patients, presented in the various pouch
groups*.
Pouch groups None One Several
UC group (n=56) 23 21 12
'early' group (n=5) 4 1
IC group (n=5) 4 1
non IBD group (n=5) 5
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
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Figure 4.14. The pouchitis disease activity index (PDA!) presented in the various
pouch groups*.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than EBD
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4.3.A.13. Pouchitis History & Disease Activity
4.3.A. 13a Previous Episodes Of 'Pouchitis Like Symptoms'
The number of previous episodes that could loosely be described as
'pouchitis' are given in Table 4.22. In total there was a history of such
'symptoms' in 59% of UC patients. This incidence is much higher than the
incidence of 'pouchitis' as seen in literature (Sandborn, 1994). The difference
however is that the above figure reflects the more subjective view of the patient's
in regard to his own symptoms and has no objectivity of a medical assessment.
The frequency of these episodes after the restoration of intestinal continuity was
0.3 per year (95%CI: 0.0, 0.5) in the UC group. However, the frequency of such
episodes in UC patients with one previous episode was higher at 0.8 (95%CI: 0.4,
1.3; p<0.05).
4.3.A. 13b The Pouchitis Disease Activity Index (PDAI)
Figure 4.14 shows the PDAI score in the patients' groups. Since this is a
composite index of disease activity with clinical, endoscopic and histological
features many of its determinants appear to correlate with its value as expected. In
the UC group, 12 patients had PDAI greater or equal to 7, and could be named as
having 'pouchitis', according to the PDAI definition.
4.3.A.13c The Moskowitz Criteria Applied To The UC Group
The description of pouchitis by Moskowitz requires diarrhoea more than 6
times per day, endoscopic stigmata of inflammation (greater than four), and
histopathological evidence of ulceration and polymorphonuclear infiltration
(greater than four). By Moskowitz definition, 7 out of 56 UC pouch patients
appeared to have 'pouchitis'.
According to the PDAI, 12 patients were considered as having 'pouchitis'.
This discrepancy between PDAI and Moskowitz criteria stems from the fact that
in four out of five patients the endoscopy or biopsy was not severe enough to
fulfill the Moskowitz criteria. This was the case despite the presence of severe
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symptoms and especially urgency. The fifth patient clinically and endoscopically
had very convincing pouchitis, but the biopsy result was essentially normal. This
may have been influenced by concomitant treatment with metronidazole prior to
the study.
If we 'define' the above seven patients as 'positive' for the Moskowitz
criteria and the five patients who had high PDAI but did not fulfill the Moskowitz
criteria as 'negative', the 'positive' group had more neutrophilia and ulceration in
the biopsy (x2=5.182; p=0.023). They had less urgency (x2=8.4; p=0.04) and
less evacuation difficulties (x2=5.182; p=0.023). They also seem to have less
history of pouch bleeding (x2=4.286; p=0.038). It is thus clear that the emphasis
in the 'negative' group was more on the symptoms and less on the biopsy results,
which may explain the differences.
4.3.A.14. The Clinical Diagnosis
The diagnosis of 'pouchitis' or otherwise was made at each patient's
interview depending on symptoms and endoscopic appearance (see Table 4.23).
19% of UC patients were described as having 'pouchitis'. This figure is within the
expected rate of occurrence for pouchitis in the literature (Sandborn, 1994). A
few patients seemed to have had other pouch problems (20%). These included:
pouch anal stenosis (4%), severe anal cuff inflammation (3%), and perianal sepsis
(1%).
A distinct group of patients had poor pouch function with no obvious
evidence of pouch inflammation (12%). Two of these patients had been operated
on for severe constipation. One of these is an epileptic on imipramine and the
other one seems to have a psychosomatic behaviour problem. One patient in this
group had ileal resection with corresponding short bowel syndrome. Another one
was on antidepressants, before and after surgery. A third is again on
antidepressants, but has an abnormally large pouch with deficient emptying. The
fourth one has alcohol problems. The fifth patient, did not ever tolerate the
medical treatment for IBD, only maintained on iron supplements. A month later
after the study she developed a perianal abscess and
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Table 4.23. The clinical categories at the time of the study, according to
investigator's assessment.
Pouch groups* Normal Pouchitis Previous pouchitis Other
UC group (n=56) 27 7 11 11
'early' group (n=5) 1 3 1
IC group (n=5) 4 1
non IBD group (n=5) 3 2
Table 4.24. The UC pouch patients with extraintestinal manifestations (EIM) and UC
patients with no EIM. The PDAI score and WCC were higher in UC patients with
EIM.
UC pouch patients with EIM (n=17) no EIM (n=39) p-value
PDAI 5 (1-9) 3(1-11) 0.0024
WCC (X 109/L) 7.5 (4.1- 15.5) 5.8 (3.6- 11.8) 0.049
The results are expressed as median (range), the Mann-Whitney test is uused for comparison.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
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later a pouch anal fistula. The sixth patient had endoscopic evidence of apparent
mucosal prolapse.
If we compare the clinical diagnosis of 'pouchitis' with the diagnosis
according to the Moskowitz criteria, then 4 patients were thought clinically to
have pouchitis and were 'positive' for the Moskowitz criteria. Three more
patients were thought clinically to have pouchitis (they also had high PDAI), but
were 'negative' for the Moskowitz criteria.
4.3.B. Correlations Of Patients' Characteristics
4.3.B.l. Medications Pre-Colectomy
The percentage of routine colectomy was significant lower in the systemic
steroid group (described in section 4.3.A.5.) compared to the other treatment
subgroups (x2= 4.677; p=0.031). The complication rate was similar between these
treatment subgroups even when they were stratified for urgency or the elective
nature of the operation.
4.3.B.2. Extraintestinal Manifestations
In the UC group there were similar characteristics in the functional and
other parameters of the pouch, except for the blood WCC. This was higher in the
patients who had a history of extraintestinal manifestations, though still within the
reference range (p=0.049). The PDAI score was also higher in these patients
(p=0.0024). Patients with 'pouchitis' according to the Moskowitz criteria had
more extraintestinal manifestations (x2=22.57; p=0.0001). Patients with a history
of extraintestinal manifestations appeared to have more chronic inflammation
manifested at their pouch biopsy (x2=l1.563; p=0.001). See Table 4.24.
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4.3.B.3. The Histology Of Resected Colon Specimens
4.3.B.3.I. Histological Extent Of Disease
In the UC group patients with pancolitis had significantly higher incidence
of dysplasia in their resected specimens (x2=5.122, p=0.024). All the other clinical
features were similar in the two groups of left colitis or pancolitis. The incidence
of pancolitis was not significantly different in patients with 'pouchitis' according
to the Moskowitz criteria compared to the rest of the UC patients.
4.3.B.3.2. Backwash Ileitis
The clinical features were similar in those with backwash ileitis as
compared to the rest of the UC patients. Patients with backwash ileitis however,
described more 'pouchitis like symptoms', when interviewed (x2=4.952, p=0.026,
RR= 3, 95%CI: 1.1, 7.8).
4.3.B.4 The Operative Characteristics
4.3.B.4.I. Number Of Urgent Operations & Operative Stages
Patients who were operated on as emergencies did not seem to differ in
their pre and postoperative characteristics. One difference emerging was that
patients with evidence of villous atrophy in their pouch biopsy, had the colectomy
performed as a routine (x2=6.017, p=0.014, OR= 5.2, 95%CI: 1.9, 13.8). Patients
who had a single operation, appeared to have more villous atrophy in their
pouches (x2=5.204, p=0.028, OR= 4, 95%CI: 1.16, 14).
4.3.B.4.2. Pouch Design
The endoscopic score, the incidence of villous atrophy and PDA! were
higher in the 'J' group compared to the 'W' pouches in UC patients. These
differences however could have been caused by the bias of patient selection in
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each group. When the same parameters were examined in the pouches thought to
be absolutely normal, indeed there was no difference. The 'J' group had more
mucosal neutrophilia compared with the 'W' group (x2=4.754, p=0.029, OR=
10.8, 95%CI: 1.2, 9.1). The functional score was comparable in the two pouch
designs. See Table 4.25.
4.3.B.4.3. Postoperative Complications
Patients with a history of complications, had lower pouchoscopy score
(p=0.0150) and less villous atrophy (x2=6.740, p=0.01). See Table 4.26.
4.3.B.5. The 'Functional' Characteristics
4.3.B.5.I. The Bowel Activity
In the UC group, the bowel activity during the day correlated to the bowel
activity during the night (r=0.29, p=0.0298). The dose of metronidazole also
correlated with the bowel activity during the day (r=0.36, p=0.0071), whereas the
codeine dose related to the night bowel activity (r=0.33, p=0.0052). The dose of
Loperamide also correlated with the night bowel activity (r=0.42, p=0.0016).
Patients with previous 'pouchitis like symptoms' appeared to have more nocturnal
evacuations (r=0.37, p=0.0052). Systemic parameters of inflammation, WCC,
platelet count and ESR related to the night bowel activity (r=0.37, p=0.0061;
r=0.39, p=0.0061 ; & r=0.44, p=0.0029 respectively).
4.3.B.5.2. Pouch Related Difficulties:
Urgency - Difficult Evacuation - Perianal Discomfort - Social Handicap
A. Patients with urgency had more evacuation difficulties (x2=6.292,
p=0.012) and more day and night soiling (x2=7.418, p=0.007). These patients
admitted to more social difficulties because of the pouch (x2=7.418, p=0.007). In
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Table 4.25. UC patients with 'J' and 'W' pouch and their platelet count. The
platelet count was higher in the UC patients with 'J' pouch.
UC pouch patients 'J' pouch (n=21) 'W' pouch (n=5) p-value
Platelet count (X 109/L) 275 (153-535)* 199 (169-248)* 0.033
Table 4.26. The pouchoscopy score in UC patients with & without complications.








pouchoscopy score 2 (0-4)* 2 (0-6)* 0.015
Table 4.27. The ESR, PDAI and bowel activity in UC pouch patients with and
without urgency. Patients with urgency had higher ESR, PDAI, bowel activity per
day and night.
UC pouch patients With urgency Without urgency p-value
(n=14) (n=42)
ESR 21 (2-52)* 6(1-85)* 0.0438 ;
PDAI 6 (1-11)* 3 (1-9)* 0.0091
Day bowel activity 10(7-15)* 6 (2-10)* 0.0001
Night bowel activity 2 (0-7)* 1 (0-5)* 0.0116
*The results are expressed as median (range). Mann-Whitney test is used for comparison.
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these patients the ESR and PDA! were higher (p=0.0438 and p=0.0091,
respectively). These patients had more bowel actions both during the day and
night (p=0.0001 and p=0.0116, respectively). See Table 4.27.
B. Patients with evacuation difficulties appeared to have more bleeding per
pouch (x2=13.71, p=0.0.000; OR= 11.24, 95%CI: 3.1, 39.5).
C. Patients with perianal discomfort used more night pads (x2=4.879,
p=0.027), and changed their diet after surgery (x2=4.424, p=0.036). The
pouchoscopy score was higher (p=0.0297). See Table 4.28.
D. Patients who changed their diet post surgery had a higher pouchoscopy
score (p=0.0252). See Table 4.29.
E. Patients who complained that the pouch interfered with their life, had a
higher bowel activity both during the day and night (p=0.0196 and p=0.0125
respectively). These patients also reported more frequent 'pouchitis like
symptoms' (p=0.0006). The pouchoscopy score and PDAI were higher
(p=0.0069 and p=0.0001, respectively). See Table 4.30.
4„3.B.5.3. Pouch Continence & Use Of Incontinence Pads
The social functioning of patients was adversely affected by incontinence
problems both during the day and night (x2=7.405, p=0.007; x2=10.567, p=0.001,
respectively). Patients who complained of day incontinence, were on higher doses
of Metronidazole (p=0.0354). See Table 4.31.
4.3.B.5.4. Pouch Bleeding
Patients with pouch bleeding had higher pouchoscopy score and PDAI
(p=0.014; p=0.003, respectively). See Table 4.32.
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Table 4.28. The pouchoscopy score in UC pouch patients with & without perianal
discomfort. This score is higher in UC patients with perianal discomfort.





pouchoscopy score 2 (0-6)* 1 (0-5)* 0.0297**
Table 4.29. The pouchoscopy score in UC pouch patients with and without diet
change. The score is higher in the UC patients with change of diet.
UC pouch patients With change of diet
(n=22)
No change of diet
(n=34)
p-value
pouchoscopy score 3 (0-6)* 2 (0-4)* 0.0252**
Table 4.30. The bowel activity, 'pouchitis like' symptoms, pouchoscopy score,
PDAI and metronidazole dose in UC pouch patients with & without social handicap
due to pouch. All these parameters were higher in UC patients with social handicap.





Day bowel activity 8 (2-15)* 1 (2-10)* 0.0196**
Night bowel activity 2 (0-5)* 1 (0-7)*
**
0.0125
pouchitis like symptoms 3 (0-6)* 1 (0-6)* 0.0006**
pouchoscopy score 3 (0-5)* 2 (0-6)*
**
0.0069
PDAI 7(3-11)* 3 (1-9)* 0.0001**
Metronidazole mg/day 200 (0-1200)* 0 (0-600)* 0.0006**
*The results are expressed as median (range). ** Mann-Whitney test is used for comparison.
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Table 4.31a. Treatment with Metronidazole in UC pouch patients with and without
incontinence. Patients with incontinence required higher doses of treatment.





Metronidazole mg/day 100 (0-1200)* 0 (0-600)*
**
0.0354
Table 4.31b. The PDAI in UC pouch patients with and without night incontinence.
The index is higher in UC patients with nocturnal incontinence.





PDAI 6(1-11)* 3 (1-9)*
**
0.0030
Table 4.32. The pouchoscopy score, PDAI, and serum IgM in UC pouch patients
with and without bleeding per pouch. These parameters are higher in UC patients
with bleeding per pouch.





pouchoscopy score 3 (0-6)* 2 (0-4)* 0.0102**
PDAI 6 (2-11)* 3(1-8)* 0.0030**
Serum IgM g/L 1.46 (0.27-2.80)* 1,08 (0.73-3.07)* 0.0093**
* The results are expressed in median (range). ** Mann-Whitney test is used for comparison.
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4.3.B.5.5. Medications
The doses of codeine and loperamide correlated with the night bowel
activity (r=0.33, p=0.0151; r=0.42, p=0.0016, respectively).
Patients on metronidazole, as mentioned earlier, had more urgency
(x2=5.34; p=0.021), more evacuation difficulties (x2=4.041; p=0.045), more day
soiling (x2=5.091; p=0.0354) and consequently worse social handicap (x2=12.055;
p=0.001). The dose of metronidazole correlated with the day bowel activity
(r=0.36, p=0.0071), the pouchoscopy score (r=0.37, p=0.0049) and the number of
previous 'pouchitis like episodes' reported by the patient (r=0.30, p=0.025).
There was a positive correlation between the metronidazole dose and the CRP
(r=0.63, p<0.0001).
4.3.B.5.6. The 'Functional' score
The blood haemoglobin was inversely related to the 'functional' score, i.e.
the worst the score the lowest the haemoglobin (r=0.45, p=0.0013). Platelet
count, ESR and CRP correlated to the 'functional' score (r=0.32 p=0.024; r=0.45,
p=0.0021; r=0.43, p=0.005, respectively). The 'functional' score correlated with
the pouchoscopy score (r=0.40, p=0.0019). The medications codeine,
loperamide, and metronidazole were also related to this functional score (best
figure for metronidazole: r=0.46, p=0.0004). Patient's age at the time of pouch
construction also seemed to influence the functional score (r=0.40, p=0.0019).




ESR was relating both to serum IgG and IgM, (r=0.31, p=0.0460 and
r=0.36, p=0.0216 respectively).
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There was also a correlation between serum IgA and the age of colitis
presentation and colectomy (r=0.31, p=0.0335). Serum IgG correlated with the
number of previous episodes of 'pouchitis like symptoms' reported by the patient
(r=0.31, p=0.0387).
Serum IgM was higher in patients who gave a history of pouch bleeding
(p=0.0093). See Table 4.32.
4.3.B.7. Endoscopic Characteristics At Pouchoscopy
4.3.B.7.I. The Endoscopic Score
The pouchoscopy score correlated with the nocturnal bowel activity
(r=0.36, p=0.0071) and the 'functional' score (r=0.40, p=0.0019). Patients who
complained of perianal discomfort had a higher pouchoscopy score (p=0.0297; see
Table 4.28). Patients who had to change their diet or had a considerable social
handicap also had a higher pouchoscopy score (p=0.0252; p=0.0069, respectively;
see Tables 4.29, 4.30). Patients who complained of pouch bleeding, had a higher
score (p=0.014; see Table 4.32). The 'J' pouch seemed to have more
inflammation, but if we looked at the ones that were clinically normal pouches,
there was no difference.
The pouchoscopy score related to the total WCC and the platelet count
(r=0.32, p=0.0244 and r=0.29, p=0.0487 respectively). There was also
correlation with CRP (r=0.45, p=0.0031).
The use of metronidazole was related again to the pouchoscopy score
(r=0.37, p=0.0348). The number of previous episodes of 'pouchitis like
symptoms' reported by the patient related to the pouchoscopy score (r=0.28,
p=0.0348). Patients with villous atrophy appeared to have higher pouchoscopy
scores (p=0.0435). See Table 4.33.
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4.3.B.7.2. Anal Cuff Inflammation & Pouch Anal Stenosis
Patients with anal cuff inflammation had higher pouchoscopy score
(p=0.0113) and complained more of perianal discomfort (x2=5.034, p=0.025).
See Table 4.34.
4.3.B.8. Pouch Biopsy Characteristics
4.3.B.8.I. Biopsy Neutrophilia & Ulceration
Patients with biopsy neutrophilia had a higher incidence of family history
of IBD (x2=4.278, p=0.031; RR= 1.56; 95%CI: 1.04, 2.30). These patients had
fewer complaints of urgency (x2=4.561, p=0.033). Their pouch biopsy was
characterized by high incidence of ulceration (x2=7.88, p=0.01) and villous
atrophy (x2==5.439, p=0.02). Consequently patients with biopsy neutrophilia had a
higher PDA! score (p=0.0221). See Table 4.35a.
Patients with severe biopsy neutrophilia appeared to have some extra
features. They tended to have more routine surgery (x2=4.278, p=0.039), a higher
WCC (p=0.0417), higher serum IgG (p=0.027) and IgM (p=0.0083). These
patients appeared to have modified diet more often (x2=4.801, p=0.029). See
Table 4.35b.
Patients with ulceration had more neutrophilia at their biopsy (x2=6.109,
p=0.014) and more villous atrophy (x2=5.654, p=0.018).
4.3.B.8.2. Chronic Inflammation & Villous Atrophy
A. Patients with chronic inflammation in the pouch biopsy had a history of
extraintestinal manifestations some time in their life (x2=35.073, p=0.001; RR=
1.8; 95%CI: 1.2, 2.5).
UC patients with severe inflammation had a higher platelet count
(p=0.0290), increased incidence of previous episodes of 'pouchitis like
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Table 4.33. The pouchoscopy score in UC pouch patients with and without villous
atrophy in pouch biopsy. The score is higher in UC patients without villous atrophy.







pouchoscopy score 2 (0-6)* 2(1-6)*
**
00oo
Table 4.34. The pouchoscopy score in UC pouch patients with and without anal










pouchoscopy score 2(1-6)* 2 (0-6)*
**
0.0113
* The results are expressed as median (range). ** Maim-Whitney test is used for comparison.
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Table 4.35a. The PDA! in UC pouch patients with and without neutrophilia in
pouch biopsy. The index was higher in patients with pouch neutrophilia.





PDAI 4(1-9/ 2(1-11/ 0.0221**
Table 4.35b. The white cell count (WCC), serum IgG and IgM in UC pouch
patients with and without severe neutrophilia in pouch biopsy. Patients with severe
pouch neutrophilia had higher WCC and immunoglobulins.





WCC in X109/L 8.2 (6.0-11.4) 5.9 (3.6-15.5) 0.0253
serum IgG g/L 13.60 (9.80-19.20) 11.35 (6.80-21.00) 0.0227
serum IgM g/L 1.35 (0.31-3.07) 1.08 (0.27-2.80) 0.0083
* The results are expressed as median (range). **Mann-Whitney test is used for comparison.
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Table 4.36. The platelet count, 'pouchitis like' symptoms, pouchoscopy score,
pouchitis disease activity index (PDA!) and the dose of metronidazole in UC pouch
patients with and without severe chronic inflammation in pouch biopsy. The platelet
count was higher in patients with severe chronic inflammation in pouch biopsy. These
patients with severe chronic inflammation in pouch biopsy had a higher pouchoscopy
score and PDAI. The dose of Metronidazole was significantly greater in patients with
severe chronic inflammation as compared to those with mild chronic inflammation in
pouch biopsy.







Platelet count X109/L 331 (206-585)* 249 (137-588)* 0.0290**
Pouchitis like symptoms 1 (0-6) 1 (0-6) 0.0190
Pouchoscopy score 3 (1-6) 2 (0-6) 0.0220
PDAI 7(1-9) 3(1-11) 0.0036
Metronidazole in mg/day 100 (0-600) 0 (0-1200) 0.0030
* The results are expressed as median (range). **Mann-Whitney test is used for comparison.
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symptoms' (p=0.0190), worse pouchoscopy score (p=0.0022) and were on higher
doses of metronidazole (p=0.03), had a higher PDA1 score (p=0.0036). These
patients gave also a history of pouch bleeding (x2=6.629, p=0.01) and admitted
to a change in their diet (x2=8.167, p=0.004). Their anal cuff was more
commonly inflamed (x2=4.197, p=0.041). In these patients there was no
significant dysplasia reported in the resection specimen (x2=4.006, p=0.046).
B. Patients with villous atrophy had mostly routine colectomies
(X2=6.077, p=0.014), with restoration performed at the same session as the
colectomy (x2=5.240, p=0.022), and accordingly with a lower total number of
reported complications. They also seemed to belong mostly to the 'J'
configuration pouch; the latter difference was not sustained when the pouches that
were clinically normal were looked at separately. The biopsy neutrophilia in these
patients with villous atrophy was higher (x2=5.028, p=0.025) and their
pouchoscopy score was worse (p=0.0435). See Table 4.33.
4.3.B.9. Pouchitis History & Disease Activity
4.3.B.9.I. The PDAI
The PDAI in UC patients correlated with the bowel activity during the day
and during the night (r=0.39, p=0.0033 and r=0.42, p=0.0016 respectively). There
was a correlation with the Oresland functional score (r=0.59, p=0.0001). Patients
with urgency had a higher PDAI (p=0.0091). Similarly patients with a history of
night soiling had a higher index (p=0.0030). Patients with pouch bleeding history
also had a higher index (p=0.0006). The 'J' pouches appeared initially to have
higher scores; however the latter observation did not substantiate when only the
absolutely normal 'J' or 'W' pouches were studied. The dose of metronidazole
was related to the PDAI (r=0.39, p=0.0023). See Tables 4.27, 4.31b, 4.32.
The PDAI correlated with the ESR, CRP and serum IgM (r=0.36,
p=0.0138; r=0.50, p=0.0008; r=0.32, p=0.0264, respectively).
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The endoscopic score correlated with the PDAI (r=0.81, p<0.0001).
Patients with minimal neutrophilia in their pouch biopsy had lower PDAI
(p=0.0221). Moreover patients with severe chronic inflammation in the pouch
biopsy had a higher PDAI score (p=0.0036). See Tables 4.35a and 4.36.
4.3.B.9.2. The Clinical Diagnosis
Urgency in our series seemed to relate to 'other' problems (x2=19.989,
p=0.001; RR= 7; 95%CI: 2.7, 17.6) and less to active pouchitis. The recent onset
of nocturnal soiling pointed towards active pouchitis (x2=8.366, p=0.04; RR= 4.3;
95%CI: 1.1, 15.4). Another characteristic of active pouchitis appeared to be the
change in diet that patient undertook to alleviate symptoms (x2=8.464, p=0.038;
RR= 10.2; 95%CI: 2.0, 50.0). This observation does not seem to be true for
patients who were categorized as having 'other' problems. Patients who belong
to this 'other' group complained more frequently of perianal discomfort
(X2=8.366, p=0.04; RR= 7.5; 95%CI: 1.5, 36) and were characterized by
anastomotic stenosis (x2=l 1 252, p=0.013; RR= 7.5; 95%CI: 1.5, 36).
4.4. DISCUSSION
Patients with extraintestinal manifestations appear to have increased
incidence of pouchitis (Lohmuller et al, 1990). In this study, patients with
'pouchitis' according to the Moskowitz criteria also had a higher incidence of
extraintestinal manifestations. Furthermore, patients with extraintestinal
manifestations had a higher PDAI score, a higher systemic WCC and more
evidence of chronic inflammation in the pouch biopsy.
Backwash ileitis was not associated with pouchitis in our study. This is in
agreement with previous reports (Gustavsson et al, 1987).
Patients who were operated for pancolitis did not appear to have higher
incidence of pouchitis. This is in agreement with reports from Samarasekera and
colleagues (1995), although Mikkola et al (1995) reported a higher incidence of
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pouchitis in patients with previous pancolitis. In our study, patients with pancolitis
had a higher incidence of dysplasia. This may be due to the bias of selection for
colectomy. It may also be explained on the basis of more detailed histological
analysis of specimens or as a true characteristic of IBD as seen in Scotland.
Another hypothesis may be that this group represents patients with either more
severe disease or disease of longer duration.
Patients who have been operated as routine and consequently had a single
stage operation had a higher incidence of villous atrophy in their pouch biopsies.
One hypothesis may be that patients had been on different immunomodulation
treatment before surgery, which in turn may have affected epithelial kinetics.
Indeed patients on high doses of steroids were hardly ever operated at a single
stage, whereas those on combinations of 5-ASA and steroids or 5-ASA alone
were very often operated routinely at one stage.
There were no differences in functional score between the two designs
groups of'J' and 'W\ The biopsy neutrophilia was higher in the 'J' pouch. This
may be explained by either a stronger reaction to staples than to suture material
used. On the other hand, the period of epithelial conduct with the antigenic faecal
load may be different and thus may influence the mucosal neutrophilia? It is
noticeable however, that one study has described a higher incidence of pouchitis in
'J' pouches (Hewett et al, 1995), whereas another study reported no difference in
the evacuation parameters of either design (Heppel et al, 1987).
The overall complication rate of 52.4% is comparable to the one reported
earlier (Fazio et al, 1995, Grotz & Pemberton, 1993).
The day and night bowel activity, as expected, related to each other and to
the use of antidiarrhoeal medications. Urgency, since it is one of the constitutes of
the PDAI, not surpisingly related to this index. Furthermore the patients who
complained of urgency seemed to exhibit more neutrophilia in their biopsy, and
had a higher ESR. These patients also had increased bowel activity during day
and night. If mucosal neutrophilia in pouches is associated with luminal
neutrophilia, then urgency and diarrhoea are to be expected in pouches, whenever
there is mucosal neutrophilia. This was shown in experiments by Madara et al
who showed that luminal neutrophilia is a cause of diarrhoea (1991)
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Pouchoscopy score related to the history of bleeding per pouch. This may
signify the importance of the inclusion of bleeding in the calculation of the PDAI.
The functional score was related to many parameters as expected, mainly to its
own functional constituents and parameters of inflammation, systemic or
endoscopic. This is probably due to the influence of bowel frequency onto score
calculation, and the importance of this frequency as an indicator of pouch
inflammation.
The pouchoscopy findings correlated with some of the systemic indices of
inflammation: platelet count, WCC and CRP. This was not the case for the ESR
or serum immunoglobulins. This once again indicates the difficulty in relating
mucosal immune reactions and their histopathology to systemic immunity. It also
discloses the need for a test to examine separately gut mucosa immune events.
The endoscopic score was higher in patients on metronidazole; presumed
treatment for pouchitis?. The association of the pouchoscopy score and villous
atrophy may be explained since inflammation in the pouch mucosa, almost
invariably involves a degree of villous atrophy. The observation that the
endoscopic score was higher when there was anal cuff inflammation may signify
that there is no real water-shed between anal cuff and pouch mucosa. In this case
inflammation may spread from one area to the other. On the other hand, the
amount of anal cuff left behind may at times inadvertently be much more in
quantity than the operators estimate.
The histological characteristics, neutrophilia, ulceration and villous atrophy
seemed to relate to each other. This may indicate that the immune cascade
responsible diversified as to produce separate phenomena.
The calculation of the PDAI takes into consideration many parameters:
clinical, endoscopic, histological. Accordingly the index associates with many of























Figure 4.15. The functional score according to the clinical diagnosis in various
groups. These include the 'normal' group - UC patients with normal pouches; the
'pouchitis' group - UC patients with pouchitis according to the Investigator's
diagnosis; the 'pr ptis' group - UC patients with previous episodes of pouchitis; and
the 'other' group - UC patients with pouch anal stenosis, anal cuff inflammation,
perineal sepsis and pouch dysfunction. The functional score was higher in the
'pouchitis' group as compared to 'normal' group. However, the functional score was
















normal pouchitis pr ptis other
Figure 4.16. The pouchoscopy score in the various groups. These include the
'normal' group - UC patients with normal pouches; the 'pouchitis' group - UC
patients with pouchitis according to the Investigator's diagnosis; the 'pr ptis' group -
UC patients with previous episodes of pouchitis; and the 'other' group - UC patients
with pouch anal stenosis, anal cuff inflammation, perineal sepsis and pouch
dysfunction. The score was higher in the pouchitis group as compared to the
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Figure 4.17. The pouchitis disease activity index (PDAI) in the various groups.
These include the 'normal' group - UC patients with normal pouches; the 'pouchitis'
group - UC patients with pouchitis according to the Investigator's diagnosis; the 'pr
ptis' group - UC patients with previous episodes of pouchitis; and the 'other' group -
UC patients with pouch anal stenosis, anal cuff inflammation, perineal sepsis and
pouch dysfunction. The PDAI was higher in 'pouchitis' group as compared to the
'normal', 'pr ptis' and 'other' groups.
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Clinical Remarks: The Diagnosis of Pouchitis
Patients with ileoanal pouches share clinical features which are complex
yet interrelated. It may be advantageous to the difficulties in establishing the
diagnosis of pouchitis by using the information collected from the pouch patients.
The functional score, comprehensive as may be, only enables the
separation of the normal pouches from the inflamed ones or the 'other' group
(Figure 4.15). It cannot distinguish between the rest of the groups. For a more
accurate assessment, endoscopic examination is needed, which will record
inflammation, and obvious anastomotic stenosis (Figure 4.16). The use of the
PDAI may be advantageous for the confirmation of the clinical status and a more
objective means of comparing between patients (Figure 4.17).
The use of the routine systemic haematological parameters was not
particularly helpful. Only the WCC and the platelet count were significantly
higher in the acute pouchitis group compared to the normal group (p=0.0448;
p=0.0287 respectively). ESR fluctuated irrespective of the clinical category.
It is already known that pouchitis is more common in patients with
previous extraintestinal manifestations of IBD. This was also true in our series.
In conclusion, a previous history of extraintestinal manifestations,
symptoms of urgency, nocturnal soiling, recent change in diet, bleeding,
perianal discomfort along with the endoscopic inflammatory appearances
were the most helpful clinical indices for the detection of the pouch pathology and
thus the establishment of pouchitis in the outpatient setting. The addition of
information from the pouch biopsy, especially the presence of neutrophilia aided
the diagnosis. The PDAI is a useful tool for confirmation of the correctness of the
clinical impression. It has to be said however, that in our study there was not
always agreement between the PDAI and the Moskowitz criteria. This
disagreement urges the development of a more objective test of inflammation, as it
will be discussed in chapter VI.
♦ ♦♦
CHAPTER V







The whole gut lavage method has been used to categorise IBD patients
according to their disease activity irrespective of the diagnosis of UC or CD. It is
of interest to know however, whether the amount of substances retrieved in the
WGLF is proportional to the length of the gut. One may expect that WGLF
features may differ depending on the source if this is small bowel, large bowel or
both. If either is true, then ileostomy patients may be perhaps expected to have
lower levels of some of the substances measured in the lavage fluid. It is
important to address the above mentioned questions before detailed analysis on
the use of WGLF in ileoanal pouches is undertaken.
This chapter therefore, presents the study of whole gut lavage
methodology in various groups of patients. This includes the study of patients
with IBD and intact colon. Measurements obtained from these patients during
whole gut lavage are compared to those obtained from patients with ileostomies.
This will form the basis for the study of patients with ileoanal pouches using the
whole gut lavage.
5.2. MATERIALS & METHODS
5.2.1. IBD & Ileostomy Patients - IBD Database
Data on the whole gut lavage procedure and analysis have been collected
prospectively since 1991. This led to creation of a database in the GI laboratory
at the Western General Hospital. The GI laboratory database allowed the
identification of groups of IBD patients with intact colon and patients with
ileostomies. These groups were fully characterised with both clinical and systemic
parameters of inflammation. Table 5.1 describes the UC patients, whereas CD
patients are described in Table 5.2. Ileostomy patients are presented in Table 5.3.
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Table 5.1 Demographic details of patients with ulcerative colitis and intact colon.
Extent of Disease M : F Age* j
Pancolitis (n=17) 8: 9 35.5 (11-72) years
Distal colitis (n=24) 11:13 43.0 (23-83) years
Table 5.2 Demographic details of patients with Crohn's disease and intact colon.
Extent of Disease M : F Age*
Oral disease (n=2) 1: 1 33.5 (22-45) years
Small bowel disease (n=36) 15:21 41.0 (13-77) years j
Ileocolonic disease (n=l 1) 5: 6 21.0 (16-63) years
Colonic disease (n=25) 15:10 43.0 (21-78) years
Anorectal disease (n=25) 13:12 44.0 (10-90) years
Table 5.3 Demographic details of patients with ileostomies.
Disease M : F Age*
Ulcerative Colitis (n=l) 0: 1 71 years
Crohn's Disease (n=21) 4:17 38 (21-77) years
*The results are expressed in median (range). M:F male to female ratio.
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5.2.2. The Pouch Patients
Sixty-six consecutive patients attending the General Surgical Departments
of the Royal Infirmary and the Western General Hospital of Edinburgh were
recruited for the study. Five patients were excluded as described in chapter III.
Three more patients had to be excluded from the analysis, because the procedure
followed did not comply fully with the protocol. In all three, although a gut
lavage and pouchoscopy were performed, a biopsy was not taken because patients
could not tolerate the procedure.
Consequently 66 patients were analysed. Male to female ratio was 37:29.
Age ranged from 18.2 to 76.4 years (median: 40.7 years). The period of time
between the study and restoration of intestinal continuity (i.e. closure of the
ileostomy) ranged from 1.1 to 83.7 months postoperatively (median: 28.1
months). From the 66 patients, 61 patients had UC and 5 had IC. The
characteristics of these groups are described in Table 5.4. The 'median time post
pouch' is defined as the time between the gut lavage study and the restoration of
intestinal continuity after pouch surgery. For our study the 61 UC patients and
the 5 IC patients were combined in one IBD group and later compared with the
ileostomy group.
5.2.3. Protocol & Assays Of WGLF
Bowel preparation with polyethylene glycol (PEG) electrolyte solution is
commonly used prior to colonoscopy, barium enema or surgery. The
immunological study of the bowel with the WGLF methodology is as follows: the
patient fasts overnight, and then consumes the PEG solution at a steady rate. The
rate of consumption is kept to one litre per hour adhering to the protocol as
described by Choudari et al (1993).
It has been shown that after the passage of clear fluid, the concentration
of immunoglobulins in the WGLF remains stable over time (Ferguson et al 1995).
Because of the steady state thus achieved and for convenience, the first clear
specimen obtained is processed immediately as described earlier in chapter III
(see section 3.3.A.4. WGLF Processing).
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Table 5.4 Demographic details of the 66 pouch patients who participated in the study.
There were no significant differences in age or sex between the groups (ulcerative colitis,
indeterminate colitis).
Pouch groups M : F Age* Median time post pouch
UC (n = 61) 36:25 43.0 (18.2-74.6) years 26.6 months
IC (n = 5) 1: 4 43.7 (35.7-61.0) years 26.5 months
Table 5.5 WGLF parameters in IBD patients with intact colon (n=140)
WGLF Parameter Median (range)
IgG 18 (0-781) pg/ml
Albumin 20.5 (0-470) pg/ml
al-Antitrypsin 8 (0-190) pg/ml
Haemoglobin 4.75 (0-106) pg/ml
Granulocyte Elastase <0.039 (<0.039-2.742) pkat/1
IL-ip 31.6 (0-4031) pg/ml
IL-8 6.15 (0-785.10) pg/ml
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This protocol was approved by the Medicine Subcommittee of the
Lothian's Area Ethics of Research Committee. The assays that are performed on
the WGLF are described in detail in the appendix I, chapter III. In this chapter
however, IL-8 is measured in filtered and processed samples. It has been shown
that filtration gives lower values of detectable IL-8
5.2.4. Statistical Analysis
The statistical analysis of the results used the median values and
range; the non-parametric Mann-Whitney U test for unpaired comparison of
observations; and the Kruskal-Wallis test for comparison of three groups. P
values less than 0.05 were considered significant.
5.3. RESULTS
5.3.1. WGLF-IBD Patients With Intact Colon
Whole gut lavage parameters measured in these patients included IgG,
albumin, a 1-antitrypsin, haemoglobin, neutrophil granulocyte elastase (GE) and
the cytokines IL-1 (3 and IL-8. Table 5.5 presents an overview of the values
obtained in IBD patients with intact colon.
5.3.2. WGLF - Ileostomy Patients
Table 5.6 presents the values obtained in ileostomy patients. Two patients
were excluded because of missing IgG result.
5.3.3. WGLF - Pouch Patients
Table 5.7 presents the WGLF parameters in the pouch patients recruited.
Table 5.6 WGLF parameters in ileostomy patients (n=20)
WGLF Parameters Median (range)
IgG 6 (0-117) pg/ml
Albumin 13 (0-140) pg/ml
al- antitrypsin 4.5 (0- 24) pg/ml |
Haemoglobin 2.8 (0- 9) pg/ml |
Granulocyte elastase <0.039 (<0.039- 0.1500) pkat/1
IL-ip 0.6 (0.0-228.2) pg/ml
IL-8 15.4 (0.0-116.4) pg/ml ;
Table 5.7 WGLF parameters in IBD ileoanal pouch patients (n=66)
WGLF Parameters Median (range)
IgG 4 (1 - 69) pg/ml
Albumin 9 (1 - 71) pg/ml
al- antitrypsin 4.5 (1 - 44) pg/ml
Haemoglobin 3 (0.4-199) pg/ml
Granulocyte elastase <0.039 (<0.039- 0.5110) pkat/1
IL-lp 6.56 (0.0-143.15) pg/ml
IL-8 17.95 (0.0-164.52) pg/ml
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5.3.4. Comparisons Between Patients' Groups
Studies performed in the Gastrointestinal laboratory showed that the level
of WGLF IgG>10pg/ml characterises active IBD (Brydon et al, 1993). This
appears to be a more objective means of distinction between active and inactive
disease (Acciuffi et al, 1996). Accordingly the patients with IBD and intact colon,
patients with ileostomy and patients with pouch were separated into two groups of
'active'(WGLF IgG>10p.g/ml) or 'inactive' disease (WGLF IgG<10pg/ml). The
groups of'active' disease were compared with the groups of'inactive' disease as
the Latin Square principle dictates.
All parameters (IgG, albumin, a 1-antitrypsin, haemoglobin, IL-ip, IL-8
and GE) were significantly higher in 'active' disease as compared to the 'inactive'
disease. WGLF haemoglobin and GE measured in ileostomy patients however,
were not different in 'active' compared to 'inactive' disease groups.
5.3.4.1. Inactive Disease: WGLF IgG< lOpg/ml
Table 5.8 presents the values and the comparisons between IBD patients
with intact colon (IBD, n=49), ileostomy patients (n=12) and with pouch patients
(n=49). All patients had 'inactive' disease with WGLF IgG<10pg/ml.
WGLF albumin was lower in the ileostomy patients compared to the pouch
and IBD with intact colon (see Figure 5.1). WGLF IL-8 however, was lower in
patients with intact colon compared with ileostomy and pouch patients devoid of
colon (see Figure 5.2).
5.3.4.2. Active Disease: WGLF IgG>10|rg/mI
Table 5.9 describes the values obtained in active disease in IBD patients
with intact colon (n=92), ileostomy patients (n=8), and pouch patients (n=17). All
patients had WGLF IgG >10p.g/ml.
WGLF IgG and a 1-antitrypsin were higher in IBD patients with intact
colon (see Figures 5.3 and 5.4). There was no difference in GE between pouch
and ileostomy. However, when pouch patients on metronidazole were excluded,
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Table 5.8 The WGLF parameters in the various groups of patients, all with inactive
disease (WGLF IgG<10p.g/ml). The albumin and IL-ip were higher in the pouch group
as compared with the ileostomy group. The haemoglobin was lower, whereas IL-8 was











IgG ftg/ml 4 (1-9) 3 (0-6) 3 (1-8)
Albumin pg/ml 7 (0-26) 4 (0-14)* 8 (1-25)* 0.0183
A1AT pg/ml 3 (0-18) 1 (0-10) 3 (1-15)







IL-ip pg/ml 2.6 (0-931) 0.0 (0-17)* 4.2 (0-143.15)* 0.0157
IL-8 pg/ml 0.6 (0-14.4)* 7.5 (0.0-15.4) 5.9(0.0- 42.8)* 0.0001
The results are presented in median (range). Mann-Whitney test was used for comparison of groups of patients,
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IBD intact colon ileostomy pouch
Figure 5.1 The WGLF albumin in IBD patients with intact colon, ileostomy, or ileoanal
pouch with inactive disease (WGLF IgG<10|ag/ml). Highest values observed in pouch
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IBD intact colon ileostomy pouch
Figure 5.2. The WGLF IL-8 in IBD patients with intact colon, ileostomy, or pouch with
inactive disease (WGLF IgG<10p,g/ml). The WGLF IL-8 was higher in patients with
pouch and ileostomy. Transverse lines represent the mean values.
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Table 5.9 The WGLF parameters in the various groups of patients with active disease
(WGLF IgG>10pg/ml). The WGLF IgG, A1AT, IL-ip were higher in the IBD group as
compared with the pouch group; the A1AT and Hb were higher in the IBD group as












IgG pg/ml 39.5 (10-781)* 18.5(10-117) 17(11-69)* *0.0019
Albumin pig/ml 46(2-470) 66(15-140) 29(12-71)
A1AT pg/ml 17(0-190)*+ 8.5(3-24)+ 8(4-44)*
+0.0254
*0.0126






















The results are presented as median (range). The Mann-Whitney test was used for comparison.
'*',<+' represent the significant results and their p value
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Comparison in 'active' disease
of IBD patients with intact












■ IBD intact colon
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IBD intact colon ileostomy pouch
Figure 5.3. The WGLF IgG in IBD patients with intact colon, ileostomy and pouch; all
with active disease (WGLF IgG>10pg/ml) Highest values are observed in IBD intact
colon patients. Transverse lines represent the mean values.
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Figure 5.4. The WGLF A1AT in IBD patients with intact colon, ileostomy and pouch;
all with active disease (WGLF IgG>10p.g/ml). Highest values are observed in IBD intact
colon patients. Transverse lines represent the mean values.
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GE in pouch patients appeared to be higher than in ileostomy patients (p-0.0412).
5.5. DISCUSSION
The WGLF methodology has been used in IBD to categorise patients
according to the disease activity as expressed by the gut protein loss of WGLF
IgG (Choudari et al 1993). A cut off point of lOpg/ml is used to separate active
from inactive IBD. This cut off point was used in this study for all groups
examined: IBD intact colon, ileostomy and pouch.
All the WGLF parameters differ in active compared with inactive disease,
both in IBD patients and in pouch patients. Similar results were obtained for the
ileostomy patients, except for haemoglobin and GE. This study shows that
WGLF methodology may be readily applicable in patients with ileoanal pouches
and ileostomies. Furthermore, the levels of substances measured in ileoanal
pouches and ileostomies do not differ from those measured in patients with intact
colon.
In active disease, as defined by WGLF IgG > 10p.g/ml, the WGLF IgG and
al-antitrypsin were higher in patients with intact colon. This may indicate that the
phenomenon of protein loss in active inflammation may be different in the
presence of intact colon compared to those devoid anatomically of colon.
Albumin, however, is not different in the various groups. This may be due to the
fact that albumin may decay more readily in whole gut lavage samples (Gaspari et
al, 1988).
In inactive disease, albumin was lower in ileostomies, with similar levels
between patients with intact colon or pouches. Albumin in ileoanal pouches is
high. This may indicate that the pouch function as a capacitance organ influences
the observed protein loss in pouches. On the other hand the levels of IL-8 were
equally high both in ileostomies and in pouches; this may indicate that the
mechanisms of luminal cytokine release or even of luminal chemotaxis for
neutrophils differ between colon and small bowel. Differences in luminal
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neutrophilia between small bowel and colon have already been described (Handy
et al, 1996). Neutrophilia is seen mainly in active UC and Crohn's colitis but not








The use of whole gut lavage to obtain information about immunological
aspects of UC patients and ileostomies has been explored earlier (see Chapters III
& V). Studies in inflammatory bowel disease (IBD) showed that disease activity
in IBD may be associated with gut protein loss (O'Mahony et al, 1991). The
WGLF methodology allows measurement of immunoglobulins such as IgG (see
Chapter III). The WGLF IgG provides an objective and accurate quantification of
disease activity in IBD (Choudari et al, 1993). The cut off point for WGLF IgG of
10p.g/ml is used by the GI laboratory (WGH) to identify 'activity' in IBD (Brydon
et al, 1993). On the other hand, approximately 43% of IBD patients studied with
WGLF method appear to have gut blood loss (Ferguson et al, 1996).
The pro-inflammatory mediators such as IL-la and IL-ip are of particular
interest in IBD. IL-1(3 appeared to be elevated in mucosa of endoscopic biopsies,
correlating with disease activity (Brynskov et al, 1992). The interleukin IL-8 is a
potent chemoattractor and activator of neutrophils, which can cause mucosal
destruction. WGLF studies on IL-ip and IL-8 showed that these proinflammatory
cytokines are higher in active IBD (Ghosh, 1995). Furthermore, neutrophil
polymorphs are a prominent feature of the intestinal inflammatory infiltrate in IBD
(Lobos et al, 1987). Cytology of the WGLF led to the study of neutrophil
migration to the gut lumen (Handy et al, 1995). Luminal neutrophilia
characterised active colonic Crohn's and UC. Thus, the neutrophil granulocyte
elastase (GE) measurement in the WGLF was utilised to assess luminal
neutrophilia in IBD (Handy et al, 1996). Total immunoglobulins were assessed in
WGLF: total IgA was higher in UC patients and IgA antibodies to bacteroides
were higher in Crohn's disease (Srivastava et al, 1991; Poxton et al, 1995;
respectively).
Pouchitis is relatively common in UC accounting up to 30% of the patients
(Fozard and Pemberton, 1992). Many common elements in the natural history,
pathology, response to treatment and complications between pouchitis and IBD
led to the hypothesis that pouchitis may be considered as a form of IBD (Banerjee,
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1994). Thus, the WGLF method as described earlier (see Chapter III) along with
pouch assessment including clinical, endoscopic, and histological criteria have
been combined in an attempt to characterise ileoanal pouches in health and during
pouchitis.
In this chapter the parameters studied in the WGLF are presented, both in
the main UC group of pouches and in the other diagnostic groups. Possible
correlations have been sought amongst the parameters studied, but also to the
range of clinical entities described already in Chapter IV.
The parameters studied in WGLF are presented in five main groups:
A. Gut protein loss (IgG, albumin, a 1-antitrypsin)
B. Gut blood loss (haemoglobin)
C. Cytokine profile (IL-ip, IL-8)
D. Luminal neutrophil migration (neutrophil granulocyte elastase)
E. Immunoglobulins (total IgA & IgM)
6.2. PATIENTS & METHODS
6.2.1a. Patients
Seventy-four consecutive patients attending the General Surgical
Departments of the Royal Infirmary and the Western General Hospital of
Edinburgh were recruited for the study. Five patients were excluded as described
in Chapter III. Three more patients had to be excluded from the analysis, because
the procedure followed did not comply fully with the protocol. Consequently 71
patients were analyzed.
Male to female ratio was 40:31. Age ranged from 18.2 to 76.4 years
(median: 41.7 years). The period of time between the study and restoration of
intestinal continuity (i.e. closure of the ileostomy) ranged from 1.1 to 83.7 months
(median: 26.9 months) postoperatively.
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Table 6.1. Demographic details of the 71 pouch patients who participated in the
study. There were no significant differences in age or sex between groups (UC,
'early' UC group, 'non IBD', and IC).
Pouch groups M : F Age (years) Median time post pouch
UC (n = 56) 32:24 42.8 (18.2-74.6) 28.9 months
UC 'early' (n=5) 4:1 36.3 (23.0-35.0) 3.4 months
IC (n = 5) 1:4 43.7 (35.7-61.0) 26.5 months
'non IBD' (n = 5) 3:2 48.2 (23.2-76.8) 25.6 months
'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early UC group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
The results are expressed as median (range)
M:F= male to female ratio
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6.2.1b. Patient Subgroups
Patients were subdivided according to the original diagnosis for which the
pouch was created. Sixty-one patients had UC, 5 had indeterminate colitis (IC),
and 5 patients had other diseases: refractory constipation, familial adenomatous
polyposis coli (FAP) or multiple synchronous cancers (non IBD group; see
Chapter III, section 3.2.3.4)
Another subdivision became apparent in the early stages of the study.
There were several patients who had recently had their pouch constructed for UC.
A cut off point of six months was taken to separate this 'early' group, which
corresponded to the differences in the clinical profile observed for these patients.
This group numbered five patients (Chapter III, section 3.2.3.2).
The characteristics of these groups are described in Table 6.1. The 'non
IBD' group included 2 patients who had their colectomy for multiple synchronous
cancers, one FAP patient, and two who had their colectomy for intractable
constipation, after failure of ileorectal anastomosis. The term 'median time post
pouch' is the time between my study and when the patient had the intestinal
continuity restored after his/her pouch surgery.
6.2.2. Methods
6.2.2.1. Introduction
Detailed analysis of the method followed is given in Chapter III. The
patients were seen first in the outpatient department, except from the inpatients,
and the procedure was explained to them. If they agreed, they were called for the
investigation on another day.
The study took place in the investigation room of the Gastrointestinal
Laboratory at the Western General Hospital or on ward 39 and the attached
endoscopy suite at the Centre of Liver and Digestive Disorders (CLDD) at the
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Royal Infirmary of Edinburgh. The inpatients were studied in the corresponding
Surgical wards of the two Hospitals (Surgical South and Wards 11 and 12).
The protocol followed included:
A. Whole gut lavage
B. History taking
C. Blood tests
D. Pouchoscopy and biopsy
6.2.2.2. The Whole Gut Lavage
Patients after overnight fasting consumed the polyethylene glycol
electrolyte (PEG) solution at a steady rate (one litre per hour), adhering to the
protocol (Choudari et al, 1993). After the passage of fluid stools, it has been
shown that the concentration of immunoglobulins in the WGLF remains stable
over time (Ferguson et al 1995). Because of the steady state thus achieved and
for convenience, the first clear specimen obtained was processed immediately the
way it is described earlier (see Chapter III; section 3.3.A.4.2: Preparation &
handling of WGLF). The assays performed are described in detail in appendix I
in Chapter III.
6.2.2.3. The Clinical Investigations
In brief, the patients were attending for whole gut lavage study of their
pouch and at the same time their medical history was obtained with the help of a
pre-structured questionnaire (see appendix III, Chapter III). Blood tests were
performed for full blood count, erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), and serum immunoglobulins (IgG, IgM, IgA). Following that,
pouchoscopy and biopsy were performed, as described in Chapter III, section 3.6.
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6.2.2.4. Statistical Analysis
The statistical analysis of the results used the median values; 95%
confidence interval (CI), interquartile (IQ) or range; the Pearson correlation
coefficient and its p value; the non-parametric Mann-Whitney U test for unpaired
comparison of observations; %2 with Yates correction with Odds Ratio (OR) or
Relative Risk (RR). P values less than 0.05 were considered significant.
6.3. RESULTS
6.3.A. Gut Protein Loss In Ileoanal Pouches
6.3.A.I. WGLF Immunoglobulin G (WGLF IgG)
6.3.A. 1.1. WGLF IgG In The Various Diagnostic Groups
The values of IgG ranged from 1 to 69 |ag/ml (Figure 6.1). The WGLF
IgG was higher in the 'early' group (patients who had their pouch functioning for
less than six months) as compared to the rest of the UC patients (p=0.086).
6.3.A. 1.2. WGLF IgG, Pouchoscopy & Pathology Findings
Pouchoscopy Score
WGLF IgG correlated with the pouchoscopy score (r=0.50, p=0.0001; see
Figure 6.2). The pouchoscopy score may vary from 0-6. If we separate the
patients with a score 0-1 from the rest, these patients should have a 'normal'
pouch endoscopically. The cut off point for WGLF IgG of lOpg/ml is used by the
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Figure 6.1. The WGLF IgG in the various diagnostic groups*. The WGLF IgG was
higher in the 'early' UC as compared to UC group.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early UC group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis




Figure 6.2. The pouchoscopy score related to the WGLF IgG (n=56, r=0.50,
p=0.0001)
Table 6.2. The pouchoscopy score & WGLF IgG in pouch patients. Patients with
high WGLF IgG have high pouchoscopy score.
Pouchoscopy Score 0-1 2-6
WGLF IgG<10pg/ml n=20 n=24
WGLF IgG>10pg/ml n=l* n=T2
*The patient who had a WGLF IgG >10pg/ml, but low pouchoscopy score, is diabetic on NSAID,
who had a poor functional score with high systemic WCC, platelet count, ESR and iron deficiency
anaemia; the pouch biopsy characteristics were unremarkable.
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IgG was invariably less than 10p.g/ml in the subgroup with a pouchoscopy score
0-1 (see Table 6.2). For a higher pouch score (>2) the WGLF IgG varies.
Pouch Biopsy Neutrophilia
WGLF IgG was higher in pouches with moderate/severe neutrophilia as
compared to the pouches with minimal or with mild neutrophilia (p=0.0130,
p=0.0118 respectively; see Figure 6.3). The patients with moderate/severe pouch
neutrophilia and WGLF IgG<10|o.g/ml: 3 out of 5 had a pouch score 0-1.
Chronic Inflammation in Pouch Biopsy
WGLF IgG was lower in the subgroup with minimal changes in their
biopsies. (P<0.05, Figure 6.4). Patients with moderate/severe chronic
inflammation but with WGLF IgG<10p.g/ml were all but one on metronidazole as
compared to the ones with WGLF IgG>10p.g/ml (p=0.048; see Table 6.3).
Pouch Biopsy Ulceration & Villous Atrophy
There was no apparent correlation between WGLF IgG and the presence
of biopsy ulceration or villous atrophy.
6.3.A.I.3. WGLF IgG &PDAI
Since the pouchoscopy score and the biopsy characteristics are a part of
the Pouchitis Disease Activity Index (PDAI), one may anticipate that there should
be a relation between PDAI and WGLF IgG. There was a significant positive
correlation between PDAI and WGLF IgG (r=0.58, p<0.0001, Figure 6.5).
Not all the patients with high PDAI had high WGLF IgG. Four patients
had high PDAI but low IgG (see Table 6.4). Equally there were patients with high
WGLF IgG but low PDAI score.
To summarise, WGLF IgG correlates with the disease activity index
PDAI and also the pouchoscopy score and the pouch biopsy characteristics of


















Figure 6.3. The biopsy neutrophilia and the WGLF IgG. The WGLF IgG was higher
in patients with moderate biopsy neutrophilia as compared to those with minimal or


















Figure 6.4. The presence of chronic inflammation in pouch biopsies and the WGLF
IgG. The WGLF IgG was higher in moderate and mild chronic inflammation as
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Figure 6.5. The WGLF IgG related to the PDAI score (n=56, r=0.58, p<0.0001).
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Figure 6.6. WGLF IgG in the various groups: patients with pouchitis, with 'other'
problems and normal pouches. Patients with pouchitis had higher WGLF IgG as
compared with patients with 'other' problems or 'normal' pouches. Lines represent
the mean of the samples.
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Table 6.3. UC patients with moderate chronic Inflammation in pouches, the WGLF
IgG and metronidazole treatment. The dose of metronidazole was higher in the
subgroup with low WGLF IgG.










Metronidazole mg/day 0(0-400) 300 (0-600) 0.048
The results are presented as median (range). The Mann-Whitney test was used for comparison.
Table 6.4. The PDAI & WGLF IgG. Patients with low WGLF IgG had low PDAI.
PDAI<7 PDAI>7
WGLF IgG<10(j.g/ml n=39 n=4*
WGLF IgG>10pg/ml n=5** n=8
*Patients with high PDAI but low WGLF IgG:
1. Patient on antipsychotic drugs
2. Patient complained of pouch dysfunction - a month later developed pouch vaginal fistula
3. Patient had pouchitis 2 months prior to study; clinically was improving still on metronidazole
4. Patient had an inflamed anal cuff with extension of the inflammation cephalad
**Patients with low PDAI but high WGLF IgG:
1&2. Two patients with florid anal cuff inflammation, one had pyoderma gangrenosum as well
3. Patient had pouch dysfunction having had previous ileal resection for small bowel infarction; it
was difficult for the patient to distinguish further deterioration of function,. Pouchoscopy and biopsy
did not further increase the PDAI.
4. Patient was on 400 mg metronidazole, had pouch dysfunction, but not particularly disturbed
pouchoscopy or biopsy results
5. Patient , diabetic on NSAID, had a high WCC, platelet count, ESR and iron deficiency anaemia
but did not complain of any symptoms and neither had florid inflammation on pouchoscopy or
biopsy (same patient as * in table 6.2).
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6.3.A. 1.4. WGLF IgG & Clinical Diagnosis
During each session, after the pouchoscopy a decision was taken of
whether this particular patient had 'pouchitis' or not. Other endoscopic and
clinical entities were also considered, and a 'clinical diagnosis' was reached which
did not actually had the benefit of histological confirmation (Figure 6.6). The
PDA1 was in good agreement with this global assessment, though two patients
were ascribed to the 'other' group, later to have a PDA! calculated at 7. These
were the patients *1 & *2 in Table 6.4.
6.3.A.I.5. WGLF IgG: Stratification Of Pouch Patients
6.3.A.1.5.i The Three Subgroups
Since the WGLF IgG may reflect disease activity in pouches, we used the
IgG results to separate the patients of the UC group in 3 subgroups. In the
Gastrointestinal laboratory WGLF IgG shows activity in IBD patients if
>10p.g/ml, while in normal volunteers, outside hospital controls, a value of 4p.g/ml
is commonly found.
There were patients who had very low WGLF IgG (IgG<4p,g/ml; n=35),
who also had low values for all the other tests of WGLF. A medium WGLF IgG
group, possibly 'abnormal'(IgG: 5-9 pg/ml; n=8) and a variety of range for the
other results. Lastly, a third group had high IgG (>10pg/ml; n=13).
6.3.A.1.5.ii Comparisons Between Low & High WGLF IgG Subgroups
The clinical characteristics that were different between the very low IgG
(<4p.g/ml, n=35) and high IgG (>10p.g/ml, n=13) groups are given in Table 6.5a.
In addition to that, the biopsy neutrophilia was worse in the high group (x2=9.965;
p=0.007). The chronic inflammation at pouch biopsy was greater in the high
group (x2=7.741; p=0.021). Lastly the high group had more anal cuff
inflammation (x2=4.255; p=0.039). See Table 6.5b.
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Table 6.5a. The clinical parameters in the low (IgG<4pg/ml) and high IgG
(IgG>10pg/ml) pouch groups. These were higher in the high WGLF IgG group.
Clinical parameters Low IgG group High IgG group p value
(IgG<4pg/ml) (lgG>10pg/ml)
n=35 n=13
PDAI score 2(1-7) 6(2-11) 0.0001
pouchoscopy score 2 (0-4) 3 (0-6) 0.0004
functional score 4 (0-11) 8 (1-14) 0.0095
bowel activity nocturnal 1 (0-3) 1.5 (0-7) 0.0463
wcc 5.8 (3.6-11.6) 9.5 (6.4-13.3) 0.0002
Platelet count 243 (153-454) 342 (137-588) 0.0051
Table 6.5b. The WGLF parameters in the low and high IgG pouch groups. These
were higher in the high WGLF IgG group.
WGLF Low IgG group High IgG group p value
parameters (IgG<4pg/ml) (IgG>10pg/ml)
n=35 n=13
Albumin pg/ml 7(1-22) 28 (12-69) 0.0001
A1AT pg/ml 4(1-10) 8 (4-44) 0.0002
Hb pg/ml 2 (0.4-12) 7 (2-156) 0.0003
IL-1 (3 pg/ml 4(0-34) 59.8 (8-137) 0.0001
IL-8 pg/ml 43 (0-184) 548 (47-1000) 0.0001
IgA pg/ml 43 (1-105) 77 (31-318) 0.0028
IgM pg/ml 8 (1-76) 21 (2-154) 0.0050
GE pkat/1 <0.039 (0.039-0.079) 0.095 (0.039-0.511) 0.0008
The results are expressed as median (range). The Maim-Whitney test was used for comparison.
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Table 6.5c. The clinical & WGLF parameters in the low and medium IgG pouch
groups. The functional score and WGLF albumin & IL-8 were higher in the medium
WGLF IgG group.
WGLF / clinical Low IgG group Medium IgG group p value
parameters (IgG<4mg/ml) (4<IgG< 1 Omg/ml)
n=35 n=8
WGLF albumin pg/ml 7(1-22) 15 (3-25) 0.0178
WGLF IL-8 pg/ml 37 (0-184) 154 (55-907) 0.0006
functional score 4(0-11) 7.5 (1-10) 0.0459
Table 6.5d. The clinical & WGLF parameters in the medium and high IgG pouch
groups. These were higher in the high WGLF IgG group.
WGLF / clinical Medium IgG group High IgG group p value
parameters (4<IgG< 1 Omg/ml) (IgG>l Omg/ml)
n=8 n=T3
WGLF albumin pg/ml 15 (3-25) 28 (12-69) 0.0296
WGLF A1AT pg/ml 4 (1-6) 8 (4-44) 0.0017
WGLF IL-lp pg/ml 8.3 (0.7-143.0) 59.9 (8.8-137.4) 0.0390
WGLF IL-8 pg/ml 154.2 (55-907) 611.0 (47-1000) 0.0317
WGLF GE pkat/ml <0.039 (0.039-0.042) 0.095 (0.039-0.511) 0.0165
pouchoscopy score 2 (0-5) 3 (0-6) 0.0302
PDA! 4 (1-7) 6 (2-11) 0.0447
The results are expressed as median (range). The Mann-Whitney test was used for comparison.
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6.3.A.1.5.iii Comparisons Between Low & Medium WGLF IgG
Subgroups
The WGLF albumin of the medium group was higher compared to the low
group (p=0.0178). Similarly, the WGLF IL-8 was higher (p=0.0005). The
medium IgG group of patients had a worse functional score at the time of lavage
(p=0.0459). See Table 6.5c.
6.3.A.1.5.iv Comparisons Between Medium & High WGLF IgG Subgroups
The WGLF albumin was lower in the medium IgG group as compared to
the high group (p=0.0296). The WGLF a 1-antitrypsin was lower in the medium
IgG group compared to the high group (p=0.0017). The WGLF IL-8 in the
medium group was lower compared to the high group (p=0.0277). In addition,
the medium group had lower IL-ip, when compared to the high group
(p=0.0464). Granulocyte elastase was lower in the medium group, compared to
the high group (p=0.0165). The pouchoscopy score was worse for the high group
(p=0.0302) and also the PDA! score was higher (p=0.0447) compared to the
medium group. See Table 6.5d
6.3.A.1.5.V The High Group: Subdivisions According To Moskowitz Criteria
In the high WGLF IgG group (IgG>10p.g/ml), all patients with clinical
active 'pouchitis' according to Moskowitz criteria were included (n=7). When the
'positive' for pouchitis patients were compared with the rest of the high IgG
('negative' for pouchitis), the only difference in the WGLF parameters was
albumin levels (Figure 6.7).
Other differences between the 'negative' and the 'positive' high IgG
patients were mainly centred on the histological differences, on which the
Moskowitz criteria heavily rely; the 'positive' group had worse biopsy
neutrophilia (x2=6.198, p=0.013), worse score for ulceration (x2=4.952, p=0.026),
and worse chronic inflammation (x2= 9.551, p= 0.002). There was no significant

















Figure 6.7. WGLF albumin in the high IgG group of patients with pouchitis
('positive') or without pouchitis ('negative') according to the Moskowitz Criteria.















Figure 6.8. The WGLF IgG in the 'J' pouch was higher as compared to the
'W' pouch.
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The 'positive' group versus the 'negative' group was characterised by:
a. less urgency (x2- 8.4, p=0.04)
b. less evacuation difficulties (x2= 5.182, p=0.023);
c. less history of bleeding per pouch (x2= 4.286, p=0.038).
d. more extraintestinal manifestations (x2= 9.479, p= 0.002).
e. more prone to change their diet more (x2= 4.55, p=0.033).
f. less narrow anastomoses on clinical examination (x2= 6.741, p=0.010).
PDA! >7 was evident in all the 'positive' group patients, i.e. they had
pouchitis according to the PDAI 'definition'.
6.3.A.1.5.vi Comparisons Between 'High Group' & 'Low+Medium Group'
To explore the relationship of the WGLF IgG and the other clinical
characteristics of the patients, we combined the low and medium IgG groups (IgG
<10p.g/ml; the 'combined' group) and compared them to the high IgG group
(IgG>10p.g/ml). 10 pg/ml is considered to be the laboratory's cut off point for
IBD disease activity assessment.
Patients with high IgG (>10p.g/ml) appeared to have more extraintestinal
manifestations (x2= 7.786, p=0.005; RR= 3.6; 95%C1: 1.46, 8.52). None of them
had been treated immediately before the colectomy with high doses of steroids
(X2= 4.139, p=0.042; RR= 1.4; 95%CI: 1.01, 1.93). 'Atypia' described in the
histopathology of their colectomy report was common (%2= 4.15, with Yates
correction, p=0.05; RR= 3.5; 95%CI: 1.04, 11.68). Patients had to change their
diet more often after pouch surgery (x2= 10.055, p=0.002; RR= 5.1; 95%CI: 1.86,
13.96) and had worse social handicap (x2=4.998, p=0.026; RR= 2.8; 95%CI:
1.13, 6.9). Anal cuff inflammation was seen more often (x2= 5.299, p=0.022;
RR= 2.9; 95%CI: 1.17, 7.17).
6.3.A.1.5.vii WGLF IeG & Comparisons Of Various Clinical Subgroups
Patients with a history of extraintestinal manifestations had higher WGLF
IgG (p=0.0113). Patients with anal cuff inflammation had higher WGLF IgG
(p=0.0032). Patients who were complaining of day soiling and had social
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Table 6.6. WGLF IgG in the subgroups of patients with present or absent clinical
parameters. WGLF IgG was higher in patients with extraintestinal manifestations,
anal cuff inflammation, day incontinence and social handicap.
Clinical parameters WGLF IgG WGLF IgG p value
in patients with in patients with
present parameters absent parameters
EIM 6(1-69) 3 (1-33) 0.0113
n=17 n=39
Anal cuff inflammation 6(2-33) 3 (1-69) 0.0031
n=16 n=40
Day incontinence 4.5 (2-17) 3 (1-69) 0.0424
n=12 n=44
Social handicap 6 (1-45) 3 (1-69) 0.0180
n=13 COIIa
The values are expressed as median (range)
Mann-Whitney test was used for comparison
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handicap also had higher IgG (p=0.0424, & p=0.018, respectively). See Table 6.6.
6.3.A.1.5.viii WGLF IgG & 'J' Or 'W' Pouch Configuration
No patient with a 'W' pouch had clinical pouchitis, or had a value of
WGLF IgG>10p.g/ml. In the 'combined' IgG group, patients with 'J' pouches
appeared to have higher WGLF IgG than patients with 'W'(p=0.0137). This
difference was sustained even in the subgroup of clinically normal pouches
(p=0.0408). See Figure 6.8.
6.3.A.1.5.ix. WGLF IgG & Previous Tonsillectomy
The incidence of tonsillectomies recorded in the high IgG group was
compared to that in the 'combined' IgG group. The group of high IgG had
significantly more tonsillectomies in their past medical history (x2 =13.626,
p=0.001; RR= 3.5; 95%CI: 1.56, 7.84).
6.3.A.2. WGLF Albumin
6.3.A.2.I. WGLF Albumin In The Various Diagnostic Groups
The WGLF albumin in the ileoanal pouches ranged from 1 tig/ml to
71pg/ml (median: 9p.g/ml; 95%CI 7.2, 12.8). The 'early' group had higher
albumin compared to the main group of UC pouch patients (p= 0.0234). The 'non
IBD' cases, however, had lower albumin (p=0.0451). See Figure 6.9.
6.3.A.2.2„ WGLF Albumin & Inflammatory Parameters
WGLF albumin correlated with blood WCC (r=0.35, p=0.0193), and the
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Figure 6.9. The WGLF albumin in the various diagnostic groups. WGLF albumin
was higher in the 'early' group as compared to the UC group. The albumin in the UC













Figure 6.10. WGLF albumin in patients according to biopsy neutrophilia. Albumin
was higher in the subgroup with moderate neutrophilia as compared to mild or
minimal neutrophilia.
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The WGLF albumin was higher in patients with moderate/severe
neutrophilia in pouch biopsy compared to those with mild or minimal neutrophilia
(p=0.0213, and p=0.0248, respectively; see Figure 6.10).
Furthermore, the WGLF albumin was higher in patients with moderate
chronic inflammatory changes in the pouch biopsy (p=0.0404; see Figure 6.11).
6.3.A.2.3. WGLF Albumin, PDAI & The Clinical Diagnosis
The WGLF albumin correlated with the PDAI (r=0.52, p<0.0001; Figure
6.12) and also with the investigator's overall assessment of the pouch
inflammation (Figure 6.13).
6.3.A.2.4. WGLF Albumin & The Various WGLF IgG Groups
The levels of WGLF albumin are presented in the three subgroups ('low'
IgG<4pg/ml; 'medium' IgG:5-9p.g/ml; 'high' IgG>10p,g/ml; see section
6.3.A. 1.5.ii) in Table 6.7. The albumin levels followed very closely the general
pattern of low, medium and high protein loss as described by the WGLF IgG.
Furthermore, the WGLF albumin in the 'high' WGLF IgG subgroup was the main
parameter distinguishing the 'positive' pouchitis from the 'negative' according to
the Moskowitz criteria (p=0.0122; see section 6.3.A. 1.5.iii).
6.3.A.2.5. WGLF Albumin: Stratification Of Pouch Patients
The cut off point for WGLF albumin is 26pg/ml. Eight patients had
values above this level. These all had high WGLF IgG. Patients, however, with
relatively increased levels of WGLF albumin (but less than 26p.g/ml) were present
in both the other two groups of medium and low IgG.
In the previous section 6.3.A.l.5.iv the medium and low IgG groups were
combined, in order to elicit some differences. The same principle was followed
here. In order to discover the characteristics of these patients with the relatively
high WGLF albumin, patients were divided first according to the WGLF IgG (<10










Figure 6.11. WGLF albumin results according to the degree of chronic inflammation
in the biopsy. Albumin was higher in patients with moderate chronic inflammation as
compared to those with minimal chronic inflammation.
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Figure 6.12. WGLF albumin relates to the PDA1 (n=56, r=0.52, p<0.0001). The



























Figure 6.13. WGLF albumin in the various groups according to clinician's overall
assessment of pouch inflammation. Albumin was higher in the pouchitis group as
compared with the 'other' group or patients with normal pouch.
Table 6.7 The WGLF albumin in the low, medium and high WGLF IgG groups.



















The results are expressed as median (range). Mann-Whitney test was used for comparison
* low versus medium WGLF IgG group
** medium versus high WGLF IgG group
*** low versus high WGLF IgG group
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Table 6.8a. Clinical parameters in UC pouch patients with WGLF IgCKlOpg/ml and
high (LH) or low (LL) WGLF albumin groups. Cut off point for albumin: 10p,g/ml.






Pouchoscopy score 2 (0-5) 1 (0-4) 0.0443
PDAI 4(1-7) 2(1-7) 0.0453
Functional score 7(1-10) 4(0-11) 0.0480
Table 6.8b The PDAI in UC pouch patients with WGLF IgG>10|j.g/ml & high (HH)
or low (HL) WGLF albumin groups. Cut off point for albumin: 26p.g/ml. The PDAI






PDAI 8 (4-11) 5 (2-7) 0.0321
Table 6.9. WGLF albumin was higher in patients with present clinical parameters as
compared to those with absent clinical parameters.
WGLF albumin WGLF albumin
Clinical parameters in patients with in patients with p value
present parameters absent parameters
Day incontinence 14.5 (6-29) 8 (1-69) 0.0383
n=12 n=44
Stenosis pouch anal 6.5 (3-12) 9(1-69) 0.0308
anastomosis n=8 n=48
Routine operation 12.5 (3-69) 7(1-45) 0.0128
n=32 n=24
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Using the principle of the Latin Square, the patients in the UC group were divided
according to their albumin and IgG in the WGLF in four groups:
1. The first group (LL) had low WGLF IgG and albumin (n=31)
2. The second (LH) had relatively low IgG, i.e. below 10p,g/ml, but relatively high
albumin > 10p.g/ml (n=12)
3. The third group (HL) was characterised by high (>10|j.g/ml) IgG, but relatively
low albumin <26pg/ml (n=5)
4. The fourth group had both IgG and albumin (>26pg/ml) high (HH; n=8)
The LL and the LH groups
The biopsy characteristics were not significantly different, however the LH
group had a higher pouchoscopy score (p=0.043). Similarly the PDAI score was
higher (p=0.0453). The functional score was also higher (p=0.0480). The day
soiling appeared to be the main functional characteristic different between the two
groups (x2=5.846, p=0.016). See Table 6.8a.
The HL and HH groups
The PDAI was significantly higher in the HH group (p=0.0321). The rest
of the clinical, endoscopic, biopsy and WGLF parameters were not significantly
different. See Table 6.8b.
6.3.A.2.6. WGLF Albumin & Other Observations
There was a correlation observed between the albumin of WGLF and the
use of loperamide, which was not seen between IgG and loperamide (r=0.32,
p=0.0146). The WGLF albumin differed between patients who complained of day
soiling or otherwise (p=0.0383). Patients who had a tight pouch anal
anastomosis, had lower albumin in their WGLF (p=0.0308). Lastly, patients who
underwent routine colectomies appeared to have higher WGLF albumin
(p=0.0128). See Table 6.9.
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6.3.A.3. WGLF al-Antitrypsin
6.3.A.3.I. WGLF al-Antitrypsin & Various Diagnostic Groups
The al- antitrypsin (A1AT), was considered as a marker of protein gut
loss in the WGLF. The WGLF A1AT in the UC pouch patients ranged from
lpg/ml to 41pg/ml (median: 4.5pg/ml; 95%CI: 4.0, 6.0). Outwith results were:
one case of pouchitis (WGLF IgG 45pg/ml, albumin 29pg/ml); and another with a
relatively normal pouch and is referred previously in Tables 6.2 (*) and 6.4 (**)
(WGLF IgG 16pg/ml, albumin 18p.g/ml; diabetic patient on NSAIDs, with high
WCC, platelets, ESR and iron deficiency anaemia). There were no statistical
differences in the four diagnostic categories: UC pouch patients, 'early' UC pouch
patients, IC pouch patients and 'non IBD' pouch patients (Figure 6.14).
6.3.A.3.2. WGLF A1AT & The Various WGLF IgG Groups
In the previous section 6.3.A. 1.5.ii, the pouch patients were stratified
according to the disease activity as measured by the WGLF IgG into three groups:
low IgG (<4pg/ml), medium IgG (5-9pg/ml), high (>10pg/ml). The levels of
A1AT in the three groups were also described.. The A1AT levels in the three
groups are presented again in Table 6.10.
6.3.B. Bleeding In Ileoanal Pouches
6.3.B.l. WGLF Haemoglobin
6.3.B. 1.1. WGLF Haemoglobin & The Various Diagnostic Groups
Whole gut lavage was also used to assess the bleeding diathesis of pouch
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Figure 6.14. WGLF A1AT in the various diagnostic groups*. There was no
difference in the various groups.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early UC group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
'non IBD group' - patients underwent restorative proctocolectomy for causes other than IBD
Table 6.10. The WGLF A1 AT in the low, medium & high WGLF IgG groups. The














M-g/ml 4 (1-10) 4 (1-6) 8(4-44)
0.002**
0.0002***
** medium versus high WGLF IgG group
*** low versus high WGLF IgG group
The results are expressed as median (range)
Maim-Whitney test was used for comparison
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Hb ranged from 0.4 ug/ml to 199 ng/ml. There were no significant differences
between the miscellaneous diagnostic categories: UC pouch patients, 'early'
group, IC patients and 'non IBD' group (Figure 6.15).
6.3.B. 1.2. Haemoglobin, PDAI & Inflammatory Parameters
There was no correlation with the systemic Hb. Neither did patients, who
admitted that at times they had noticed blood in their motions, have higher WGLF
Hb. The WGLF Hb did not relate with any other of the clinical parameters,
parameters of inflammation or the PDAI.
6.3.B. 1.3. WGLF Haemoglobin: Stratification Of Pouch Patients
6.3.B.1.3.i High & Low WGLF Haemoglobin Groups
Since bleeding may be a phenomenon not always related to gut protein
loss, or disease activity, it was decided to separate the patients according to the
WGLF Hb with a cut off point of 5 pg/ml. The value 5 p,g/ml was selected
because it is the reference value used in the laboratory for establishing significant
bleeding at gut lavage, as mentioned above. With this separation indeed the two
groups of low WGLF Hb (n=38) and high Hb (n=18) were significantly different
with regard to the gut lavage parameters (Table 6.11).
6.3.B. 1.4. Characteristics Of Patients With Very High WGLF Hb
It was noticeable that five patients (4 in the UC group, and 1 in the 'early'
group) had distinctly high WGLF Hb. Two of them had pouchitis, but not on
metronidazole. The other two patients, were on metronidazole, one being only 6
weeks postoperatively, the other having pyoderma gangrenosum from florid anal
cuff inflammation. The fifth patient was essentially 'normal' in other effects, but
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Figure 6.15. WGLF Hb in the various diagnostic groups.
IC
Table 6.11. The WGLF parameters in the groups with low and high WGLF Hb.
These parameters were higher in the high WGLF Hb group as compared to the low
WGLF Hb.
WGLF Low Hb High Hb p value
parameters n=38 n=18
IgG pg/ml 3 (1-17) 9.5 (3-69) 0.0005
Albumin pg/ml 8 (1-57) 15.5 (3-69) 0.0217
A1AT pg/ml 4 (1-10) 8 (1-44) 0.0029
IL-8 pg/ml 53 (0-906) 294 (23-1000) 0.0111
IgA pg/ml 42 (1-153) 64 (40-318) 0.0003
IgM pg/ml 8(1-76) 18(8-154) 0.0011
GE pkat/l <0.039 0.0230 0.0017
(0.039-0.226) (0.039-0.511)
The results are expressed as median (range)
Mann-Whitney test was used for comparison
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aetiology (Hb 103 g/1; WGLF IgG: 6|ag/ml, albumin: 3pg/ml, A1AT: 6p.g/ml, Hb:
199(ag/ml).
The WGLF characteristics of the above 5 patients were very similar to the
characteristics of the other high WGLF Hb patients. Most noticeably they
presented with higher WGLF IgG, al- antitrypsin, IL-113, IL-8 and higher PDAI
score compared to the rest of the patients. They did not seem to differ in their
functional characteristics, or their systemic Hb.
6.3.C WGLF Cytokine Profile Of Ileoanal Pouches
6.3.C.I. The WGLF Interleukin IL-ip
6.3.C.I.I. WGLF IL-ip In The Various Diagnostic Groups
The interleukins IL-ip and IL-8, that are involved in many
proinflammatory reactions, are readily measured in WGLF. The WGLF IL-lp in
pouches ranged from 0 pg/ml to 143 pg/ml (median: 6.7 pg/ml; 95%CI: 4.26,
9.62) for the UC group, with no statistical differences between the diagnostic
categories: UC pouch patients, 'early' group, IC patients and 'non IBD' group
(Figure 6.16).
6.3.C.I.2. WGLF IL-ip, PDAI & Inflammatory Parameters
The WGLF IL-ip correlated with the disease activity index PDAI (r=0.37,
p=0.0037), but also related to many other parameters of the clinical sphere. Most
noticeable was the relationship with the blood WCC (r=0.61, p<0.0001); the
platelet count (r=0.42, p=0.0020); and the ESR (r=0.42, p=0.0032). The



















Table 6.12. WGLF IL-lp in patients with present or absent clinical parameters.
The WGLF IL-ip was higher in patients with diet change, social handicap and
perianal discomfort.






















The results are expressed as median (range)
Mann-Whitney test was used for comparison
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6.3.C.I.3. WGLF IL-ip & The Functional Parameters
The WGLF IL-ip related to the functional score at the time of the gut
lavage and to related to night bowel activity (r=0.28, p=0.0384; and r=0.44,
p=0.0008, respectively).
Patients, who reported change in their diet after pouch surgery, had higher
WGLF IL-ip (p=0.0047). Similarly, patients with a considerable social handicap
had also higher WGLF IL-ip (p=0.0228). Likewise, patients who complained of
perianal discomfort had again higher WGLF IL-ip (p=0.0035). See Table 6.12.
6.3.C.I.4. WGLF IL-ip & The Clinical Diagnosis
The WGLF IL-ip levels were scattered independently of the clinical
impression of pouchitis or not, as illustrated in Figure 6.17. In the 'pouchitis'
group, the two patients who had low WGLF IL-ip had also low WGLF IgG,
while the third one was already on maximum treatment with Ciproxin,
Metronidazole and TPN one week prior to the WGLF. The WGLF IgG was
raised, while the WGLF IL-8 was relatively elevated (200pg/ml).
The patient who was thought to be 'normal' and had high WGLF IL-ip,
was anaemic (Hb: 10.4g/l), with raised systemic platelet count (535X109/1),
slightly raised ESR (23mm/h), but essentially normal pouchoscopy and biopsy
characteristics. This patient was diabetic and on Voltarol® for arthritis. The rest
of the WGLF parameters were equally raised (WGLF IgG: 16pg/ml, albumin:
18p.g/ml, A1AT: 44pg/ml, Hb: llpg/ml, GE: 0.176pkat/l; see Tables 6.2 and 6.4).
The patient with the very high IL-ip, belonging in the 'other' group was a
patient with a perianal abscess at the time of lavage. The rest of the WGLF
parameters were: IgG: 8pg/ml, albumin: 21p.g/ml, A1AT: 5p.g/ml, Hb: 13pg/ml.
The patient made initially a good recovery following drainage of the abscess, to


















Figure 6.17. The WGLF IL-ip in the various groups according to the investigator's
clinical assessment of pouch inflammation. Patients with pouchitis had higher levels
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Figure 6.18. WGLF IL-8 in the various diagnostic groups. No significant
differences were detected between the different groups.
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The three other patients were :
1. One patient with anal cuff inflammation and pyoderma gangrenosum (see
Table 6.4)
2. One patient with previous ileal resection following pouch construction, with
pouch dysfunction, who on the day of the lavage had high platelet count and
ESR. The pouchoscopy and biopsy characteristics were not particularly
abnormal, giving eventually a PDAI score of 5. The WGLF IgG was raised
(12p/ml) as well as the WGLF Hb (7pg/ml) and the neutrophil GE
(0.095pkat/1). See Table 6.4.
3. One patient with pouch dysfunction, and troublesome night frequency, and had
4 previous episodes of pouchitis. At the time of lavage the pouchoscopy and
biopsy characteristics gave a PDAI score of 5. The WGLF parameters were
not deranged (WGLF IgG: 5pg/ml). The patient was on 600mg of
metronidazole long term.
6.3.C.2. The WGLF Interleukin IL-8
6.3.C.2.I. WGLF IL-8 In The Various Diagnostic Groups
The second cytokine measured in the WGLF for pouch patients was IL-8.
The WGLF IL-8 ranged from 0 to 1000 pg/ml. The WGLF IL-8 in the 'early'
group was not significantly higher from that of the UC group as a whole (Figure
6.18).
6.3.C.2.2. WGLF IL-8, PDAI & Inflammatory Parameters
The PDAI, as a measure of disease activity, correlated to the IL-8 (r=0.37,
p=0.0046). On the other hand, haematological indices of inflammation were
related to the IL-8: blood WCC (r=0.59, p<0.0001); and platelet count (r=0.51,
p=0.0003). The pouchoscopy score correlated to the IL-8 (r=0.33, p=0.0233).




















Figure 6.19. WGLF IL-8 in pouch patients with variable biopsy neutrophilia.





















Figure 6.20. WGLF IL-8 in patients with variable pouch chronic inflammation. The
WGLF IL-8 was higher in patients with moderate chronic inflammation.
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moderate neutrophil infiltration had higher WGLF IL-8. Figure 6.19 shows these
differences between the patients with minimal (44.3 pg/ml), mild (53.7 pg/ml) and
moderate/severe neutrophilia. The patients who had minimal or mild neutrophilia
and high levels of WGLF IL-8 were those described previously in section
6.3.C.1.4.
Similar differences were noted with the chronic inflammation in biopsies
and the IL-8. Figure 6.20 presents these variances The group of patients with
moderate/severe chronic inflammation had higher IL-8 compared to those with
minimal changes. The patients who had minimal or mild chronic inflammation but
elevated WGLF IL-8 were again those already described under section 6.3.C. 1.4.
6.3.C.2.3. WGLF IL-8 & The Clinical Diagnosis
The overall assessment of the investigator of the presence or absence of
active pouchitis, agreed with the levels of IL-8 in the WGLF, with some
exceptions. Figure 6.21 depicts that the highest levels of IL-8 were mainly
observed in the active pouchitis group (median 297.8 pg/ml) and not in the
clinically normal pouches (median 37 pg/ml, p=0.0069).
The patients with 'normal' pouches who had high WGLF IL-8 were the
same as those with 'normal' pouch and high WGLF IL-1(3 (Figure 6.17, section
6.3.C. 1.4), with the addition of two patients. These patients were considered
initially to have a relatively normal pouch (mainly inflamed at the lower 1/2), but
the biopsy characteristics altered the clinical/endoscopic diagnosis to a final
diagnosis of pouchitis. The WGLF parameters were also raised (IgG: 12pg/ml &
20pg/ml, albumin: 57pg/ml & 16pg/ml, A1AT: 8pg/ml & 5 pg/ml, Hb: 2 pg/ml &
5pg/ml , IL-ip: 18.6 pg/ml & 16.7 pg/ml, respectively). A fourth patient had
anal cuff inflammation, with abnormal WGLF IgG (llpg/ml); in retrospect the
patient should have been classified under the 'other' group.
In the 'other' group, apart from those 4 mentioned already in Figure 6.17,
section 6.3.C. 1.4, there was one patient for whom the diagnosis had to be
























Figure 6.21. WGLF IL-8 in the various groups according to the investigator's
assessment of active or non-active pouchitis. Patients with pouchitis had higher levels
of WGLF IL-8 as compared to the patients with normal pouches.
Table 6.13. The WGLF parameters in the two patients in the'other'group.
Patients' Diagnosis IgG Albumin A1AT Hb IL-ip GE
Pg/ml pg/ml M-g/ml M-g/ml pg/ml pkat/1
1. Pouchitis 14 54 10 5 24.7 0.176
2. Pouch dysfunction 7 16 3 51 16.7 <0.039
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parameters were again deranged (Table 6.13). The other patient had unexplained
pouch dysfunction (patient 2). Table 6.13 gives details of their WGLF
parameters.
6.3.C.2.4. WGLF IL-lp IL-8 & The Various WGLF IgG Groups
The WGLF IL-ip and IL-8 differed according to disease activity as
measured by the WGLF IgG in ileoanal pouches. Details of these differences are
given in Table 6.14.
6.3.C.2.5. WGLF IL-8: Stratification Of Pouch Patients
6.3.C.2.5.i High & Low WGLF IL-8 groups
Elevation of the cytokine levels in the WGLF may be independent to the
gut protein loss or the gut blood loss. The patients therefore were divided into
subgroups according to the cytokine levels. Most patients with high IL-8 had also
had high IL-IP; effectively a common separation was possible for these cytokines.
The patients were divided accordingly to:
A. Low cytokine group (n=42)
EL-ip ranged from 0-34 pg/ml (median: 4.3 pg/ml, 1Q range: 2.3- 8.1 pg/ml) and
IL-8 ranged from 0-200 pg/ml (median: 44.7 pg/ml, 1Q range: 27.1- 62.2 pg/ml);
B. High cytokine group (n=14)
IL-ip ranged from 15.4-420.3 pg/ml (median: 69.7 pg/ml, IQ range: 21.6- 94.4
pg/ml) and IL-8 ranged from 293-1000 pg/ml (median: 656 pg/ml, IQ range: 394-
953 pg/ml).
Table 6.15 presents the WGLF parameters in these two groups.
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Table 6.14. WGLF IL-1|3 and IL-8 in the low, medium and high WGLF IgG groups.













IL-1(3 pg/ml 4(0-34) 8.3 (0.7-143) 59.8 (8.8-137) 0.0464**
0.0000 ***
IL-8 pg/ml 43 (0-184) 154 (55-907) 548 (47-1000) 0.0005 *
0.0277**
0.0000 ***
* low versus medium WGLF IgG group
** medium versus high WGLF IgG group
*** low versus high WGLF IgG group
Table 6.15. The WGLF parameters in the low and high WGLF cytokine subgroups.








IgG pg/ml 3 (1-17) 13.5 (5-69) 0.0001
Albumin pg/ml 8 (1-28) 23.5 (7-69) 0.0001
A1AT pg/ml 4 (1-10) 8 (3-44) 0.0002
Hb pg/ml 2 (1-199) 7.5 (1-156) 0.0003
IgA pg/ml 44 (1-105) 102 (42-318) 0.0001
IgM pg/ml 9(1-76) 22 (10-154) 0.0007
GE pkat/1 <0.039 (0.039-0.0440) 0.097 (0.039-0.5110) 0.0005
The results are expressed as median (range).
Mann-Whitney test was used for comparison.
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The biopsy neutrophilia and presence of chronic inflammation were greater
in the high cytokine group (p=0.010, and p=0.026, respectively). The incidence of
biopsy ulceration and villous atrophy were similar in the two groups. Table 6.16
summarises the clinical characteristics that appeared to be different in the low and
high cytokine groups.
6.3D. The Luminal Neutrophil Migration
6.3.D.I. WGLF Neutrophil Granulocyte Elastase
6.3.D.I.I. WGLF GE In The Various Diagnostic Groups
Whole gut lavage can be utilised to assess neutrophil luminal migration
either by cytological methodology or by measuring specific neutrophil enzyme
activity such as the neutrophil granulocyte elastase. The detection limit of the
elastase method is 0.039p,kat/ml (Handy et al, 1996). The WGLF GE in pouch
patients ranged from 0.039 to 0.5110 p.kat/1. There were no differences in the
WGLF GE in the various groups: UC pouch patients, 'early' group, IC pouch
patients and 'non IBD' group. The WGLF GE in the high IgG subgroup was not
different from the one detected in the low IgG subgroup in the UC pouch patients
(Figure 6.22).
6.3.D.I.2. WGLF GE, PDAI, Functional & Other Parameters
The WGLF GE correlated with the PDAI (r=0.41, p=0.0056), the
pouchoscopy score (r=0.44, p=0.0009), and with the history of previous
'pouchitis-like episodes' recorded by the patients (r=0.40, p=0.0022).
The WGLF GE related also to pouch functional parameters: the nocturnal
bowel activity correlated with WGLF GE (r=0.44, p=0.0010).
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Table 6.16. The clinical characteristics of the two subgroups of high and low
cytokines IL-ip and IL-8 in the WGLF of UC pouches. These were higher in the
high WGLF cytokine subgroup.
Clinical Low cytokine High cytokine p value
parameters n=42 n=14
WCCX 109/1 5.8 (3.5-11.6) 10.0(6.4-15.5) 0.0001
PLTX 109/1 248 (153-454) 331 (137-588) 0.0118
pouchoscopy score 2 (0-6) 3 (0-6) 0.0063
night bowel activity 1 (0-3) 1.5 (0-7) 0.0241
PDAI 3(1-11) 6 (2-9) 0.0009
The results are expressed as median (range).






















UC early non IBD IC
Figure 6.22. WGLF GE in the various diagnostic pouch groups. The dotted line
represents the detection limit of the method (0.039 g.kat/1); the solid lines represent
the mean values.
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Table 6.17 The WGLF GE in the low, medium and high WGLF IgG groups. The
WGLF GE was higher in the high WGLF IgG subgroup.
WGLF Low IgG group Medium IgG group High IgG group p value
IgG<4p.g/ml IgG 5-9pg/ml IgG>10fig/ml
n=35 n=8 n=13
GE <0.039 <0.039 0.095 0.0165**
pkat/1 (<0.039-0.079) (<0.039-0.042) (<0.039-0.511) 0.0008***
The results are expressed as median (range).
Maim-Whitney test was used for comparison.
** medium versus high WGLF IgG group
*** low versus high WGLF IgG group
Table 6.18. WGLF and clinical parameters in UC pouch patients with WGLF
IgG<10pg/ml and detectable or undetectable WGLF GE. WGLF albumin, A1AT,






WGLF albumin pg/ml 11 (9-22) 7(1-25) 0.0379
WGLF A1AT p,g/ml 8 (5-9) 3 (1-10) 0.0071
WGLF IgA pg/ml 62.0 (56-105) 41.5 (1-102) 0.0177
pouchoscopy score 2 (2-4) 1.5 (0-5) 0.0308
PDAI 5 (3-7) 2 (1-7) 0.0215
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6.3.D.L3. WGLF GE In The Various WGLF IgG Groups
The WGLF GE is presented in the three subgroups according to disease
activity measured by the WGLF IgG (low IgG<4pg/ml, medium IgG:5-9p,g/ml,
high IgG>10p.g/ml). See Table 6.17.
There were patients (n=4) who had high IgG (>10pg/ml), but had
undetectable GE (<0.039p.kat/l). These patients did not seem to have any different
characteristics to the rest of the high IgG patients (n=9) who had detectable GE in
the WGLF.
Patients (n=38) with undetectable WGLF GE and WGLF IgG<10p.g/ml
had lower albumin (p=0.0379), A1AT (p=0.0071), IgA (p=0.0177) in their WGLF
compared to the rest of the patients with detectable WGLF GE and WGLF
IgGKlOpg/ml. These patients had also lower pouchoscopy score (p=0.0308) and
lower PDAI (p=0.0215). See Table 6.18.
6.3.D.I.4. WGLF GE: Stratification Of Pouch Patients
6.3.D.1.4.i High & Low WGLF GE Groups
Significant luminal neutrophilia is considered with WGLF GE>0.1 p.kat/1
(Handy et al, 1995). This level was used to separate the patients to the high or
low WGLF GE subgroups. Seven patients had WGLF GE>0.100 p.kat/1 ('high').
The rest 49 patients had WGLF GE<100 p.kat/1 ('low'). The differences in the
WGLF parameters between the low and high WGLF GE groups are presented in
Table 6.19. The clinical parameters in the high and low WGLF GE groups are
presented also in Table 6.19.
6.3E WGLF Immunoglobulins In Ileoanal Pouches
6.3E.1. WGLF Immunoglobulin A
6.3E.1.1. WGLF IgA In The Various Diagnostic Groups
Total IgA and IgM were measured in the WGLF of ileoanal pouches.




















UC early non IBD IC
Figure 6.23. WGLF IgA in the various diagnostic pouch groups. The transverse lines
represent the means.
Table 6.19. WGLF & clinical parameters in the two GE subgroups in UC pouch
patients. These are higher in the high GE subgroup. Cut off point for WGLF GE:
0. lpkat/ml.





IgG pg/ml 3 (1-69) 16 (12-33) 0.0002
Albumin pg/ml 8 (1-69) 18 (12-54) 0.0052
A1AT pg/ml 4(1-32) 8 (4-44) 0.0035
Hb pg/ml 2 (1-199) 7 (3-30) 0.0045
IL-ip pg/ml 4.2 (0-143) 75.8 (16-137) 0.0001
IL-8 pg/ml 49.9 (0-906) 726 (394-1000) 0.0001
IgA pg/ml 46 (1-277) 146 (51-318) 0.0029
IgM pg/ml 12(1-76) 44 (10-154) 0.0154
pouchoscopy score 2 (0-6) 3 (0-6) 0.0182
WCC X109/l 6.0 (3.6-15.5) 10.1 (6.4-13.3) 0.0125
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between the diagnostic pouch categories (Figure 6.23). The WGLF IgA for the
UC pouch group was 51p,g/ml (median; 95%CI: 42.0, 58.6 pg/ml). The WGLF
IgA was similar in the 'early' group as compared to the rest of the UC pouch
patients. However, the WGLF IgA in the 'early' group was higher compared to
the WGLF IgA in the 'combined'(IgG<10|j.g/ml) WGLF IgG group of UC
patients (p=0.0345).
One patient had very low WGLF IgA (lpg/ml). This was an elderly male
with previous ulcerative pancolitis and a past history of alcoholic hepatitis. After
the creation of his pouch he had two episodes of pouchitis, but at the time of the
study he had good pouch function and no evidence of inflammation at either
pouchoscopy or biopsy. The WGLF IgM was also low (lp.g/ml), but the serum
levels were within normal limits (IgA 2.3, IgG 13.5, IgM 0.45 g/1). The rest of the
WGLF parameters were not raised (IgG Ipg/ml, albumin 8p,g/ml, A1AT 2p.g/ml,
Hb lpg/ml, IL-ip 2.3pg/ml, IL-8 22.6 pg/ml, GE<0.039 pkat/1).
6.3E.1.2 WGLF IgA, Functional Parameters & Clinical Diagnosis
The WGLF total IgA correlated with the functional score (r=0.30,
p=0.0216). The WGLF total IgA related to the overall investigator's assessment
of patient's condition; patients with active pouchitis according to the
investigator's clinical diagnosis had a raised WGLF total IgA (Figure 6.24). The
outlier in the normal group is the patient mentioned before with diabetes, NSAID
etc. The two outliers in the pouchitis group are patients with long standing,
almost 'chronic' pouchitis.
6.3E.1.3. WGLF IgA In The Various WGLF IgG Groups
In the previous section 6.3.A. 1.5.ii, the pouch patients were stratified
according to the disease activity as measured by the WGLF IgG into three
subgroups: low IgG (<4p.g/ml), medium IgG (5-9pg/ml), high (>10pg/ml). The
























Figure 6.24. WGLF total IgA in UC pouch patients. The patients' status at the time
of the gut lavage according to the investigator's clinical assessment. WGLF IgA was
higher in pouchitis patients.
Table 6.20. The WGLF total IgA in the low, medium and high WGLF IgG













M-g/ml 43 (1-105) 50 (34-102) 77 (31-318) 0.0028*
The results are expressed as median (range). Mann-Whitney test was used for comparison.























UC early non IBD IC
Figure 6.25. WGLF total IgM in the various diagnostic groups. The transverse lines
represent the means of the samples.
Table 6.21. The WGLF total IgM in the low, medium and high WGLF IgG













M-g/ml 8(1-76) 16 (3-35) 21(2-154) 0.005*
* low versus high WGLF IgG group









Female sex 16(3-59) n=24 9(1-154) n=32 0.0319
Diet change 16(1-76) n=22 9(1-154) n=34 0.0330
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6.3E.2. WGLF Immunoglobulin M
6.3E.2.1. WGLF IgM In The Various Diagnostic Groups
WGLF IgM was measured in the lavage samples of pouch patients. This
ranged from 1 pg/ml to 154 pg/ml. The WGLF IgM for the UC group was
12pg/ml (median; 95%CI: 8.3,16.0). There were no differences between the
various diagnostic groups (Figure 6.25). Moreover, the IgM of the 'early' group
was not different from either the low or high IgG UC pouch patients, that were
previously described. The outlier in the UC group is the patient with the
pyoderma gangrenosum and the anal cuff inflammation that was mentioned before.
He also had high WGLF IgA (318pg/ml).
6.3E.2.2. WGLF IgM In The Various WGLF IgG Groups
In the previous section 6.3.A.1.5.ii, the pouch patients were stratified
according to the disease activity as measured by the WGLF IgG into three
subgroups: low IgG (<4p.g/ml), medium IgG (5-9pg/ml), high (>1 Opg/ml). The
total WGLF IgM levels in the three groups are presented in Table 6.21.
6.3E.2.3. WGLF IgM & Other Observations
Women appeared to have higher levels of WGLF IgM (p=0.0319). The
villous atrophy noticed in pouch biopsy was more often noticed in a group with
Patients with high WGLF IgM (IgM>23pg/ml) had more frequent villous atrophy
in pouch biopsy compared with those with WGLF IgM<23 p,g/ml (x2=4.816,
p=0.028). Patients with a change in their diet after pouch surgery had higher
WGLF IgM (p=0.0330). See Table 6.22.
6.3.F. Correlations Between WGLF Parameters
Table 6.23 presents the correlations between the various WGLF
parameters. WGLF IgG correlated with albumin, A1AT, WGLF IgA & IgM,
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IL-ip and IL-8. Furthermore, WGLF IL-lp correlated with IL-8; WGLF IL-8
correlated with IgA. Lastly the WGLF IgA correlated with IgM.
6.4. CONCLUSION: WHICH TEST?
The whole gut lavage study in ileoanal pouches showed a multiplicity of
parameters that relate to various aspects of inflammation and injury in pouches. In
the literature, various algorithms, scores and criteria have been also described for
the diagnosis of active pouchitis. The main and most strict criteria remain the
Moskowitz criteria. Moskowitz criteria have been used for many years. These
have been valuable in differentiating pouchitis. The recently described PDAI,
combines aspects of clinical and pathological approach to the problem of
pouchitis. PDAI ranges from 0 to 18, with pouchitis defined by a score of seven
or greater.
Seven of the patients could be described as having pouchitis according to
Moskowitz criteria. Twelve patients had pouchitis according to the PDAI. The
WGLF IgG attributed increased disease activity in 13 patients (IgG>10p,g/ml).
All the pouchitis patients according to Moskowitz criteria had PDAI>7. All of
these patients had also WGLF IgG >10p.g/ml (Figure 6.26).
In the group of the 'normal' pouches (by global clinical assessment) two
patients had to change their diagnosis to 'histological' pouchitis after the biopsy
result was known. These also had raised WGLF IgG. Two other patients had high
WGLF IgG, but low PDAI; these were the patients **1 and **4 in Table 6.4: the
diabetic patient on NSAID, iron deficiency anaemia, with high systemic WCC,
platelet count and ESR; and the patient with good function but severe anal cuff
inflammation.
In the group that I diagnosed as 'pouchitis' (according to investigator's
clinical assessment), two patients had a PDAI of 7 without a raised WGLF IgG.
These patients did not fulfil the Moskowitz criteria. They were patients *3 and *4
in Table 6.4; one patient had pouchitis 2 months prior to the study and clinically
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Table 6.23. WGLF parameters & correlations between WGLF parameters.
WGLF Parameter A WGLF Parameter B r value p value





















IL-8 GE 0.66 0.0001
IgA 0.67 0.0001
IgM 0.49 0.0007
IgA IgM 0.72 0.0001
GE 0.28 0.0407
Patiensdescr ptionaccordingto
clinical,Moskowitz,PDAI&WGLFIgG criteria 123456789011235 NumberofPatients
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was improving still on 600 mg of metronidazole; and the second patient had anal
cuff inflammation with extension of the inflammation cephalad.
A patient in the 'other' group was diagnosed to have pouchitis after the
biopsy result became available. The PDAI was high and the WGLF IgG was also
raised, and the patient could be categorised as pouchitis according to the
Moskowitz criteria. In the same group there were two patients (* 1 and *2 in
Table 6.4) with low WGLF IgG, but had a PDAI of 7: one patient was on
antipsychotic drugs; the other complained of pouch dysfunction and a month later
developed pouch-vaginal fistula.
Patients in the 'other' group who had high WGLF IgG>10pg/ml, but low
PDAI were: a patient with florid anal cuff inflammation and pyoderma
gangrenosum; and a patient on metronidazole who endoscopically gave the
impression of pouch mucosal prolapse.
The WGLF IgG may reasonably describe the disease activity in ileoanal
pouches. The discrepancy between the PDAI and the WGLF IgG might be
explained from the similarities of PDAI with the other disease activity parameters
like the CDAI. The WGLF IgG in combination with clinical common-sense
judgement could be the 'gold standard' for categorisation of ileoanal pouches
according to disease activity. Furthermore, it may be a tool of dissection and









The hypothesis of this thesis was that inflammation of the ileoanal pouch
behaves as a form of IBD. If this analogy is correct, one may expect three separate
entities describing pouch inflammation as observed in IBD. First, the initiating event,
the inflammatory disease activity (correlating closely with symptoms), and if analogies
with Crohn's Disease are to be exact, an indolent, virtually asymptomatic destructive
ulceration (Ferguson, 1996). Admittedly the latter does not seem to happen in
ileoanal pouches.
Inflammation of the ileoanal pouch is a unique 'man-made' disease. It is true
that the initiating event that sparks IBD is unknown. If one assumes that a form of
IBD operates in ileoanal pouches, then valuable information may be gathered from the
study of ileoanal pouches. This is because the time that the pouch is constructed is
well known in each and every case. Accordingly a very good approximation of the
time when the pouch mucosa comes in contact with the new antigenic environment
can be easily identified. Thus observation of how inflammation begins in the gut from
time 'zero'(time of pouch creation) till any future time is feasible. If a method of
observation that is easily applicable and reliable could give information about the
various facets of gut mucosal events, then a major advance in the understanding of
IBD immune mechanisms will effect.
7.2. WGLF Parameters In The 'Early' Group
In our study we recruited five pouch patients within the first six months of
pouch construction - the 'early' group. We observed that WGLF IgG and albumin -
parameters indicating gut protein loss - were higher from those of the rest of UC
pouch patients. Gut protein loss is a phenomenon clearly beheld in IBD, and it
accurately describes disease activity (Choudari et al, 1993). The 'early' presence of
such a phenomenon in ileoanal pouches may indicate that gut protein loss is an early
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and non specific process. This process may be observed in the gut whenever an
increase of the antigenic (?bacterial) load of the gut occurs.
In this 'early' group of pouch patients, the other whole gut lavage parameters
and especially the cytokines IL-ip and IL-8 varied in such a way that it was difficult
to conclude of any cytokine 'profile' of early pouches. Yet the number of patients
recruited was small. The WGLF total IgA however was higher compared to that of
pouch patients with WGLF IgG less than 10p.g/ml. This again may be an early non
specific reaction of the gut to the new increased antigenic load.
On the other hand, Apel et al (1994) has shown that in these first six months,
morphological changes take place. Infiltration by neutrophils and eosinophils, a mild
villous atrophy, and a progressive increase of mononuclear infiltration with
lymphocytes, plasma cells, eosinophils and histiocytes being the chronic inflammatory
infiltrate (Meuwissen et al 1989). With such a mucosal neutrophil activity one would
have expected that luminal neutrophilia may also occur and the WGLF parameter
granulocyte elastase, a marker of luminal neutrophilia, would have been invariably
detectable in the lumen of early pouches. This however does not seem to be the case
in the few pouches examined. This may be due to the fact that luminal and mucosal
neutrophilia may not be the same phenomenon. On the other hand luminal and
mucosal chemoatraction for neutrophils may be different. An alternative explanation
may be based on work in our laboratory. This showed that luminal neutrophilia is a
feature of active UC and active colonic CD but not of active small bowel CD (Handy
et al, 1996). A large prospective study with patients having a whole gut lavage from
the very beginning of pouch creation and for regular intervals afterwards will enable
the study and accurate description of what happens in the lavage parameters during
the initial 'adaptation' period of the first six months. This will also allow the study of
mucosal immunity changes for the corresponding phases.
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7.3. Gut Protein Loss & Disease Activity In Pouches
In the group of UC pouch patients outwith the six months period, it was
shown that a certain number of ileoanal pouches exhibits gut protein loss. The latter
was revealed by levels of WGLF IgG greater than 10p.g/ml. Furthermore, there is a
correlation of the protein loss as described by the WGLF IgG and the pouch disease
activity parameter PDAI (r=0.58, p<0.0001). This relation of disease activity and gut
protein loss is a feature distinctively noticeable in IBD (Choudari et al, 1993). In
IBD the WGLF IgG closely portrays disease activity such as fever, anorexia,
tiredness, arthropathy, diarrhoea, pain. Thus, it has been suggested that this protein
loosing enteropathy measures the same phenomenon as disease activity (Acciuffi et al,
1996).
The above observations are in agreement with earlier work suggesting the
presence of protein loosing enteropathy in pouchitis (Boerr et al, 1995). Moreover,
these observations support the assumption that inflammation of the ileoanal pouch is a
form of IBD. There is however the puzzling question why the agreement of WGLF
IgG with the PDAI is not as good as in other forms of IBD. The WGLF IgG
identified precisely all the cases who had 'active' pouchitis according to the
Moskowitz criteria. The cases which did not comply the Moskowitz criteria for
pouchitis and had high WGLF IgG (>10p.g/ml) had lower levels of WGLF albumin,
and less inflammatory stigmata and ulceration in their biopsies. It seems as if the
Moskowitz criteria describe in an 'all or nothing' philosophy the same phenomenon
as the WGLF IgG. However, some cases of inflammation (with high WGLF IgG)
may not be severe enough to be included within the 'active' pouchitis group.
It is of interest that there are no large prospective studies relating the newer
PDAI with the Moskowitz criteria. The original description of PDAI is based on
observations on 10 patients only (Sandborn et al, 1994). There is however a study
that uses the PDAI to describe disease activity in 28 pouches and relate this to faecal
levels of a 1-antitrypsin (Boerr et al, 1995), but no comparison is made with the
Moskowitz criteria.
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From a direct comparison, it seems that PDAI has close similarities with the
CDAI and other disease activity indices with prominence given mainly on the
symptoms and endoscopic stigmata of inflammation. For the patients with high PDAI
but low WGLF IgG there was apparently an emphasis on the symptoms in three cases
out of four, while on the fourth, the difference arose from biopsy from an inflamed
area in continuity to anal canal inflammation. Thus, it seems that the PDAI shares the
pitfalls of CDAI with the added disadvantage of biopsy sampling error. Similar
observations on the limitations of the CDAI as compared to the whole gut lavage
methodology have been made on patients with ileostomies, patients who are
psychologically disturbed, or in children (Acciuffi et al, 1996).
If we concentrate on the cases who had high WGLF IgG and a PDAI<7, two
cases exhibited pathology consistent with gut inflammation: anal cuff inflammation.
The other three cases indicated the difficulties a clinician faces when a patient has
pouch dysfunction but not clearly abnormal endoscopy. Added areas of pitfalls is the
difficulty to obtain good views of the entire pouch mucosa in an unprepared pouch;
and the alarming patchy appearance of inflammation in some pouches (Madden et al,
1990). The whole gut lavage methodology therefore, has the advantage of offering
information about the inflammatory status of the patients' gut in a 'holistic' way.
This in conjunction with the clinicopathological presentation may give a common-
sense approach in solving patients' problems, thus avoiding a 'therapeutic' diagnosis
of pouchitis with the blind administration of metronidazole.
Another indicator that the protein loosing enteropathy in ileoanal pouches is a
true biological phenomenon is the observation that endoscopic stigmata of
inflammation, the severity of mucosal neutrophilia and the incidence of chronic
inflammation related to levels of the WGLF IgG. We have shown that in all but one
patients with high levels of WGLF IgG (>10pg/ml) there was invariably a high
endoscopic score; the patients with severe neutrophilia and chronic inflammation had
also significantly higher levels of WGLF IgG. It is of interest that metronidazole
seemed to play a role in the separation of patients with severe chronic inflammation
who had high or low WGLF IgG. Patients with low WGLF IgG were also on
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metronidazole. This may explain the study by Madden et al (1994) where
metronidazole was found to affect the diarrhoeal state of patients in chronic pouchitis,
but not their histopathology or endoscopy.
The protein loosing enteropathy of IgG revealed in inflamed ileoanal pouches
may be a result of local production since the lympho- plasmacellular infiltrate in
pouchitis is mainly composed by IgA and IgG bearing cells (Meuwissen et al, 1989).
On the other hand the presence of albumin in the whole gut lavage in parallel to the
IgG may indicate that the protein loss is mainly plasma derived; this is a well-
established observation in IBD cases (Choudari et al, 1993).
It is of interest that another protein indicator of gut protein loss, the al-
antitrypsin, has not been as helpful in ileoanal pouches as in IBD. The levels observed
were distinctly low, similar to those of ileostomies with WGLF IgG >10p.g/ml. This
failure of WGLF a 1-antitrypsin to relate with parameters of disease activity in our
cases is in contrast to the study by Boerr on faecal a 1-antitrypsin (Boerr et al, 1995).
Our method of immunoturbimetry though may be less sensitive than the method of
radial immunodiffusion used (Boerr et al, 1995). However, one should take in
consideration that the a 1-antitrypsin detection yield in faeces may vary from 2.2-97%
of the amount produced by the gut at any time (Ferguson et al, 1995).
7.4. Gut Blood Loss In Ileoanal Pouches
The WGLF methodology showed that there are cases with considerable
bleeding in their pouches; whether this is a constant or transient phenomenon, this
cannot be clearly established. The absence of relation however, with levels of
systemic haemoglobin may indicate that the observed bleeding may have been of
transient nature. On the other hand it was very noticeable that those cases with
WGLF Hb >5p.g/ml, a level indicator of gut blood loss, had invariably raised all other
WGLF parameters indicating inflammation. This therefore indicates that gut
inflammation in pouches is accompanied by some blood loss.
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7.5. Cytokines & Luminal Neutrophilia In Pouches
The presence of cytokines IL-ip, and IL-8 in the WGLF is in agreement with
studies that showed the presence of these cytokines in mucosal pouch biopsies -
especially during inflammation (Gionchetti et al, 1994). In this study, the levels of
those cytokines related to the PDAI. Furthermore, the WGLF IL-8 related to the
severity of mucosal neutrophilia and the chronic inflammatory response.
The systemic indices of inflammation (WCC, platelet count, CRP, ESR)
related either to the cytokine profile of the pouch patients or to the protein loosing
enteropathy. This again has been described in IBD (Clark & Kumar, 1994).
It is difficult to speculate at present, whether the IL-8 measured in WGLF is
produced mainly locally into the lumen from exudating neutrophils. Moreover, the
strong relation shown between IL-8 and the neutrophil granulocyte elastase - an
indicator of luminal neutrophilia - is similar to the association noticed between IL-8
and granulocyte elastase in UC but not in CD (Ghosh, 1995). This again may indicate
that in pouches the neutrophil migration is a process with more similarities to the one
noticed in UC than in CD. On the other hand, Teahon et al (1993) shown that
neutrophils become activated in the mucosa in UC patients, whereas endoluminal
chemoattractant is present in CD.
The detection of neutrophil granulocyte elastase in a number of ileoanal
pouches, makes ileoanal pouches quite distinct entities. It is known that luminal
neutrophilia - high levels of WGLF neutrophil granulocyte elastase - accompanies
active UC, active colonic CD and it is fairly rare in active small bowel CD (Handy et
al, 1996). In Chapter V, it was shown that WGLF GE is low in ileostomies with
active CD, especially when compared to pouches of patients not on metronidazole.
Whether this change in pattern between the ileostomy and the 'continent ileostomy',
i.e. the ileoanal pouch, is due to bacterial flora and the partial colonic metaplasia
observed is difficult to speculate. Future studies are required to examine the
association of elastase with a marker of metaplasia such as colonic type sulphomucin.
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It is however noticeable that we did not find any relation with the amount of villous
atrophy and the levels of elastase in this study.
Luminal and mucosal neutrophilia have already been described with
measurement of H1In-labelled autologous granulocytes in scans and faecal collections
of patients with pouchitis (Kmiot et al, 1993). Our study however enlarges on the
observation relating the phenomenon to the luminal WGLF IL-8.
7.6. Other Observations In WGLF In Pouches
Total IgA and IgM were measured in the WGLF of pouches and noticeably
levels of IgM were the only parameter found relating to the phenomenon of villous
atrophy.
The higher degree of protein loss observed in patients with 'J' pouch, even the
clinically normal ones, may be related to the presence of staples in the 'J' pouches.
Invariably staples extruding through the mucosa were noticed in 'J' pouches years
even after pouch construction. A study indicated that 'J' pouches suffer more from
pouchitis (Hewett et al, 1995). This was not seen in this study, but the differences in
WGLF IgG between various pouch designs, urge a closer and more extensive
appreciation of this phenomenon.
Another observation was centred on the notion that patients with high WGLF
IgG invariably had tonsillectomy in the past. Though not such an association has
been seen up to now with IBD, it may be worth an exploration in the future.
Finally it was noticed that the various WGLF parameters were associated
between themselves, but not always strongly. In spite of the separate methodology
used for each parameter (different margin error each time), and also the possibilities
of uneven destruction by proteases, the close association of some of the parameters
with each other is impressive. It seems that the cytokines, IgG and albumin form a
close group indicating the probable relationship of the protein loss to cytokine
expression. The a 1-antitrypsin relates only very weakly to IL-8 and granulocyte
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elastase, a clear link of this 'buffer' protein to the deleterious effect of neutrophils.
The immunoglobulins on the other hand relate between themselves and also relate to
the cytokines. This probably may indicate another parallel phenomenon to the one
of the protein loosing enteropathy.
In conclusion, WGLF parameters may be informative of disease activity in
ileoanal pouches in a similar way as in IBD. One single parameter may not portray
disease activity in pouchitis as in inflammatory bowel disease. However, a
combination of inflammatory parameters in the WGLF may accurately characterise
the mechanisms of inflammation and injury in ileoanal pouches. This will be discussed
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8.1. INTRODUCTION
The chemotactic signals in whole gut lavage fluid needed to be assessed in
order to determine the mechanism of luminal migration of neutrophils from the gut
wall. Therefore, I needed to develop a simple method that can initially be used to
screen lavage samples for any chemotactic effect on neutrophils. A simple method
that allows a good number of specimens to be assessed at each time is the
neutrophil polarization assay (Haston and Shields, 1985). This assay is used to
determine the chemotactic and neutrophil activating effect of various biological
proteins in body fluids such as FMLP (N-formyl-methionyl-leucyl-phenylalanine)
and IL-8. The principle of the assay relies on the fact that neutrophils floating in
suspension with no chemotactic agent retain a spherical morphology. In contrast,
when a chemotactic agent is present, they assume a polarized morphology. The
percentage of neutrophils polarized is related quantitatively to the concentration of
the chemotactic agent present.
No study has yet investigated chemotactic potential of gut derived fluid
using this assay, although the polarization assay has been applied to various body
fluids, especially joint synovial fluid. To utilize the method for the whole gut
lavage fluid, a number of modifications had to be applied, both to the polarization
assay method and to the whole gut lavage specimen processing itself. The
development of these modifications along with the effect of IL-8 on the modified
test and analysis of the variance of the test will be presented in this chapter.
8.2. MATERIALS & METHODS
8.2.1. Equipment






d) laminar flow sterile hood
e) Neubauer counting chamber
f) 12 ml conical centrifuge tubes with a cap (Greiner)
g) sterile disposable pipettes (Greiner), and
h) Phase contrast microscope with a X40 objective
8.2.2. Reagents
Initially sterile bottles were used for all the reagents. Later I discovered
that this is not necessary as long as the media are prepared on the day of the
experiment and a strict routine of non-contamination of the stock material is
followed. I also followed a policy of alliquoting the reagents, to avoid
deterioration during the cycles of thaw and re-freezing.
8.2.2A. Stock Reagents
a. Hanks' balanced salt solution (10X HBBS, ICN), stored sterile at 4°C.
b. Dextran powder average MW 150,000 (Sigma), storage at room temperature
c. Hepes (1M, Sigma), stored sterile at 4°C.
d. TV-formyl-methionyl-leucyl-phenylalanine (FMLP, Sigma), prepared as
0.002M solution in DMSO and aliquoted in Epindorfs at -20°C.
e. Dimethyl Sulphoxide (DMSO, Sigma), stored at room temperature
f. Heparin mucous (Leo), stored at 4°C.
g. Glutaraldehyde 25% solution (BDH), stored at 4°C.
h. PEG electrolyte solution (Norgine), 1 sachet diluted in 1 It. of water. The
PEG solution is described as 'PEG+' when it contained the processing reagents
described previously and 'PEG-' when no processing reagents were added.
'PEG+/-' was prepared from PEG solution with the addition of processing
213
reagents as described in the whole gut lavage processing, but without the
additional newborn calf serum (NBCS).
j. Lymphoprep™ (Nycomed Pharma, Oslo), stored sterile in 4° C.
8.2.2B. Reagent Preparation
8.2.2B.a„ Media
The media preparation had to be performed just before the experiment. 25
ml of 10X stock dilution of HBBS were mixed with 5 ml Hepes and made up to
250 ml with sterile water. From this HBBS/Hepes solution, 45 ml were mixed
with 5 ml of PEGH7- to give the 1/10 PEGU/- in HBBS/Hepes media.
8.2.2B.b. FMLP dilutions
On the day of the experiment 5pJ of the stock FMLP were diluted in 4995
pi of HBBS/Hepes media to make a 10"5M solution. Ten pi of the previous is
then mixed with 990pl of media to prepare the 10"7 M solution. These dilutions
are 10- fold higher than those needed to make the final solutions in the test tubes.
8.2.2B.C. Dextran solution
6g of dextran powder were added into 10 ml of normal saline to give a 6%
W/V solution.
8.2.2B.d. Glutaraldehyde solution




Twenty ml of blood are mixed with 500 Units of Heparin (0.5 ml) and then
6 ml of the prepared blood are laid on top of 4 ml of Lymphoprep. The conical
tubes are then centrifuged at room temperature for 30 min. at 200g.
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Following centrifugation, the two lower layers of cells are collected: the
pellet of red blood cells and the pink cloudy layer above it. With the addition of 8
ml HBBS/Hepes and 2 ml Dextran 6% for 45 min., two layers are again separated.
The upper cloudy layer is collected.
The collected fluid is centrifiiged at 200# for 8 minutes. The supernatant
is discarded and 1 ml of sterile water is added to the pellet for 30 seconds and
quickly topped with HBBS/Hepes. This step will lyse any remaining erythrocytes.
The fluid is then again centrifuged at 200# for 8 minutes and the pellet is
resuspended in 0.5 ml of HBBS/Hepes.
8.2.3B. Initial Cell Count
Ten pi of the above mentioned suspension are added to 10 pi Trypan Blue
(i.e. 1:2 dilution). Ten pi of the above is applied onto the Neubauer chamber.
Five grids are counted (a) and the total of cells available per ml are calculated as
the previous total number divided by 10 (in 106 cells/ml, i.e. a/1 OX 106 cells/ml).
At this point any evidence of abnormal neutrophil morphology should lead to
abandonment of the experiment.
8.2.3C. Preparation Of Test Tubes
The cells are dispensed into tubes containing the chemotactic agent e.g.
FMLP, so as each tube may contain 106 cells,
i.e. lOOpl of agent
1000/a pi cells
900-1000/a pi media
The agent may be media alone (for the negative control) or FMLP 10"5 M
or FMLP 10"7 M (for the positive control). When the chemotaxis of a WGLF
specimen is assessed, 1 OOpl of lavage is added as an agent and the media is 900-
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1000/a pi of HBBS/Hepes. In this case though as positive and negative control
media 1/10 PEGH7- in HBBS/Hepes is substituted.
When the tubes are prepared, they are incubated for half hour in 37°C.
The cells are then fixed with the gluteraldehyde 2.5% solution adding an equal
volume. The cells are then washed with normal saline and centrifuged at 2000
RPM for 7 minutes. The pellet is resuspended in normal saline and the cells are
washed again with normal saline and re-centrifuged. The pellet is resuspended and
the tubes may be kept at 4° C for few days for further cell counting.
8.2.3D. Cell Microscopy & Count
The phase microscope was used to examine the cells with the X40
objective. Any cell deviating from spherical was scored as 'polarised' and
expressed as a percentage of the total. Neutrophils that were mainly spherical but
had filamentous projections or blebs were counted as negative i.e. 'non polarized'.
If there was a part of the cell that was ruffled and separated by a band from the
smooth part, then the cell was counted as 'polarised'. 300 cells were counted per
preparation tube. In all assays a negative control and a positive control were
included. Pouch or IBD WGLF specimens were examined in duplicates.
Negative control <5% of polarised cells was considered acceptable.
8.2.4. The Method Development
Whole gut lavage has as constituents: PEG, various proteins and
substances from the gut, and processing material. In theory the influence of either
PEG or the processing reagents on the percentage of polarization could not be
excluded, so it was decided to examine separately the behavior of the assay
towards these factors.
8.2.4A. PEG Electrolytes
When 'neat' PEG electrolyte solution was added to the neutrophils in the
test tubes, the neutrophils did not survive. The same was true for a 1:1 dilution.
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Thus a 1:10 dilution was selected as the one where the 'deleterious' effects of
PEG might not affect the cells. An assumption was made, that in a 1:10 dilution
there might be enough chemotactic agents to cause polarization in a lavage
sample. In the original description of the assay (Haston and Shields 1985), a
concentration of 1/10 of the agent is recommended for the test tube in the
polarization assay. Figure 8.1 shows the FMLP dose response curve for
HBBS/FIepes (n=5 experiments) and 1/10 PEG in HBBS/Hepes(n=3 experiments)
It is characteristic of the FMLP response that the 10"8M concentration is
the most potent. This is known to happen with HBBS alone, but it seems to be so
for the PEG solutions in HBBS as well. There were no significant differences
between the group of values of the dose response curve in HBBS or in PEG.
8.2.4B. The Processing Reagents
When the WGLF is obtained, a series of protease inhibitors is added to
prevent protein breakdown. To test the influence of those on the assay, neat
processed PEG (PEG+) was first assayed. As expected, the cells did not survive.
Following this, a 1/10 of the PEG+ was examined. It was observed that the
polarization of the neutrophils in 1/10 PEG+, without the addition of any other
agent, was exceptionally high (p=0.011). A hypothesis was formed that the
substance responsible for this polarization was the newborn calf serum (NBCS).
The experiment was repeated with PEG processed up to the stage of adding the
NBCS, but omitting this substance (PEG+/-). The resultant dose curve was very
much alike the usual FMLP curve (Figure 8.2). There were no differences in the
values of the FMLP dose curve obtained in either PEG+/- media or HBBS.
From this group of experiments (n=4 for the PEG+ and n=2 for PEG+/-) it
was obvious that the standard processing of the WGLF had to be modified to use
WGLF for the polarization assay. WGLF specimens with protease inhibitors
without NBCS were collected and later analyzed in batches. Other experiments
using 1/100 PEG+ were also performed, but still the negative control was high
(Figure 8.3; n=3 experiments), though not significantly different from the HBBS
controls. The option of using 1/100 dilutions of fully processed lavage samples
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Figure 8.1. The dose response curve of FMLP in the neutrophil polarisation for
(I) HBBS/Hepes and (II) 1/10 PEG in HBBS/Hepes.
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FMLP concentrations in 1/10 PEG+/- in HBBS/Hepes
Figure 8.2. The dose curve response for the FMLP in (I) 1/10 PEG'+'
& (II) 1/10 PEG+/- in HBBS/Hepes
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Figure 8.3. Part of the dose curve ofFMLP for 1:100 PEG+ in HBBS/Hepes.
220
probably have been greatly reduced by excessive dilution of the possible
chemotactic agents.
8.3. THE IL-8 EXPERIMENTS
Cytokine IL-8 is one of the known chemoattractants of neutrophils. This
was of particular interest to us, since IL-8 is present in the WGLF, measured by
ELISA techniques (as seen in chapters V and VI). The concentrations found are
up to 1000 pg/ml. It would be of interest to study the effect of IL-8 in the
presence of PEG and processing reagents in relation to the polarization assay. A
dose curve for IL-8 was performed using Human recombinant IL-8 purchased
from R&D systems. Figure 8.4 depicts the dose response curve for IL-8 both in
HBBS(n=9 experiments) and PEG+/- (n=3 experiments).
In spite of the differences, both curves seem to be sigmoid in nature, i.e.
for IL-8 a concentration is reached where further increases made little difference
to the percentage of the polarization.
Another observation was made at this stage. Different blood donors, in
spite of having similar responses to FMLP, varied as far as the response to IL-8 is
concerned. This observation meant that there are people in whom the same
concentration of IL-8 will give a constantly high, medium or low % polarization of
neutrophils (Figure 8.5). This difference may be due to different expression of IL-
8 receptors on neutrophils in different individuals. On the other hand this
observation created a difficulty in the use of the assay in whole gut lavage. It
meant that, for the same lavage specimen one may get different polarization
depending not only on the level of the chemotactic factors, but also on the
sensitivity of the donor neutrophils to the IL-8. This hypothesis necessitated the
calculation of the inter and intra assay variation, using a Quality Control (QC)


























IL-8 in 1/10 PEG+/- in HBBS/Hepes
Figure 8.4. The dose response curve for the IL- 8 (ng/ml) in




























Figure 8.5. The polarisation response to 10 ng/ml IL-8 of different donors
(5 neutrophil donors a,b,c,d,e)
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8.4. THE INTER & INTRA ASSAY VARIATION
AUDIT OF RESULTS
8.4.1. QC Experiments - Multiple Cell Donors
The polarisation assay is a biological assay and so the risk of non
reproducibility is high. To control all possible variables as much as possible a
study sheet was filled for each assay, which helped the later analysis of results.
To measure the inter and intra assay variation, four cell donors were
utilized each been repeated twice. Specimens were run in quadruplicates in the
first set of experiments and in triplicates at the second. Agents that were tested
were the 10 ng/ml of IL-8, 10"8M FMLP. The media used in the test tubes was
the 1/10 PEGH7- in HBBS/Hepes. As negative control 1/10 PEGH7- in
HBBS/Hepes was used. The QC lavage specimen was derived from the same
pouch patient, been aliquoted in small Eppendorf after processing without NBCS.
Figure 8.6 illustrates the distribution of the values obtained for these parameters.
The intraassay variation for QC in the above experiments was 4.8%, and
for the between assay was 28% (Tijssen, 1985). The variation for FMLP was
much lower, 2.2% and 5.2% respectively. These high numbers were also seen for
the IL-8 (5.5% and 37.8%) and prompted further experiments of QC using one
cell donor.
8.4.2. QC Experiments - One Cell Donor
A single donor was then used for successive experiments. Figure 8.7
shows the distribution of the values obtained. The 5 ng/ml IL-8 was also assessed,
along with the re-frozen QC sample, which seemed to maintained its potency.
It was noticeable that the variation for QC was much less, 4.6% and 3.6%
for the within and the between assay variation. To exclude any bias in the
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Figure 8.6. The distribution of values obtained at the 8 experiments of the QC
in the multiple cell donors set
100-1



















Figure 8.7. The distribution of values for a single cell donor at the QC experiments
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analysis, further calculations were made on the results of the other donors. These
showed again a 'within assay' variation of 2.5-8.1 and 'between assay' variation of
8-14.5%. The median values for the QC in either set of one or four donors, in
spite of the difference in variation, were not statistically significant. On the
contrary, the values for IL-8 were significantly different (p=0.0006; Figure 8.8).
8.4.3. The Inter Observer Variation
The experiments were a joint effort of two observers. There were
however, a few cases that each one performed the assay individually. The scarcity
of blood cell donors prevented the two observers from formally assessing the
interobserver variation. On the other hand the two observers both constantly
counted all cells of all the experiments and compared the results. For the QC
experiments for example, the variation in the counts of QC was 8.7%. An attempt
to automate counting by a computerized image analyzer proved unfruitful, since
the computer could not easily recognize artifacts.
8.5. NEUTRALIZATION: Polarisation Assay
8.5.1. Introduction
Whole gut lavage fluid contains a variety of active substances, many of
which are chemotactic; an example of one such a substance is IL-8. It would be
important, to test whether the chemotactic effect of one of the constituents could
be blocked, so that the effect of the other possible agents could be studied
separately. For IL-8, antibodies are commercially available; but for FMLP, these
have just been synthesized and were not available to us. For this reason, the





























Figure 8.8. QC experiments with the one (no arrow) & the multiple donors (arrow).
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Figure 8.9. The neutralizing effect of anti IL-8 in the polarisation by:
5 ng/ml, 10 ng/ml & 40 ng/ml of IL-8 in HBBS/Hepes media
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8.5.2. Materials
The materials and reagents used were similar to the ones used for the main
assay with the addition of the following reagents:
a. Recombinant Human IL-8 (R&D Systems). The lOpg vial was reconstituted
with 1 ml normal saline with 0.1% BSA to give a 10 ng/pl solution. This was
aliquoted and kept as stock IL-8 at -70° C for up to 3 months. On the day of the
experiment, the working dilutions were made 10 fold higher than the dilutions that
are required for the test tubes.
b. anti-human IL-8 polyclonal neutralizing antibody (R&D Systems). It was
reconstituted in PBS pH 7.4, to give a stock solution of 1 mg/ml. This remains
stable for 3-6 months at -20° C. This antibody when used in direct ELISA and
Western blots shows 10% cross-reactivity with rhGROa, but does not cross-react
with other chemokines. It does not neutralize the biological activity of rhGROa.
On the day of the experiment, again 10 fold dilutions were made from stock.
8.5.3. Methods
The assay was performed as before with the exception that during the
dextran step, an equal amount of anti IL-8 and the agent in question was incubated
together in 37° C for an hour. To the resultant mixture the media and the cells
were added for the half hour incubation that is required for the polarization assay.
Therefore the needed volumes and concentrations of both the agents and the anti




The effect of the anti IL-8 was firstly assessed in HBBS/Hepes media and
using IL-8 as the main agent. It was noticed that anti IL-8 indeed was able to
neutralize some of the polarizing effects of IL-8, depending on the concentration
of both substances. For the dose of 10 ng/ml of IL-8 (n=6 experiments), where
most of the individuals will reach their maximum plateau, the 1:125 dilution of
antibody (i.e. 0.008|j.g/pl) was enough to almost fully abolish the polarisation
response (Figure 8.9). It is noted that this dose of antibody is quadruple the dose
that theoretically is required to neutralize 50% of the biological activity of the
rhIL-8.
Having examined the feasibility of the experiment in HBBS/Hepes the
experiment was run again with 1/10 PEG+/- in HBBS/Hepes as a medium. Only
one concentration of IL-8 was checked across a variety of anti IL-8
concentrations both in HBBS and PEG+/- media (n=2 experiments; Figure 8.10).
The response obtained was very similar to the one for HBBS/Hepes.
Encouraged by these preliminary results, the response of the QC sample
was checked when 1:125 anti IL-8 was added. Four experiments were run in
duplicates using two cell donors (Figure 8.11). The inter and intra assay variation
for the QC and the QC + anti IL-8 were acceptable (2.1%, 7.4% and 1.4%, 9%
respectively). As it can be seen from the graph, no change in the value of the QC
was observed with the addition of the antibody. This is not surprising since the
WGLF IL-8 measured in this patient was as low as 44 pg/ml.
At this point we obtained a new QC lavage from another pouch patient,
which happened to have a high titre of IL-8 in his WGLF (725 pg/ml). On this
occasion, the polarization of the new QC was lower than the polarization of the
old QC, and becomes even lower at the addition of the antibody (Figure 8.12).
These results however did not reach statistical significance.
The next step was to utilize WGLF specimens collected from patients with
IBD and check their polarization and its neutralization against the disease activity.
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Figure 8.12. The new QC neutralisation experiment
























Figure 8.13. Neutralisation of polarisation in WGLF samples from IBD patients;













Figure 8.14. Polarisation in IBD patients of varied disease activity & controls.
Experiments in two batches, samples in duplicates.
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in EBD patients. There did not seem to be an obvious pattern of behaviour
relating to the clinical disease activity.
Further experiments were performed to elucidate this matter, with the
inclusion of disease controls. Still however there was not a recognizable pattern
of the chemotaxis of IBD patients (Figure 8.14).
The experiments of polarisation in pouch patients are described in Chapter









Neutrophils migrate from the wall of the gut mucosa into the gut lumen
during active mucosal inflammation. Subsequent to this migration, the neutrophils
are activated in the gut lumen and degranulate. This releases noxious proteases
which amplify gut inflammation and destructive ulceration. The chemotactic
signal for migration of neutrophils from the blood vessels into the gut wall are well
known. IL-8 plays a major role and interaction between ICAM-1 and the
CDll/18a causes neutrophils to adhere to the vascular endothelium prior to
migration. The chemotactic signals for migration of neutrophils from the gut wall
into the gut lumen are however largely unknown. I wished to use the polarisation
assay to screen whole gut lavage fluid for the presence of neutrophil
chemoattractants in the lumen of the pouch.
9.2. PATIENTS & METHODS
9.2.1. Patients
In Chapter III, the recruitment of pouch patients is presented. The analysis
of patients' clinical characteristics is given in Chapter IV. Chapter VI deals with
the WGLF parameters of the obtained samples.
As explained in chapter VIII, WGLF processing without NBCS is essential
to avoid high polarisation in the negative control samples. Consequently 58 pouch
WGLF samples were assayed. 49 patients had UC, 4 were non IBD patients and
5 had IC. Two UC patient samples were obtained early (within 6 months of
creation of the pouch). Age ranged from 18.2 to 76.8 years (median: 40.8 years).
There were 30 males: 28 females. The median pouch function time was 29.8
months (range: 1.6- 66.8 months).
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WGLF specimens without NBCS were analyzed from a variety of patients
with intact colon. These served as controls and were used for comparison with
pouch patients. Patients with intact colon included constipated patients, patients
with active or inactive Crohn's disease and patients with UC. These patients had
whole gut lavage as part of investigation of their GI symptoms.
9.2.2. Methods
Patients consumed the polyethylene glycol electrolyte solution at a steady
rate. The first clear specimen was obtained and processed omitting the NBCS
step. Full description of the whole gut lavage methodology is given in Chapter
III.
The WGLF samples thus obtained were analyzed with the polarisation
assay following the methodology described in Chapter VIII. For the study of
ileoanal pouch patients, neutrophils from a single donor were utilized and all tests
were performed by the same investigator in duplicates. For the patients with
intact colon two cell donors were used. The time interval between tests for each
batch was one week. In each assay a negative and a positive control were
included along with the QC sample, all in duplicates. The means of the duplicate
samples were considered.
9.2.3. The Statistical Analysis
The statistical analysis of the results used the median values; 95%
confidence interval (CI), interquartile range (IQ) or range; the Pearson correlation
coefficient and its p value; the non-parametric Mann-Whitney U test for unpaired
comparison of observations; %2 with Yates correction with Odds Ratio (OR) or
Relative Risk (RR). P values less than 0.05 were considered significant.
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9.3. RESULTS
9.3.1. Polarisation In Various Diagnostic Groups
Whole gut lavage fluid samples from 58 pouch patients were assayed
(Figure 9.1). The two patients who had their pouch functioning for less than six
months ('early') had low % polarisation. The other groups of patients were the
non IBD and indeterminate colitis pouch patients. It seems that the variation of
the polarisation results is considerable. The median for the UC group is 32% with
a 50% IQ range from 20% to 51%. Figure 9.2 shows the results of pouch patients
as compared with patients with intact colon. It is of interest to note that the
control group, i.e. patients with constipation or irritable bowel syndrome, had
similar results to the ones for the main UC pouch group.
9.3.2. Polarisation & Clinical Parameters
The association of the pouchoscopy score and the disease activity PDAI
with the % polarisation observed for the WGLF of patients in the main UC pouch
group are presented in Figures 9.3 and 9.4. There was no apparent correlation of
the above scores with the % of polarisation. Patients with high pouchoscopy or
PDAI scores had a variety of % polarisation.
The % of polarisation was then studied in relation to pouch biopsy
characteristics and the various functional parameters, including the Oresland
functional score. Yet again there were no apparent correlations.
9.3.3. Polarisation & WGLF Parameters
9.3.3.1. Polarisation & WGLF IgG
The WGLF IgG appeared to correlate with disease activity in ileoanal
pouches (see Chapter VI). The WGLF IgG however, did not correlate with the
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Figure 9.1. The % neutrophil polarisation in the various pouch patient groups.
There were no significant differences between the various groups*.
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
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Figure 9.2. The % polarisation in pouch* patients & patients with intact colon**
*'UC group' - patients who underwent restorative proctocolectomy for ulcerative colitis
'early UC group' - patients who underwent restorative proctocolectomy for UC within the last 6 months
'IC group' - patients who underwent restorative proctocolectomy for indeterminate colitis
**intact colon patients: disease controls
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Figure 9.4. The PDAI & % polarisation of WGLF specimens in UC pouch patients.
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Figure 9.5. The WGLF IgG and % polarisation. The dotted line represents WGLF
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Figure 9.6. The preoperative management in the high WGLF IgG subgroup. (Steroid
+ ASA: systemic steroids with 5-ASA derivatives; AZA: azathioprine; ASA: 5-ASA
derivatives).
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Furthermore, five patients with high WGLF IgG (>10p.g/ml) appeared to
have polarisation less than 20%. These patients with high WGLF IgG and low
polarisation differed in their preoperative medical management as compared with
the rest of the patients (n=7) with high WGLF IgG (see Figure 9.6).
It is evident that patients with low % polarisation and high IgG in the
WGLF of ileoanal pouches, have been prescribed fewer combinations of systemic
steroids and 5-ASA (x2=4.955, p=0.026), and more often 5-ASA alone (x2=4.955,
p=0.026) as compared to the rest of the high WGLF IgG patients. This group
also had more often routine colectomies performed (x2=6.122, p=0.014).
When the biopsy characteristics of the patients with high IgG were
considered, the subgroup of patients with low % polarisation had more ulceration
in their pouch biopsies, when compared to the rest of the high WGLF IgG patients
(X2=5.6, p=0.018).
9.3.3.2. Polarisation & WGLF GE & IL-8
WGLF GE is a marker of luminal neutrophilia. One would have expected
that patients with detectable WGLF GE should have high values of % polarisation
if the measured % polarisation is analogous to the luninal chemotactic activity.
Patients with detectable GE had a variety of values for % polarisation (see Figure
9.7). Patients with low (<20%) polarisation and detectable GE had lower WGLF
Hb (p=0.0412).
IL-8 is detectable in WGLF (see Chapter VI & VIII) and also can cause
polarisation of the donor neutrophils. There was no relation, however, of the %
polarisation with the IL-8 in WGLF (see Figure 9.8).
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Figure 9.8. The WGLF IL-8 and % polarisation in UC pouch patients
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9.4. DISCUSSION
The results of polarisation in control patients, i.e. patients with
constipation or IBS show a great variation of % polarisation. Yet the numbers
tested are small. The finding of considerable variation of % of polarisation in the
WGLF of patients with ileoanal pouches may represent what may happen in
'normal' people. It may even support the concept that the luminal antigenic load
present in ileoanal pouches is not fundamentally different to that of patients with
intact colon. Thirdly it may indicate the presence of substances,
antichemoattractants, that prevent the constant shedding of neutrophils into the
gut lumen towards this chemoattractant gradient.
If we hypothesize that the % polarisation of WGLF is analogous to the
luminal chemotactic drive for the patients' neutrophils during the WGLF process,
then it is disappointing that there was no correlation of the % polarisation and the
WGLF GE, a marker of luminal neutrophilia. On the other hand patients with
detectable GE and low polarisation had low WGLF haemoglobin, compared to the
rest of the patients with detectable GE. Clearly the level of WGLF Hb 9.5pg/ml
in the later indicates bleeding into the lumen (the cut off level is 5pg/ml for our
laboratory). Thus it seems that bleeding has a relation to the polarisation noticed
when GE is detectable.
The disease activity parameters, and especially WGLF IgG did not
correlate with the % of polarisation. For the high WGLF IgG group though,
patients with low (<20%) polarisation had more ulceration in their pouch biopsies,
apart from the deference in the pre-operative medical management mentioned.
Thus ulceration seems to be another influential parameter for the % of
polarisation.
To try to explain all these observations two hypotheses could be made:
either there is such a high inter and intra variation of the assay that results may be
less meaningful; or that the assay itself gives the picture of a phenomenon which is
influenced by so many parameters, that essentially it becomes independent from
any other WGLF tests.
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The first hypothesis is based on the fact that the polarisation assay is a
biological assay. Its application on the WGLF has its difficulties as analyzed in
Chapter VIII. However, we have shown in Chapter VIII that for a single cell
donor, as the one used for the pouch patients, the inter and intra assay variation is
acceptable. The practicality of course for using one cell donor for testing all IBD
or other specimens is such that it prevents the universal application of the test for
screening WGLF samples. On the other hand as a test itself has been used with
success in synovial fluid, where again a multiplicity of chemotactic factors were
found to be influential. In the gut however the situation may be more complicated
than the synovium due to the presence of multiple bacterial species.
The second hypothesis is that the polarisation measures a phenomenon
which is different from disease activity, i.e. gut protein loss. In Chapter VI also
we have shown that gut protein loss and luminal neutrophilia have no strong
correlation. If now the polarisation is dependent on a multiplicity of parameters of
chemo and anti-chemotactic factors then it is conceivable that this polarisation
assay will have no particular association with gut protein loss.
Another observation was that there was correlation of % of polarisation
and WGLF IL-8, a potential candidate as a chemoattractant. In Chapter VI we
have seen that WGLF contains IL-8 at a level of 0-1000 pg/ml. Calculating that
for the performance of the assay a 1/10 dilution is required, then for a
concentration of 1000 pg/ml the concentration present in the specimen tube will be
in order of the 100 pg/ml or 0.1 ng/ml. In Chapter VIII we have shown that for
this concentration the expected % polarisation is close to 0%. The values
however obtained in pouch patients were significantly higher than 0%. This
indicates that the IL-8 may not be a significant factor for endoluminal chemotaxis;
the question however for other potential candidates is open to further research.
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One possible avenue for investigation is the performance of the test with
neutrophils of the patient him/herself. This may give a closer picture to reality
than what we get by using neutrophils from a normal volunteer. On the other
hand one may add possible antichemotactic factors and measure again the
influence of those to the polarisation itself. This avenue may enable the





The work in this thesis was focused on the hypothesis that inflammation of the
ileoanal pouch is a form of IBD. Consequently WGLF methodology currently in use
in IBD clinical practice and research would be readily applicable in ileoanal pouches.
In this thesis it has been shown that protein loosing enteropathy may exist in
ileoanal pouches in a similar way to what is already known in IBD. The gut protein
loss correlates with disease activity and is often accompanied by bleeding, high
cytokine activity and luminal neutrophilia. Accordingly estimations of WGLF protein
loss along with clinical and endoscopic examination can be used for the objective
assessment of inflammation in ileoanal pouches in clinical practice. The test is well
tolerated, can be repeated as often as the clinical need dictates and the experience of
over 1000 tests in IBD patients has shown that it gives reproducible results.
Protein loosing enteropathy seems to be a feature also during the first six
months of pouch function. Clinical evidence indicates that for most of the ileoanal
pouches this protein loss settles after the first six months. For some patients however
it resurfaces, accompanied often with luminal neutrophilia, in a fashion more similar
to an ulcerative colitis inflammation.
The luminal neutrophilia relates to the luminal IL-8 measured in WGLF,
showing a similar behaviour to ulcerative colitis. The chemotactic potential of the
luminal contents as WGLF were assayed. However, IL-8 failed to show any
association with this new WGLF parameter, the percentage of polarisation. On the
other hand, it was noticed that even 'normal controls' had a variable percentage of
polarisation. This observation then poses the question; which is the parameter that
prevents a massive neutrophil exodus into the gut lumen for the 'normal' people who
have a high percentage polarisation score.
The WGLF studies allowed characterisation and definition of pouch
inflammation. This may illumine facets of inflammation in ileoanal pouches and its
management. Furthermore, the studies of ileoanal pouches with whole gut lavage
methodology may throw more light into the aetiology and pathophysiology of
pouchitis.
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An algorithm of diagnosis and management of pouchitis using the WGLF
methodology is presented at the end of this chapter. If the patient presents with severe
diarrhoea (>6 per day) and a high WGLF IgG and albumin, while neutrophil
granulocyte elastase is detectable, then it may be assumed that the patient has either
severe anal canal inflammation or active pouchitis (as defined by the Moskowitz
Criteria). Pouchoscopy will help in the differential diagnosis. If however the patient
has diarrhoea <6 per day with urgency, evacuation difficulties and a history of
bleeding per pouch, and the WGLF shows a high IgG but relatively low albumin, then
it can be presumed that the patient has 'mild' pouchitis. The patient will not fulfil the
Moskowitz Criteria, but it may be argued however that treatment of the
inflammatory process is necessary in this case.
Possible avenues for further research and exploration are:
1. A prospective study of WGLF measurements at regular intervals of ileoanal
pouches from the time of their creation onwards. This will enlighten further some
facets of inflammation during the months that follow pouch construction. It may also
identify the Group C of Setti Carraro, Talbot and Nicholls (chronic inflammation and
dysplasia; 1994) and give its immunological profile.
2. A prospective study to measure immune reactions before and after treatment for
pouchitis. The study of cytokines or pouch permeability may reveal the presence of
any prognostic factors
3. The study of other facets of inflammation, like eosinophil activity (by measuring
RANTES or ECP), levels of complement and LTB4
4. The study of bacterial antigens or their antibodies (e.g. to bacteroides) in normal
and inflamed pouches.
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5. Estimation of percentage polarisation with neutrophils of the patient and with
incubation of various antichemotactic factors.
Our insights into the immunology of ileoanal pouches may only be advanced
by measurements of characteristics of the disease phenomena studied.
As Lord Kelvin's dictum states,
The more we measure something the more we understand it..'
♦
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An Algorithm of Pouchitis
1. If the patient has diarrhoea <6 per day with urgency, evacuation difficulties, a history of bleeding per pouch, and the WGLF shows a
high IgG but relatively low albumin, then the patient has 'mild' pouchitis but the patient may not fulfil the Moskowitz Criteria.
2. If the patient presents with severe diarrhoea (>6 per day) and a high WGLF IgG and albumin, with detectable neutrophil granulocyte
elastase, then the patient has either severe anal cuff inflammation or active pouchitis (as defined by the Moskowitz Criteria). Pouchoscopy
is indicated to establish the diagnosis.
251
Bibliography
Acciuffi, S., Ghosh, S., & Ferguson, A. (1996). Strengths and limitations of the
Crohn's disease activity index, revealed by an objective gut lavage test of
gastrointestinal protein loss. Aliment Pharmacol Ther, 10, 321-326.
Ambroze, W.L., Pemberton, J.H., Phillips, S.F., Bell, A.M., & Haddad, A C. (1993).
Fecal Short -Chain Fatty Acid Concentrations and effect on ileal pouch function. Dis
Colon Rectum, 36, 235-239.
Anton, P.A., Targan, S.R., & Shanahan, F. (1989). Increased neutrophil receptors for
response to proinflammatory bacterial peptide FMLP in Crohn's disease.
Gastroenterology, 97, 20-28.
Apel, R., Cohen, Z., Andrews, C.W., McLeod, R., Steinhart, H., & Odze, R.D.
(1994). Prospective evaluation of early morphological changes in pelvic ileal pouches.
Gastroenterology, 107, 435-443.
Arber, N., Berliner, S., Hallak, A., Bujanover, Y., Dotan, I., Liberman, E., Santo, M.,
Moshkowitz, M., Ratan, J., Dotan, G., Konikoff, F.M., Aronson, M., & Gilat, T.
(1995). Increased leucocyte adhesiveness/aggregation is a most usuful indicator of
disease activity in patients with inflamatory bowel disease. Gut, 37, 77-80.
Armstrong, D.N., Ballantyne, G.H., Adrian, T.E., Bilchik, A.J., McMillen, M.A., &
Modlin, I.M. (1991). Adaptive increase in peptide YY and Enteroglucagon after
proctocolectomy and pelvic ileal reservoir construction. Diseases of the Colon and
Rectum, 34, 119-125.
Atkinson, K.G., Owen, D.A., & Wankling, G. (1994). Restorative Proctocolectomy
and Indeterminate Colitis. American Journal Surgery, 167, 516-518.
Banerjee, A.K. (1994). Hypothesis - Pouchitis represents a useful clinical model of
Ulcerative Colitis. Medical Hypotheses, 42, 36-38.
Barker, G.M., Radley, S., Davis, A., Imray, C.H.E., Setchell, K.D.R., O'Connell, N.,
Donovan, I.A., Keighley, M.R.B., & Neoptolemos, J.P. (1994). Unconjugated faecal
bile acids in familial adenomatous polyposis analysed by gas- liquid chromatography
and mass spectrometry. British Journal Surgery, 81, 739-742.
Barsoum, G.H., Winslet, M., Youngs, D., Neoptolemos, J.P., & Keighley, M.R.B.
(1992). Influence of dietary calcium supplements on ileoanal pouch function and
cytokinetics. British Journal Surgery, 79, 129-132.
252
Bartolo, D.C.C., & Duthie, G.S. (1993). Physiological Studies Following Restorative
Proctocolectomy. In R.J. Nicholls, D.C. Bartolo, & N.J.M. Mortensen (Eds.),
Restorative Proctocolectomy, (pp. 83-100). Oxford: Blackwell Scientific Publication.
Bayat, M., Brynskov, J., Dige- Petersen, H., Hippe, E., & Lonborg- Jeensen, H.
(1994). Direct and quanitative vitamin Bi2 absorption measurement in patients with
disorders in the distal part of the bowel. Comparison of the stool spot test (SST) with
whole body counting in patients with ileal pelvic reservoir, ileostomy or Crohn's
disease. International Journal ofColorectal Disease, 9, 68-72.
Belluzzi, A., Campieri, M., Miglioli, M., Boschi, S., Gionchetti, P., Brignola, C.,
Rizzello, F., Bortoluzzi, L., Poggioli, G., Gozzetti, G., & Barbara, L. (1992).
Evaluation of Flogistic pattern in pouchitis before and after the treatment with
Butesonide Suppositories. Gastroenterology, 102, A593
Belsheim, J., Gnarpe, H., & Persson, S. (1981). Granulocyte chemotaxis in Crohn's
disease. Acta Chir Scandin, 147, 197-200.
Belsheim, J., Gnarpe, H., & Swahn, A. (1984). Granulocyte chemotaxis in ulcerative
colitis. Acta Pathologica, Microbiologica, et Immunologica Scandinavica - Section
C, Immunology ,92, 75-79.
Best, W.R., Becktel, J.M., Singleton, J.W., & Kern, F.Jr. (1976). Development of a
Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study.
Gastroenterology, 70, 439-444.
Binder, V., & Riis, P. (1977). The leucocyte chemotactic function in patients with
ulcerative colitis. Scandinavian Journal ofGastroenterology, 12, 141-144.
Boehme, M.W., Autschbach, F., Zuna, I., Scherbaum, W.A., Strange, E., Raeth, U.,
Sieg, A., & Stremmel, W. (1997). Elevated serum levels and reduced
immunohistochemical expression of thrombomodulin in active ulcerative colitis.
Gastroenterology, 112(1), 107-117.
Boerr, L.A.R., Sambuelli, A.M., Sugai, M., Graziano, A., Valero, J., Kogan, Z., &
Bai, J. (1995). Faecal alphal- antitrypsin concentation in the diagnosis and
management of patients with pouchitis. European Journal of Gastroenterology and
Hepatology, 7, 129-133.
Bortoluzzi, F., Valentini, M., Cernigoi, C., Toffoli, G., Boiocchi, M., Poletti, M.,
Sozzi, M., Fornasarig, M., Canizzaro, R., & Bertolissi, E. (1995). DNA flow
cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed
method for assessing severity of disease. Gut, 36(1), 50-54.
253
Brydon, W.G., Choudari, C.P., & Ferguson, A. (1993). Relative specificity for active
inflammatory bowel disease of plasma-derived proteins in gut lavage fluid. European
Journal ofGastroenterology and Hepatology, 5,269-273
Brydon, W.G., & Ferguson, A. (1992). Flaemoglobin in gut lavage fluid as a measure
of gastro-intestinal blood loss. The Lancet, 340, 138 1-1382.
Brynskov, J.,Tvede, N., Vilien, M., Anderson, C.B., & Bentzen, K. (1992). Increased
concentrations of interleukin 1(3, interleukin-2, soluble interleukin-2 receptors in
endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut,
33, 55-58
Campbell, A.P., Merrett, M.N., Kettlewell, M., Mortensen, N.J.M., & Jewell, D.P.
(1994). Expression of colonic antigens by goblet and columnar epithelial cells in ileal
pouch mucosa : Their association with inflammatory change and faecal stasis. Journal
ofClinical Pathology, 47, 834-838.
Cellier, C., Sahmoud, T., Froguel, E., Adenis, A., Belaiche, J., Bretagne, J.F.,
Florent, C., Bouvry, M., Mary, J.Y, & Montigliani, R. (1994). Correlations between
clinical activity, endoscopic severity, and biological parametrs in colonic or
ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The
Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut,
35(2), 231-235.
Chadwick, V.S., & Cammilleri, M.(1990). Pathophysiology of small intestinal
function and the effect of Crohn's disease. In R.N Alan, M.R.B. Keighley,
J.,Alexander-Williams (Eds.),Inflammatory Bowel Diseases.New York: Churchill
Livingstone.
Chaussade, S., Denizot, Y., Nicoli, J., Valleur, P., Hautefeuille, P., Benveniste, J.,
Raibaut, P., Guerre, J., & Couturier, D. (1990). Stool PAF-Acether (PAF) is
increased in patients with pouch ileo-anal anastomosis (IAA) and pouchitis.
Gastroenterology, 98, A164
Choudari, C.P., O'Mahony, S., Brydon, W.G., Mwantembe, O., & Ferguson, A.
(1993). Gut lavage fluid protein concentrations: objective measures of disease activity
in inflammatory bowel disease. Gastroenterology, 104, 1064-1071.
Christie, P.M., & Hill, G.L. (1990). Return to normal body composition after ileoanal
J- pouch anastomosis for ulcerative colitis. Diseases of the Colon and Rectum, 33,
584-586.
Clark, M.L.., & Kumar, P.J. (1994). Inflammatory Bowel Disease. In P.J. Kumar, &
ML.. Clark (Eds.), Clinical Medicine, (pp.215-220). London: Bailliere Tindall.
254
Clausen, M.R., Tvede, M., & Mortensen, P.B. (1992). short-chain fatty acids in
pouch contents from patients with and without pouchitis after ileal pouch-anal
anastomosis. Gastroenterology, 103, 1144-1153.
Corfield, A.P., Warren, B.F., Bartolo, D.C.C., Wagner, S.A., & Clamp, J.R. (1992).
Mucin changes in ileoanal pouches monitored by metabolic labelling and
histochemistry. Bitishr Journal of Surgery, 79, 1209-1212.
Counihan, T.C., Roberts, P.L., Schoetz, D.J., Coller, J.A., Murray, J.J., &
Veidenheimer, M.C. (1994). Fertility and Sexual and Gynecologic Function After
Ileal Pouc-Anal Anastomosis. Diseases of the Colon and Rectum, 37, 1126-1129.
Couper, R., Kapelushnik, J., & Griffiths, A.M. (1991). Neutrophil dysfunction in
glycogen storage disease lb: association with Crohn's-like colitis. [Review],
Gastroenterology, 100, 549-554.
Crama-Bohbouth, G., Pena, A.S., Biemond, I., Verspaget, H.W., Block, D., Arndt,
J.W., Weterman, I T., Pauwels, E.K., & Lamers, C.B. (1989). Are activity indices
helpful in assessing active intestinal inflammation in Crohn's disease? Gut, 30(9),
1236-1240.
Crissinger, K.D., Kvietys, P.R., & Granger, D.N. (1990). Pathophysiology of
gastrointestinal mucosal permeability. Journal Internal Medicine, 228(Suppl 1), 145-
154.
Croft, N.M., Marshall, T.G., & Ferguson, A. (1995). Gut inflammation in children
with cystic fibrosis on high - dose enzyme supplements. The Lancet, 346, 1265-1267.
Curran, F.T., & Keighley, M.R. (1991). Neutrophil motility in Crohn's disease.
Digestion, 48, 104-112.
Cutler, E.C. (1992). The art of surgery. Archives ofSurgery, 18(4), 1190-1199.
Damgaard, B., Wettergren, A., & Kirkegaard, P. (1995). Social and sexual Function
Following Ileal Pouch-Anal Anastomosis. Diseases of the Colon & Rectum, 38, 286-
289.
de Dombal, F.T., & Softley, A. (1987). IOIBD report nol: observer variation in
calculating indices of severity and activity in Crohn's disease. International
Organisation for the study of Inflammatory Bowel Disease. Gut, 28(4), 474-481.
de Silva, H.J., de Angelis, C.P., Soper, N., Kettlewell, M., Mortensen, N.J.M., &
Jewell, DP. (1991). Clinical and functional outcome after restorative
proctocolectomy, British Journal of Surgery, 78, 1039-1044.
255
de Silva, H.J., Ireland, A., Kettlewell, M., Mortensen, & Jewell, D P. (1989).
Short-chain fatty acid irrigation in severe pouchitis. New England Journal of
Medicine, 1416-1417.
de Silva, H.J., Jones, M., Prince, C., Kettlewell, M, Mortensen, N.J.M., & Jewell,
D.P. (1991). Lymphocyte and macrophage subpopulations in pelvic ileal pouches.
Gut, 32, 1160-1165.
Deen, K.I., Williams, J.G., Billingham, G.C., & Keighley, M.R.B. (1995). randomized
trial to determine the optimum level of pouch-anal anastomosis in stapled restorative
proctocolectomy. Diseases of the Colon & Rectum, 38, 133-138.
Deutsch, A.A., McLeod, R.S., Cullen, J., & Cohen, Z. (1991). Results of the pelvic-
pouch procedure in patients with Crohn's disease. Diseases of the Colon and Rectum,
34, 475-477.
Dozois, R.R., Kelly, K.A., Welling, D R., Gordon, H., Beart, R.W., Wolff, B.G.,
Pemberton, J.H., & Ilstrup, D.M. (1989). Ileal pouch-anal anastomosis: comparison
of results in Familial Adenomatous Polyposis and Chronic Ulcerative Colitis. Ann
Surg, 2JO, 268-273.
Dvorak, A.M., Onderdonk, A.B., McLeod, R.S., Monahan-Earley, R.A., Cullen, J.,
Antonioli, D., Blair, J.E., Morgan, E.S., Cisneros, R.L., Estrella, P., Cohen, Z., &
Silen, W. (1993). Axonal Necrosis of Enteric Autonomic Nerves in Continent Ileal
Pouches. Ann Surg, 217, 260-271.
Elmgreen, J. (1984). Subnormal activation of phagocytes by complement in chronic
inflammatory bowel disease? Neutrophil chemotaxis to complement split product
C5a. Gut, 25, 737-742.
Elmgreen, J., Berkowicz, A., & Sorensen, H. (1983). Defective release of C5a related
chemo-attractant activity from complement in Crohn's disease. Gut, 24, 525-531.
Elmgreen, J., & Binder, V. (1982). The chemotactic function of neutrophils in
ulcerative colitis. Scandinavian Journal ofGastroenterology, 17, 561-564.
Emblem, R., Erichsen, A.A., Morkrid, L., Ganes, T., Stien, R., & Bergan, A. (1989).
Failed ileoanal anastomoses : correlation between clinical findings and anal canal
neurophysiologic and histological examinations. Scandinavian Journal of
Gastroenterology, 24, 623-631.
Farouk, R., Duthie, G.S., & Bartolo, D.C.C. (1994). Recovery of the internal anal
sphincter and continence after restorative proctocolectomy. British Journal of
Surgery, 81, 1065-1068.
256
Fazio, V.W., Ziv, Y., Church, J.M., Oakley, J.R., Lavery, I.C., Milsom, J.W., &
Schroeder, T.K. (1995). Ileal Pouch-Anal Anastomoses Complications and Function
in 1005 Patients. Annals ofSurgery, 222, 120-127.
Ferguson, A. (1996). Mucosal immunology: from bench to the bedside and beyond.
Immunology, 89,475-482
Ferguson A.., & Ghosh S.. Investigation of cytokines in the inflammatory bowel
diseases of the gut by whole gut lavage analysis. International Cytokine Society, 3rd
annual Conference, Harrogate:
Ferguson, A., Brydon, W.G., Brian, H., Williams, A., & Mackie, M.J. (1996). Use of
whole gut perfusion to investigate gastrointestinal blood loss in patients with iron
deficiency anaemia. Gut, 38, 120-124.
Ferguson, A., Ghosh, S., Handy, L.M., Choudari, C., Mwantembe, O., & Mclntyre,
M.A. (1994). Analysis of disease distribution, activity and complications in the patient
with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 29;
Suppl 203, 15-19.
Ferguson, A., Humphreys, K.A., & Croft, N.M. (1995). Technical report: results of
immunological tests on faecal extracts are likely to be extremely misleading. Clin Exp
Immunol, 99, 70-75.
Ferguson, A., & Mwantembe, O. (1995). Intestinal Lavage test of Gut Inflammation
and Immunity. In S. Auricchio, A. Ferguson, & R. Troncone (Eds.), Mucosal
Immunity and the Gut Epithelium: Interactions in health and Disease. (Vol4, pp. 90-
97). Dyn Nutr Res. Basel: Karger.
Ferguson, A., Sallam, J., O'Mahony, S., & Poxton, I. (1995). Clinical investigation of
gut immune responses. Advanced drug delivery reviews, 18, 53-71.
Ferrara, A., Pemberton, J.H., Grotz, R.L., & Hanson, R.B. (1994). Motor
determinants of incontinence after ileal pouch-anal anastomosis. Br J Surg, 81, 285-
288.
Fiorentini, M.T., Locatelli, L., Ceccopieri, B., Bertolino, F., Ostellino, O., Barlotta,
A., Rolfo, P., Ferraris, R., de la Pierre, M., & Dellepiane, M. (1987). Physiology of
ileoanal anastomosis with ileal reservoir for ulcerative colitis and adenomatosis coli.
Diseases of the Colon and Rectum, 30, 267-272.
Fozard, B.J., & Pemberton, J.H. (1992). Results of pouch Surgery after ileo-anal
anastomosis: The implications of pouchitis. World J Surg, 16, 880-884.
257
Gaspari, M.M., Brennan, P.T., Solomon, S.M., & Elson, C.O. (1988). A method of
obtaining, processing, and analyzing human intestinal secretions for antibody content.
Journal ofImmunological Methods, 110, 85-91.
Gertner, D.J., Rampton, D.S., Madden, M.V., Talbot, I.C., Nicholls, R.J., &
Lennard-Jones, J.E. (1994). Increased leucotriene B4 release from ileal pouch mucosa
in ulcerative colitis compared with familial adenomatous polyposis. Gut, 35, 1429-
1432.
Ghosh, S. (1995). Investigation of proinflammatory cytokines in gut by analysis of
WGLF.In Nutritional and immunological studies in inflammatory bowel disease, MD
Thesis University of Edinburgh, (pp. 174-193).
Ghosh, S., Humphreys,K., Papachrysostomou, M., & Ferguson, A. (1997). Detection
of insulin-like growth factor-1 and transforming growth factor- B in whole gut lavage
fluid : a novel method of studying intestinal fibrosis. Eur Journal of Gastroenterology
& Hepatology, 9, 505-508
Giaffer, M.H. (1996). Labelled leucocyte scintigraphy in inflammatory bowel disease:
clinical applications. Gut, 38, 1-5.
Gionchetti, P., Campieri, M., Belluzzi, A., Bertinelli, E., Ferretti, M., Brignola, C.,
Poggioli, G., Miglioli, M., & Barbara, L. (1994). Mucosal Concentrations of
Interleukin- lb, Interleukin- 6, Interleukin- 8, and Tumor Necrosis Factor- a in Pelvic
Ileal Pouches. Digestive Diseases and Sciences, 39 (7), 1525-1531.
Gionchetti, P., Campieri, M., Belluzzi, A., Paganelli, G.M., Tampieri, M., Bertinelli,
E., Brignola, C., Poggioli, G., Miglioli, M., Gozzetti, G., & Barbara, L. (1992).
Macrophage subpopulations in pouchitis. Gut, 33, 1008
Gionchetti, P., Campieri, M., Ferretti, M., Rizzello, F., Venturi, A., Belluzzi, A.,
Brignola, C., & Miglioli, M. (1995). Bismuth carbomer enemas in tretment of chronic
unremitting pouchitis. Gut, 37, A49
Grobler, S.P., Hosie, KB., Thompson, H., & Keighley, M.R.B. (1993). Outcome of
restorative proctocolectomy when the diagnosis is suggestive of Crohn's disease. Gut,
34, 1384-1388.
Groom, J.S., Kamm, M.A., & Nicholls, R.J. (1994). Relationship of small bowel
motility to ileoanal reservoir function. Gut, 35, 523-529.
Grotz, R.L., & Pemberton, J.H. (1993). The Ileal Pouch Operation for Ulcerative
Colitis. Surgical Clinics ofNorth America, 73, 909-932.
258
Gustavsson, S., Weiland, L.H., & Kelly, K.A. (1987). Relationship of Backwash
Ileitis to Ileal Pouchitis after Ileal Pouch-Anal Anastomosis. Diseases of the Colon &
Rectum, 30, 25-28.
Hadziselimovic, F., Emmons, L.R., & Gallati, H. (1995). Soluble tumour necrosis
factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of
treatment of inflammatory bowel disease. Gut, 37(2), 260-263.
Hallgren, T., Fasth, S., Delbro, D.S., Nordgren, S., Oresland, T., & Hulten, L.
(1994). Loperamide Improves Anal Sphincter Function and Continence After
Restorative Proctocolectomy. Digestive Diseases and Sciences, 39, 2612-2618.
Hallgren, T., Fasth, S., Nordgren, S., Oresland, T., & Hulten, L. (1991). The effect of
atropine and bensilonium bromide on pelvic pouch and anal sphincter function.
Scandinavian Journal ofGastroenterology, 216, 563-571.
Handy, L.M., Ghosh, S., & Ferguson, A. (1995). Investigation of neutrophil
migration into the gut by cytology of whole gut lavage fluid. European Journal of
Gastroenterology and Hepatology, 7, 53-58.
Handy, L.M., Ghosh, S., & Ferguson, A. (1996).Investigation of neutrophils in the
gut lumen by assay of granulocyte elastase in WGLF. Scaninavian Journal of
Gastroenterology, 31, 700-705
Haston, W.S., & Shields, J.M. (1985). Neutrophil Leucocyte Chemotaxis : a
Simplified Assay for Measuring Polarising Responses to Chemotactic Factors.
Journal ofImmunological Methods, 81, 229-237.
Heppell, J., Belliveau, P., Taillefer, R., Dube, S., & Derbekyan, V. (1987).
Quantitative Assessment of Pelvic Ileal Reservoir emptying with a semisolid
radionuclide enema. Diseases of the Colon and Rectum, 30, 81-85.
Hermanowicz, A., & Nawarska, Z. (1981). Chemotaxis and random migration of
polymorphonuclear leukocytes in ulcerative colitis examined by the agarose method.
Scandinavian Journal ofGastroenterology, 16, 961-966.
Hermanowicz, A., & Nawarska, Z. (1986). Normal chemotactic migration of
polymorphonuclear leukocytes stimulated with mononuclear-derived chemotactic
factor in ulcerative colitis. International Archives ofAllergy & Applied Immunology,
81, 63-68.
Hermanowicz, A., Sliwinski, Z., & Kaczor, R. (1985). Effect of long-term therapy
with sulphasalazine, levamisole, corticosteroids and ascorbic acid and of disease
activity on polymorphonuclear leukocyte function in patients with ulcerative colitis.
Hepato-Gastroenterology, 32, 81-86.
259
Hewett, P.J., Stitz, R., & Hewett, M.K. (1995). Harry E. Bacon Oration. Comparison
of the functional results of restorative proctocolectomy for ulcerative colitis between
the J and W configuration ileal pouches with sutured ileoanal anastomosis. Diseases
of the Colon & Rectum, 38, 567-572.
Hobson, C.H., Butt, T.J., Ferry, D M., Hunter, J., Chadwick, V S., & Broom, M.F.
(1988). Enterohepatic circulation of bacterial chemotactic peptide in rats with
experimental colitis. Gastroenterology, 94, 1006-1013.
Hosie, K., Sachaguchi, M., Tudor, R., Courevitch, D., Kmiot, W.A., & Keighley,
M.R.B. (1989). Pouchitis after restorative proctocolectomy is associated with
mucosal ischaemia. Gut, 30 Suppl, A1471-A1472.
Hosie, K B., Davie, R.J., Grobler, S.P., Birch, N.J., & Keighley, M.R.B. (1993). Bile
acid absorption after restorative proctocolectomy. British Journal of Surgery, 80,
1068
Hosie, KB., Kmiot, W.A., & Keighley, M.R.B. (1990). Constipation; another
indication for restorative proctocolectomy. British Journal of Surgery, 77, 801-802.
Hulten, L., Fasth, S., & Oresland, T. (1993). Pelvic Pouch - Physiology vs. Function.
In R.J. Nicholls, D.C. Bartolo, & N.J.M. Mortensen (Eds.), Restorative
Proctocolectomy, (pp. 101-118). Oxford: Blackwell Scientific Publishers.
Hyman, N.H., Fazio, V.W., Tuckson, W.B., & Lavery, I.C. (1991). The
consequences of ileo pouch -anal anastomosis for Crohn's colitis. Diseases of the
Colon and Rectum, 34, 653-657.
Isaacs, K.L., Sartor, R.B., 8c Haskill, S. (1992). Cytokine messenger RNA profiles in
inflammatory bowel disease mucosa detected by polymerase chain reaction
amplification. Gastroenterology. 103(5), 1587-1595,
Jawary, D., Cameron, P.A., Dziukas, L., & McNeil, J.J. (1992). Drug overdose-
reducing the load. Medical Journal ofAustralia, 156, 343-346.
Juhasz, E.S., Fozard, B., Dozois, R.R., Ilstrup, D M., & Nelson, H. (1995). Ileal
Pouch-Anal Anastomosis Function Following Childbirth
An Extended Evaluation. Diseases of the Colon and Rectum, 38, 159-165.
Kazi, N., Fields, J.Z., Sedghi, S., Kottapalli, V., Eiznhamer, D., Winship, D., &
Keshavarzian , A. (1995). Modulation of neutrophil function by novel colonic factors:
possible role in pathophysiology of ulcerative colitis. Journal Laboratory & Clinical
Medicine, 126(1), 70-80.
260
Keighley, M.R.B.(1993a). Aetiology,epidemiology and natural history of Ulcerative
colitis. In M.R.B. Keighley, & N.S. Williams (Eds), Surgery of the Anus, Rectum, and
Colon, (pp. 1239-1273). London: W. B. Saunders
Keighley, M.R.B.(1993b). Crohn's Disease: natural history, morbidity and mortality.
In M.R.B. Keighley, & N.S. Williams (Eds), Surgery of the Anus, Rectum, and
Colon, (pp. 1660-1676). London: W. B. Saunders
Keighley, M.R.B., Grobler, S., & Bain, I. (1993). An audit of restorative
proctocolectomy. Gut, 34, 680-684.
Keighley, M.R.B., Winslet, M.C., Flinn, R., & Kmiot, W.A. (1976). Multivariate
analysis of factors influencing the results of restorative proctocolectomy. British
Journal of Surgery, 740-744.
Keighley, M.R.B., Yoshioka, K., Kmiot, W.A., & Heyen, F. (1988). Physiological
parameters influencing function in restorative proctocolectomy and ileo pouch anal
anastomosis. British Journal of Surgery, 75, 997-1002.
Kelly, R.E., Abedin, M.Z., Fonkalsrud, E.W., Cates, J.A., Saunders-Kirkwood, K.,
Masuda, H., Huang, E.J., Dhiman, J.K., & Roslyn, J.J. (1993). Early and long term
effects of colectomy and endorectal pullthrough on bile acid profile. Annals of
Surgery, 217, 321-328.
Kirk, A.P., Cason, J., Fordham, J.N., Brown, K.A., Goddard, D.H., Holborow, E.J.,
& Lennard-Jones, J.E. (1983). Polymorphonuclear leukocyte function in ulcerative
colitis and Crohn's disease. Digestive Diseases & Sciences , 28, 236-248.
Kmiot, W.A., Hesslewood, R., Smith, N., Thompson, H., Harding, L.K., & Keighley,
M.R.B. (1993). Evaluation of the inflammatory infiltrate in pouchitis with 111 In-
labeled Granulocytes. Gastroenterology, 104, 981-988.
Kmiot, W.A., Williams, M.R., & Keighley, M.R.B. (1990). Pouchitis following
colectomy and ileal reservoir construction for familial adenomatous polyposis. British
Journal of Surgery, 77, 1283
Kmiot, W.A., Yoshioka, K., Pinho, M., & Keighley, M.R.B. (1990).
Videoproctographic assessment after restorative proctocolectomy. Diseases of the
Colon and Rectum, 33, 566-572.
Kmiot, W.A., Youngs, D., Tudor, R., Thompson, H., & Keighley, M.R.B. (1993).
Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis.
British Journal of Surgery, 80, 1445-1449.
261
Koizumi, M., King, N., Lobb, R., Benjamin, C., & Podolsky, D.K. (1992).
Expression of vascular adhesion molecules in inflammatory bowel disease.
Gastroenterology, 103, 840-847.
Koltun, W.A., Schoetz, D.J.J., Roberts, P.L., Murray, J.J., Coller, J.A., &
Veidenheimer, M.C. (1991). Indeterminate colitis predisposes to perineal
complications after ileal pouch- anal anastomosis. Diseases of the Colon and Rectum,
34, 857-860.
Koltun, W.A., Smith, R.J., Loehner, D., Durdey, P., Coller, J.A., Murray, J.J.,
Roberts, P.L., Veidenheimer, M.C., & Schoetz, D.J. (1993). Alteration in Intestinal
Permeability after Ileal Pouch- Anal Anastomosis. Diseases of the Colon and Rectum,
36, 922-926.
Kumar, P.J., & Clark, M.L. (1994) Inflammatory bowel disease. In Kumar, P.J., &
Clark, M.L.(Eds.), Clinical Medicine (third edition), (pp. 215-220). London:
Bailliere Tindall.
Levin, K.E., Pemberton, J.H., Phillips, S.F., Zinsmeister, A.R., & Pezim, M.E.
(1992). Role of Oxygen Free Radicals in the Etiology of Pouchitis. Disease of the
Colon & Rectum, 35, 452-456.
Levitt, M.D., Kamm, M.A., Groom, J., Hawley, P R., & Nicholls, R.J. (1992).
Ileoanal pouch compliance and motor function. British Journal of Surgery, 79, 126-
128.
Levitt, M.D., Kamm, M.A., Van der Sijp, J.R.M., & Nicholls, R.J. (1994).
Ambulatory pouch and anal motility in patients with ileo-anal reservoirs. International
Journal ofColorectal Disease, 9, 40-44.
Lewis, W.G., Holdsworth, P.J., Sagar, P.M., Stephenson, B.M., Finan, P.J., &
Johnston, D. (1994). Coordinated Activity of the new "Rectum" and Anal Sphincter
After Sphincter-Saving Resection of the Rectum for Colitis or Carcinoma. Diseases
of the Colon and Rectum, 37, 1012-1019.
Lewis, W.G., Kuzu, A., Sagar, P.M., Holdsworth, P.J., & Johnston, D. (1994).
Stricture at the pouch- anal anastomosis after restorative proctocolectomy. Diseases
of the Colon & Rectum, 37, 120-125.
Lewis, W.G., Sagar, P.M., Holdsworth, P.J., Axon, A T., & Johnston, D. (1993).
Restorative proctocolectomy with end to end pouch anal anastomosis in patients over
the age of fifty. Gut, 34, 948-952.
262
Lindquist, K. (1990). Anal manometry with microtransducer technique before and
after restorative proctocolectomy. Sphincter function and clinical correlations.
Diseases of the Colon and Rectum, 33, 91-98.
Lobo, A.J., Sagar, P.M., Rothwell, J., Godwin, P GR., Johnston, D., & Axon,
A.T.R. (1993). Carriage of adhesive Escherichia coli after restorative
proctocolectomy and pouch anal anstomosis : relation with functional outcome and
inflammation. Gut, 34, 1379-1383.
Lobos, E.A., Sharon, P., & Stenson, W.F. (1987). Chemotactic activity in
inflammatory bowel disease. Role of leukotriene B4. Digestive Diseases & Sciences ,
32, 1380-1388.
Lohmuller, J.L., Pemberton, J.H., Dozois, R.R., Ilstrup, D M., & van Heerden, J.
(1990). Pouchitis and Extraintestinal manifestations of inflammatory bowel disease
after ileal pouch-anal anastomosis. Ann Surg, 211, 622-629.
Lofberg, R., Liljeqvist, L., Veress, B., Reinholt, F.P., & Tribukait, B. (1991).
Dysplasia and DNA aneuploidy in a pelvic pouch report of a case. Diseases of the
Colon and Rectum, 34, 280-284.
Luukkonen, P., Valtonen, V., Sivonen, A., Sipponen, P., & Jarvinen, H. (1988). Fecal
bacteriology and reservoir ileitis in patients operated on for ulcerative colitis.
Diseases of the Colon and Rectum, 31, 864-867.
M'Koma, A.E. (1994). Follow-up results of Hematology
Data before and After Restorative Proctocolectomy
Clinical Outcome. Diseases of the Colon and Rectum, 37, 932-937.
Macfarlane, G.T., Gibson, G.R., & Cummings, J.H. (1992). Comparison of
fermentation reactions in different regions of the human colon. Journal Applied
Bacteriology, 72, 57-64.
Madden, M.V., Farthing, M.J.G., & Nicholls, R.J. (1990). Inflammation in ileal
reservoirs: pouchitis. Gut, 31, 247-249.
Madden, M.V., Mclntyre, A.S., & Nicholls, R.J. (1994). Double- blind crossover trial
of metronidazole versus placebo in chronic unremitting pouchitis. Digestive Diseases
and Sciences, 39, 1193-1196.
Mahida, Y.R., Wu, K., & Jewell, D P. (1989).Enhanced production of interleukin 1-
(3 by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's
disease. Gut, 30, 835-838.
263
Mahmud, N., McDonald, G.S., Kelleher, D., & Weir, D.G. (1996). Microalbuminuria
correlates with intestinal histopathological grading in patients with inflammatory
bowel disease. Gut, 38(1), 99-103.
Mary, J.Y., & Modigliani, R. (1989). Development and validation of an endoscopic
index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'
Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif
(GETAID).Gwt, 30(7), 983-989.
McCall, T.B., O'Leary, D., Bloomfield, J., & O'Morain, C.A. (1989). Therapeutic
potential of fish oil in the treatment of ulcerative colitis. Alimentary Pharmacology &
Theraeutics, 3, 415-424.
McCarthy, D.A., Rampton, D.S., & Liu, Y.C. (1991). Peripheral blood neutrophils in
inflammatory bowel disease : morphological evidence of in vivo activation in active
disease. Clin Exp Immunol, 86, 489-493.
McHugh, S.M., & Diamant, N.E. (1987). Effect of age, gender and parity on anal
canal presures. Contribution of impaired anal sphincter function to faecal continence.
Digestive Diseases & Sciences, 32, 726-736.
Mclntyre, P.B., Pemberton, J.H., Wolff, B.G., Dozois, R.R., & Beart, R.W.J. (1995).
Indeterminate Colitis Long- Term Outcome in patients after Ileal Pouch- anal
anastomosis. Diseases of the Colon and Rectum, 38, 51-54.
McLeod, R.S., Antonioli, D., Cullen, J., Dvorak, A., Onderdonk, A., Silen, W., Blair,
J.E., Monahan- Earley, R., Cisneros, R., & Cohen, Z. (1994). Histologic and
Microbiologic features of Biopsy Samples from Patients with Normal and Inflamed
Pouches. Diseases of the Colon and Rectum, 37, 26-3 1.
McLeod, R.S., Taylor, D.W., Cohen, Z., & Cullen, J.B. (1986). Single patient
randomised clinical trial; Use in determining optimum treatment for patient with
infiflammation ofKock Continent Ileostomy Reservoir. The Lancet, 726-729.
Merrett, M.N., Mortensen, N.J.M., Kettlewell, M., & Jewell, D P. (1996). Smoking
may prevent pouchitis in patients with restorative proctocolectomy for ulcerative
colitis. Gut, 38, 362-364.
Meuwissen, S.G.M., Hoitsma, H., Boot, H., & Seldenrijk, C.A. (1989). Pouchitis
(pouch ileitis). Netherlands JMedicine, 35, S54-S66.
Mignon, M., Stettler, C., & Phillips, S.F. (1995). Pouchitis- Apoorly Understood
Entity. Diseases of the Colon & Rectum, 38, 100-103.
264
Mikkola, K., Luukkonen, P., & Jarvinen, H.J. (1995). Long-term results of
restorative proctocolectomy for ulcerative colitis. International Journal of Colorectal
Disease, 10, 10-14.
Morain, C.O., Segal, A.A., Walker, D., & Levi, A.J. (1981). Abnormalities of
neutrophil function do not cause the migration defect in Crohn's disease. Gut, 22,
817-822.
Morgado, P.J., Wexner, S.D., James, K., Nogueras, J.J., & Jagelman, D.G. (1994).
Ileal Pouch-Anal Anastomosis: is Preoperative Anal manometry Predictive of
Postoperative Functional Outcome? Disease of the Colon & Rectum, 37, 224-228.
Mortensen, N.J. (1992). Restorative proctocolectomy - the pouch operation: good or
bad? Scandinavian Journal ofGastroenterology, 27 Suppll92, 130-135.
Mortensen, N.J.M. (1993). Patient Selection for Restorative Proctocolectomy. In R.J.
Nicholls, D.C. Bartolo, & N.J.M. Mortensen (Eds ), Restorative Proctocolectomy.
(pp. 7-17). Oxford: Blackwell Scientific Publications.
Mortensen, N.J.M., & Madden, M.V. (1993). Pouchitis - Acute Inflammation in Ileal
Pouches. In R.J. Nicholls, D.C. Bartolo, & N.J.M. Mortensen (Eds.), Restorative
Proctocolectomy, (pp. 119-131). Oxford: Blackwell Scientific Publications.
Moskowitz, R.L., Shepherd, N.A., & Nicholls, R.J. (1986). An assessment of
inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal
reservoir International Journal of Colorectal Disease, 1, 167-184.
Myers, J.O., Rothenberger, D.A., & Goldberg, S.M. (1993). The evolution of
Surgical Procedures for anal Preservation. In R.J. Nicholls, D.C. Bartolo, & N.J.M.
Mortensen (Eds.), Restorative Proctocolectomy, (pp. 1-6). Oxford: Blackwell
Scientific Publication.
Nasmyth, D.G., Godwin, P.G.R., Dixon, M.F., Williams, N.S., & Johnston, D.
(1989). Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal
Morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship.
Gastroenterology, 96, 817-824.
Nasmyth, D.G., Johnston, D., Williams, N.S., King, J., Burkinshaw, L., & Brooks, K.
(1989). Changes in the absorption of bile acids after total colectomy in patients with
an ileostomy or pouch-anal anastomosis. Diseases of the Colon & Rectum, 32, 230-
234.
Nasmyth, D.G., & Williams, N.S. (1993). Pouch Ecology. In R.J. Nicholls, D.C.
Bartolo, & N.J.M. Mortensen (Eds.), Restorative Proctocolectomy, (pp. 119-131).
Oxford: Blackwell Scientific Publications.
265
Nassif, A., Longo, W.E., Mazuski, J.E., Vernava, A.M., & Kaminski, D.L.. (1996).
Role of cytokines and platelet activating factor in inflammatory bowel
disease.Diseases ofColon & Rectum, 39, 217-223.
Nicholls, R.J. (1993). Controversies and Practical Problem Solving. In R.J. Nicholls,
D C. Bartolo, & N.J.M. Mortensen (Eds ), Restorative Proctocolectomy, (pp. 53-82).
Oxford: Blackwell Scientific Publications.
Nicholls, R.J., Belliveau, P., Neill, M., Wilks, M., & Tabaqchali, S. (1981).
Restorative proctocolevtomy with ileal reservoir : a pathophysiological assesment.
Gut, 22, 462-468.
Nicholls, R.J., & Lubowski, D.Z. (1987). Restorative proctocolectomy: the four loop
(W) reservoir. British Journal of Surgery, 74, 564-566.
Nicholls, R.J., & Pezim, M.E. (1985). Restorative proctocolectomy with ileal
reservoir for ulcerative colitis and familial adenomatous polyposis: a comparison of
three reservoir designs. British Journal of Surgery, 72, 470-474.
Nielsen, O.H., & Elmgreen, J. (1987). Activation of neutrophil chemotaxis by
leukotriene B4 and 5- hydroxyeicosatetraenoic acid in chronic inflammatory bowel
disease. Scandinavian Journal of Clinical and Laboratory Investigation, 47, 605-
611.
Nordgren, S., Hellberg, R., Cederblad, A., Fasth, A., Lindstedt, G., & Hulten, L.
(1990). Fecal excrition of radiolabeled (51CrC13) proteins in patients with Crohn's
disease., Scandinavian Journal ofGastroenterology, 25(4), 345-351.
Nygaard, K., Bergan, T., Bjorneklett, A., Hoverstad, T., Lassen, J., & Aasa, S.
(1994). Topical metronidazole treatment in pouchitis. Scandinavian Journal of
Gastroenterology, 29, 462-467.
O'Mahony, S., Anderson, N., Nuki, G., & Ferguson, A. (1992). Systemic and
mucosal antibodies to Klebsiella in patients with ankylosing spondylitis and Crohn's
disease. Annals of the Rheumatic Diseases, 51, 1296-1300.
O'Mahony, S., Barton, J.R., Crichton, S., & Ferguson, A. (1990). Appraisal of gut
lavage in the study of intestinal humoral immunity. Gut, 31, 1341-1344.
O'Mahony, S., Choudari, C.P., Barton, J.R., Walker, S., & Ferguson, A. (1991). Gut
lavage fluid proteins as markers of activity of inflammatory bowel disease.
Scandinavian Journal ofGastroenterology, 26, 940-944.
266
Okamoto, T., Kusunoki, M., Kusuhara, K., Yamamura, T., & Utsunomiya, J. (1995).
Water and electrolyte balance after ileal J pouch-anal anastomosis in Ulcerative
Colitis and Familial Adenomatous Polyposis. International Journal of Colorectal
Disease, 10, 33-38.
Oresland, T., Fasth, S., Akervall, S., Nordgren, S., & Hulten, L. (1990).
Manovolumetric and sensory characteristics of the ileoanal J pouch compared with
the healthy rectum. British Journal of Surgery, 77, 803-806.
Oresland, T., Fasth, S., & Nordgren, S. (1989). The clinical and functional outcome
after restorative proctocolectomy. A prospective study in 100 patients. Inernationalt
Journal ofColorectal Disease, 4, 50-56.
Oresland, T., Fasth, S., Nordgren, S., Akervall, S., & Hulten, L. (1990). Pouch size :
the important functional determinant after restorative proctocolectomy. British
Journal of Surgery, 77, 265-269.
Oresland, T., Palmblad, S., Ellstrom, M., Berndtsson, I., Crona, N., & Hulten, L.
(1994). Gynaecological and sexual function related to anatomical changes in the
female pelvis after restorative proctocolectomy. International Journal of Colorectal
Disease, 9, 77-81.
Paap, C.M., & Ehrlich, R. (1993). Acute pulmonary edema after polyethylene glycol
intestinal lavage in a child. Annals ofPharmacotherapy, 27(9), 1044-1047.
Panis, Y., Poupard, B., Nemeth, J., Lavergne, A., Hautefeuille, P., & Valleur, P.
(1996). Ileal Pouch/anal anastomosis for Crohn's disease. The Lancet, 347, 854-857.
Parks, A.G., & Nicholls, R.J. (1978). Proctocolectomy without ileostomy for
Ulcerative colitis. British Medical Journal, 2, 85-88.
Patel, R.T., Bain, I., Youngs, D., & Keighley, M.R. (1995). Cytokine production in
pouchitis is similar to that in ulcerative colitis. Diseases of the Colon & Rectum, 38,
831-837.
Patel, R.T., Stokes, R., Birch, D., Ibbotson, J., & Keighley, M.R.B. (1994). Influence
of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory
bowel disease. British Journal of Surgery, 81, 724-726
Patrone, F., Dallegri, F., & Sacchetti, C. (1978). IgA-related defective neutrophil
chemotaxis in ulcerative colitis. Bollettino dell Istituto Sieroterapico Milanese, 57,
204-207.
267
Pemberton, J.H. (1993). Complications, Management, Failure and Revisions. In R.J.
Nicholls, D.C. Bartolo, & N.J.M. Mortensen (Eds ), Restorative Proctocolectomy.
(pp. 34-52). Oxford: Blackwell Scientific Publications.
Pena, J.P., Gemlo, B.T., & Rothenberger, D A. (1992). Ileal pouch-anal anastomosis:
state of the art. Bailleres Clinical Gastroenterology, 6, 113-128.
Penna, C., Dozois, R.R., Tremaine, W.J., Sandborn, W.J., LaRusso, N., Schleck, C.,
& Ilstrup, D M. (1996). Pouchitis after ileal pouch-anal anastomosis for ulcerative
colitis occurs with increased frequency in patients with associated primary sclerosing
cholangitis. Gut, 38, 234-239.
Pezim, M.E., Pemberton, J.H., Beart, R.W., Wolff, B.G., Dozois, R.R., Nivatvongs,
S., Devine, R., & Ilstrup, D.M. (1989). Outcome of "indeteminant" Colitis following
ileal pouch-anal anastomosis. Diseases of the Colon and Rectum, 32, 653-658.
Phillips, R.K.S. (1991). Pelvic pouches. British Journal of Surgery, 78, 1025-1026.
Powel- Tuck,J., Bown, R.L., & Lennard-Jones, J.E. (1978). A comparison of oral
prednisolone given as single or multiple daily doses for active proctocolitis.Scandinav
ian Journal ofGastroenterology,13, 833-837.
Poxton, I.R., Myers, C.J., Johnstone, A., Drudy, T.A., & Ferguson, A. (1995). An
ELISA to measure mucosal IgA specific for Bacteroides Surfcae antigens in Whole
Gut Lavage Fluid. Microbial Ecology in Health & Disease, 8, 129-136.
Puthu, D., Rajau, N., Rao, R., & et al. (1992). Carcinoma of the rectal pouch
following restorative proctocolectomy : report of a case. Diseases of the Colon &
Rectum, 35, 257-260.
Raab, Y., Gerdin, B., Ahlstedt, S., & Hallgren, R. (1993). Neutrophil mucosal
involvement is accompanied by enhanced local production of interleukin-8 in
ulcerative colitis. Gut, 34(9), 1203-1206.
Rauh, S.M., Schoetz, D.J., Roberts, P L., Murray, J.J., Coller, J.A., & Veidenheimer,
M.C. (1991). Pouchitis- Is it a Wastebasket Siagnosis? Diseases of the Colon and
Rectum, 34, 685-689.
Rhodes, J.M., Bartholomew, T.C., & Jewell, D.P. (1981). Inhibition of leucocyte
motility by drugs used in ulcerative colitis. Gut, 22, 642-647.
Rhodes, J.M., & Jewell, D.P. (1983). Motility of neutrophils and monocytes in
Crohn's disease and ulcerative colitis. Gut, 24, 73-77.
268
Rhodes, J.M., Potter, B.J., Brown, D.J., & Jewell, D P. (1982). Serum inhibitors of
leukocyte chemotaxis in Crohn's disease and ulcerative colitis. Gastroenterology , 82,
1327-1334.
Roberts, E.C., Hobson, C.H., Anderson, R.P., & Chadwick, V.S. (1990). Radio¬
immunoassay for formyl methionyl leucyl phenylanine. II. Demonstration of an
enterohepatic circulation of immunoreactive bacterial chemotactic peptides in man. J.
Gastroenterology & Hepatology, 5, 38-43
Roussomoustakaki, M., Louis, E., Satsangi, J., Mortensen, N.J.M., Kettlewell, M., &
Jewell, D.P. (1995). Cytokine gene polymorphisms in patients with an ileal pouch anal
anastomosis (IPAA) for ulcerative colitis. Gut, 37, A15
Ruseler-van-Emdben, J.G.H., Schouten, W.R., & van Lieshout, L.M.C. (1994).
Pouchitis : result of microbial imbalance? Gut, 35, 658-664.
Sagar, P.M., Finigan, P., & Taylor, B.A. (1994). Lack of response of pouch
dysfunction to the somatostatin analogue octreotide. British Journal of Surgery, 81,
1064
Sagar, P.M., Holdsworth, P.J., Godwin, P.G.R., Quirke, P., Smith, A.N., & Johnston,
D. (1992). Comparison of triplicated (S) and quadruplicated (W) pelvic ileal
reservoirs. Studies on manovolumetry, fecal bacteriology, fecal volatile fatty acids,
mucosal morphology, and functional results. Gastroenterology, 102, 520-528.
Sagar, P.M., Taylor, B.A., Godwin, P., Holdsworth, P.J., Johnston, D., Lewis, W.,
Miller, A., Quirke, P., & Williamson, M. (1995). Acute Pouchitis and deficiencies of
Fuel. Diseases of the Colon & Rectum, 38, 488-493.
Salemans, J.M.J.I., Nagengast, F.M., Tangerman, A., Van Schaik, A., De Haan,
A.F.J., & Jansen, J.B.M.J. (1993). Post prandial conjugated and unconjugated serum
bile acid levels after proctocolectomy with ileal pouch-anal anastomosis.
Scandinavian Journal ofGastroenterology, 28, 786-790.
Salemans, J.M.J.I., Thimister, P.W.L., Hopman, W.P.M., Kuijpers, H.C.,
Rosenbusch, G., Nagengast, F.M., & Jansen, J.B.M.J. (1995). Plasma cholecystokinin
levels and gallbladder volumes after proctocolectomy with ileal pouch-anal
anastomosis. Surgery, 117, 705-711.
Samarasekera, D.N., Stebbing, J.F., Mortensen, N.J.M., Jewell, D.P., & Kettlewell,
M. (1995). Do patients with distal ulcerative colitis undergoing ileal pouch anal
anastomosis have a better outcome than those patients with total colitis? Gut, 36, A24
Sandborn, W.J. (1994). Pouchitis Following Ileal pouch-anal Anastomosis:
Definition, pathogenesis and Treatment. Gastroenterology, 107, 1856-1860.
269
Sandborn, W.J., Landers, C.J., Tremaine, W.J., & Targan, S.R. (1995).
Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal
pouch-anal anastomosis. American Journal ofGastroenterology, 90, 740-747.
Sandborn, W.J., Tremaine, W.J., Batts, K.P., Pemberton, J.H., & Phillips, S.F.
(1993). fecal short chain fatty acid (SCFA) concentration ars are lower in patients
with pouchitis and primary sclerosing cholangitis (PSC). Gastroenterology, 104,
A775
Sandborn, W.J., Tremaine, W.J., Batts, K.P., Pemberton, J.H., & Phillips, S.F.
(1994). Pouchitis after ileal pouch-anal anastomosis : a Pouchitis Disease Activity
Index. Mayo Clinic Proceedings, 69, 409-415.
Sandborn, W.J., Tremaine, W.J., Batts, K.P., Pemberton, J.H., Rossi, S.S., Hofmann,
A.F., Gores, G.J., & Phillips, S.F. (1995). Fecal Bile Acids, Short-Chain Fatty Acids,
and Bacteria After Ileal Pouch-Anal Anastomosis Do Not Differ in Patients with
Pouchitis. Digestive Diseases and Sciences, 40, 1474-1483.
Santavirta, J., Harmoinen, A., Karnonen, A.L., & Matikainen, M. (1991). Water and
electrolyte balance after ileoanal anastomosis. Diseases of the Colon and Rectum, 34,
115-118.
Saverymuttu, S.H. (1986). Clinical remission in Crohn's disease- assessment using
faecal 11 lln granulocyte excretion. Digestion, 33(2), 74-79.
Saverymuttu, S.H., Camilleri, M., Rees, H., Lavender, J.P., Hodgson, H.J., &
Chadwick, V.S. (1986). Indium 111-granulocyte scanning in the assessment of
disease extent and disease activity in inflammatory bowel disease. A comparison with
colonoscopy, histology, and faecal indium 111-granulocyte excretion.
Gastroenterology, 90(5 Ptl), 1121-1128.
Saverymuttu, S.H., Chadwick, V.S., & Hodgson, H.J. (1985a). Granulocyte
migration in ulcerative colitis. Euopean Journal of Clinical Investigation, 15(2), 60-
63
Saverymuttu, S.H., Peters, A.M., Lavender, J.P., Hodgson, & Chadwick, V.S.
(1985b). In vivo assessment of granulocyte migration to diseased bowel in Crohn's
disease. Gut,26(4), 378-383.
Saverymuttu, S.H., Peters, A.M., Lavender, J.P., Hodgson, H.J., & Chadwick, V.S.
(1983), 111 Indium autologous leucocytes in inflammatory bowel disease. Gut, 24(4),
293-299.
270
Santos, M.C., & Thompson, J.S. (1993). Late complications of the ileal pouch-anal
anastomosis. American Journal ofGastroenterology, 88, 3-9.
Schmidt, C M., Horton, K.M., Sitzmann, J.V., Jones, B., & Bayless, T. (1996).
Simple radiographic evaluation of ileoanal pouch volume. Diseases of the Colon &
Rectum, 39, 66-73.
Sciarretta, G., Furno, A., Mazzoni, M., Basile, C., & Malaguti, P. (1993).
Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in
Crohn's disease: diagnostic and clinical relevance. Gut, 34(10), 1364-1369.
Scott, N.A., Pemberton, J.H., Barkel, D.C., & Wolff, B.G. (1989). Anal and ileal
pouch manometric measurements before ileostomy closure are related to functional
outcome after ileal pouch- anal anastomosis. British Journal of Surgery, 76, 613-
616.
Segal, A.W., & Loewi, G. (1976). Neutrophil dysfunction in Crohn's disease. The
Lancet, 2, 219-221.
Seow- Choen, A., Tsunoda, A., & Nicholls, R.J. (1991). Prospective randomized trial
comparing anal function after hand sewn ileoanal anastomosis with mucosal
mucosectomy versus stapled ileoanal anastomosis without mucosectomy in
restorative proctocolectomy. British Journal of Surgery, 78, 430-434.
Setti Carraro, P., Ritchie, J.K., Wilkinson, K.H., Nicholls, R.J., & Hawley, PR.
(1994). The first 10 years' experience of restorative proctocolectomy for ulcerative
colitis. Gut, 35, 1070-1076.
Setti Carraro, P., Talbot, I.C., & Nicholls, R.J. (1994). Longterm appraisal of the
histological appearances of the ileal reservoir mucosa after restorative
proctocolectomy for ulcerative colitis. Gut, 35, 1721-1727.
Setti-Carraro, P., Ritchie, J.K., Wilkinson, K.H., Nicholls, R.J., & Hawley, P R.
(1994). The first 10 years' experience of restorative proctocolectomy for ulcerative
colitis. Gut, 35, 1070-1075.
Shepherd, N.A. (1995). Pouchitis and Neoplasia in the Pelvic Ileal Reservoir.
Gastroenterology, 109, 1381-1383.
Shepherd, N.A., Healey, C.J., Warren, B.F., Richman, P.I., Thomson, W.H.F., &
Wilkinson, S.P. (1993). Distribution of mucosal pathology and an assessment of
colonic phenotypic change in the pelvic ileal reservoir. Gut, 34, 101-105.
Shepherd, N.A., Hulten, L., Tytgat, G.N.J., Nicholls, R.J., Nasmyth, D.G., Hill, M.J.,
Fernandez, F., Gertner, D.J., Rampton, D.S., Owen, R.W., Kmiot, W.A., Keighley,
271
M.R.B., O'Connell, P.R., Kumar, D., & Williams, N.S. (1989). Pouchitis Workshop.
International Journal of Colorectal Disease, 4, 205-229.
Shepherd, N.A., Jass, J R., Duval, I., Moscowitz, R.L., Nicholls, R.J., & Morson,
B.C. (1987). Restorative proctocolectomy with ileal reservoir : pathological and
histochemical study of the mucosal biopsy specimens. Journal of Clinical Pathology,
40, 601-607.
Siegel, P.D., Ronk, E.A., Clark, P.R., Shahan, T.A ., & Castranova, V. (1994).
Measurement of environmental formylmethionyl-peptides. Journal of Toxicology &
Environmental Health, 42, 275-288.
Silvis, R., van Eekelen, J.W., Delemarre, J.B.V.M., & Gooszen, H.G. (1995).
Endosonography of the Anal Sphincter after Ileal Pouch-Anal Anastomosis. Diseases
of the Colon and Rectum, 38, 383-388.
Srivastava, E.D., Barton, J R., O'Mahony, S., Phillips, DIM., Williams, G.T.,
Matthews, N., Ferguson, A., & Rhodes, J. (1991). Smoking, humoral immunity, and
ulcerative colitis. Gut, 32, 1016-1019.
Stern, H., Walfisch, S., Mullen, B., McLeod, R., & Cohen, Z. (1990). Cancer in an
ileoanal reservoir : a new late complication? Gut, 31, 473-475.
Stryker, S.J., Phillips, S.F., Dozois, R.R., Kelly, K.A., & Beart, R.W.J. (1986). Anal
and Neorectal function after ileal pouch anal anastomosis. Ann Surg, 203, 55-61.
Subramani, K., Harpaz, N., Bilotta, J., Bodian, C., Rubin, P H., Gelernt, I.M., &
Sachar, D.B. (1993). Refractory pouchitis : does it reflect underlying Crohn's disease
? Gut, 34, 1539-1542.
Teahon, K., & Bjarnason, I. (1993). Comparison of leukocyte excretion and blood
loss in inflammatory disease of the bowel. Gut, 34, 1535-1538.
Tonelli, F., Dolara, P., Batignani, G., Monaci, I., Caderni, G., Spagnesi, M.T., Luceri,
C., & Amorosi, A. (1995). Effects of short chain fatty acids on mucosal proliferation
and inflammation of ileal pouches in patients with ulcerative colitis and familial
polyposis. Diseases of the Colon and Rectum, 38, 974-978.
Utsunomiya, J., Iwama, T., Imajo, M., Matsuo, S., Sawai, S., Yalgashi, K., &
Hirayama, R. (1980). Total colectomy, mucosal proctectomy and ileoanal
ananstomosis. Diseases of the Colon and Rectum, 23, 459-466.
Van Dyke, T.E., Dowell, V.R.J., Offenbacher, S., Snyder, W., & Hersh, T. (1986).
Potential role of microorganisms isolated from periodontal lesions in the pathogenesis
of inflammatory bowel disease. Infection and Immunity, 53, 671-677.
272
Van Oostayen, J.A., Wasser, M.N., van Hogezand, R.A., Griffioen, G., Biemond, I.,
Lamers, C.B., & de Roos, A.. (1997). Doppler sonography evaluation of superior
mesenteric artery flow to assess Crohn's disease activity: correlation with clinical
evaluation, CDAI and a 1-antitrypsin clearance in feces. Am. J. Roent., 168(2), 429-
433
Veress, B., Reinholt, F.P., Lindquist, K., Lofberg, R., & Liljeqvist, L. (1995). Long -
term Histomorphological Surveillance of the Pelvic Heal Pouch : Dysplasia Develops
in a Subgroup of Patients. Gastroenterology, 109, 1090-1097.
Wandall, J.H. (1985). Function of exudative neutrophilic granulocytes in patients with
Crohn's disease or ulcerative colitis. Scandinavian Journal of Gastroenterology, 20,
1151-1156.
Wandall, J.H., & Binder, V. (1982). Leucocyte function in ulcerative colitis.
Quantitative leucocyte mobilisation to skin windows and in vitro function of blood
leucocytes. Gut, 23, 758-765.
Wandall, J.H., & Binder, V. (1982). Leucocyte function in Crohn's disease. Studies
on mobilisation using a quantitative skin window technique and on the function of
circulating polymorphonuclear leucocytes in vitro. Gut, 23, 173-180.
Weinryb, R.M., Gustavsson, J.P., Liljeqvist, L., Poppen, B., & Rossel, R.J. (1995). A
Prospective Study of the Quality of Life After Pelvic Pouch Operation. J Am Coll
Surg, 180, 589-595.
Weldon, M.J., Lowe, C., Joseph, A.E., & Maxwell, J.D.(1996). Review article:
quantitative leucocyte scanning in the assessment of inflammatory bowel disease
activity and its response to therapy. Alimentary Pharmacology & Therapeutics,
10(2), 123-132.
Wexner, S.D., Rothenberger, D.A., Jensen, L., & et al. (1989). Ileal pouch vaginal
fistulas : incidence, etiology, and management. Diseases of the Colon & Rectum, 32,
460-465.
Whorwell, P.J., Bennett, P., Tanner, A.R., & Wright, R. (1981). Monocyte function
in Crohn's disease and ulcerative colitis. Digestion, 22, 271-275.
Williams, N.S., Marzouk, D.E.M.M., Hallen, R.I., & Waldron, D.J. (1989). Function
after ileal pouch and stapled pouch anal anastomosis for ulcerative colitis. British
Journal of Surgery, 76, 1168-1171.
273
Winslet, M.C., Poxon, V., Allan, A., & Keighley, M. (1993). the influence of Ileal
Pouch-anal anastomosis for Ulcerative Colitis on ileal glycoprotein synthesis.
Scandinavian Journal ofGastroenterology, 28, 500-502.
Winter, T.A., Dalton, H.R., Merrett, M.N., Campbell, A., & Jewell, D.P. (1993).
Cyclosporin A retention enemas in refractory distal ulcerative Colitis and "pouchitis".
Scandinavian Journal ofGastroenterology, 28, 701-704.
Yee, J., Giannias, B., Kapadia, B., Chartrand, L.., & Christou, N.V. (1994).
Exudative neutrophils. Modulation of microbicidal function in the inflammatory





Information about the assays was retrieved from the Gastrointestinal
Laboratory manual of the Western General Hospital. Details are given of the
hazard materials and the precautions required. This information was adapted and
rephrased at places for the needs of this thesis.
1.1 Total Immunoglobulin IgG in WGLF
1.1a Principle of the Method
This Immunoglobulin is absorbed by class-specific antibodies bound to the solid
phase (ELISA plate). An anti-globulin conjugate, which is enzyme labelled, then
is added. This binds to the specific immunoglobulin.
1.1b Reagents and standard material
i. Carbonate/bicarbonate coating buffer 0.05M, pH 9.6 at 25°C (10 capsules in 1
litre of distilled water; Sigma C-3041). Store at 4°C
ii. Coating antibodies: Goat anti Human IgG, Fc specific, Affinity purified (Sigma
1-2136)
iii. ELISA wash: 0.9% saline with 0.05% Tween (Polyoxyethylene-Sorbitan
Monolaurate; Sigma P 1379). Store at +4°C
iv. ELISA diluent: 0.9% saline with 0.05% Tween 20 and 1% adult bovine serum
(SAPU, Law Hospital, Carluke, Lanarkshire, product No S026-220)
v. Alkaline phosphatase conjugate: Goat antihuman IgG (Sigma A-9544)
vi. Diethenalolamine liquid: Working reagent 100ml of Diethanolamine (BDH
Laboratory Supplies, Poole, BH15 1TD, no 10393 4J), 0.102g Magnesium
chloride (MGC126H20), 0.2g Sodium azide (NaN3) adjusted to pH 9.8 with 6N
HC1 and made up to a litre
vii. p-nitrophenyl phosphate (Sigma 104-105 Phosphatase substrate tablets. Store
at -20°C). One tablet used per 5 ml of diethanolamine working reagent
(5mg/tablet)
viii. Standard: Standard SPS 01 (Department of Immunology, PO BOX 894,
Sheffield, S5 7YTUK). Store at 4°C for one month when open.
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Top standard for IgG assay = 250 ng/ml
1.1c. Procedure and instrumentation
The Immulon 1, flat- bottomed plates (Dynatech, UK) were coated with
1/5000 dilution of coating buffer and were stored overnight at 4°C. Then the
following day the plates were washed three times with ELISA wash and then the
wells were filled with ELISA diluent and incubated at 20°C for 1 hour. At the
same time all standard, sample and QC (quality control) dilutions were made in
ELISA diluent. The WGLF samples required 1/25 dilution. A sample from a
patient (who is suspected to have raised inflammatory parameters) was used as
quality control. This sample was processed and stored at -70°C. (Prior consent of
the patient is required for testing for hepatitis B and HIV). Then the plates were
drained, loaded with samples, standard material and QC, all in duplicate and
incubated overnight at 4°C.
The following day the plates were washed three times The conjugate was
added to all wells at a dilution of 1/5000 and plates were incubated for 3 hours at
room temperature. The plates were washed further for three times prior to the
addition of the substrate. The plates should stand on the bench for 3 minutes prior
to their placement on the shaker, with manual checking of the OD of the top
standard. When the OD reached 1.0, the plate was read on the Microplate
Dynatech reader MR 5000 at 405 nm. A standard curve was then made and the
sample values were calculated. The correlation coefficient required was 0.985.
The QC values also have to fall within 95% of the current QC mean value for the
rest of the samples to be accepted.
1.1d Method validation
Between batch Coefficient Variation is 12.3% at 19.8 pg/ml
1.2. Total Immunoglobulins IgA and IgM in WGLF
Similar ELISA method was used for detection of these immunoglobulins in the
WGLF with the exception of the standard material. The standard material for the
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IgA is human IgA purified immunoglobulin from colostrum (Sigma 1-2636) at top
standard =1000 ng/ml. The coating antibody used for IgA was goat antihuman
IgA, a chain specific (Sigma, No I 2261), while the conjugated antibody was goat
antihuman IgA, alk phos conjugated (Sigma, A3036).
Standard for the IgM ELISA again was the SPS-01 mentioned above. Top
standard for IgM lOOOng/ml. As coating antibody, goat antihuman IgM was used,
p chain specific (Sigma, No I 2386); conjugated antibody: goat antihuman IgM,
alk phosph conjugated (Sigma, No A3 43 7)
1.3. WGLF Albumin and al-antitrypsin (al-AT)
1.3a Principle of the method
When either the human albumin or the al-antitrypsin react with an antibody at the
presence of polyethylene glycol (PEG), precipitating immunocomplexes are
formed that produce a turbidity, when the antibody is in excess, that can be
measured by flow through spectrophotometer (PU8610-ATI Unicam, Cambridge,
UK)
1.3b Reagents, standards
All reagents are analar grade and obtained from BDH unless otherwise stated.
i. PEG 6000 reagent: 40 g of PEG 6000 (Merck, UK) with 6 g TRIS, 2 g Tween
20, and 1 g Sodium azide, adjusted with dilute HC1 to pH 7.0 and made up to 1
litre with distilled water.
ii. Anti body reagent: Dilute antihuman (goat) al-AT (Protein Reference Unit
Central Antiserum Procurement Unit, Sheffield, UK) or antihuman (sheep)
albumin (SAPU S034-205) 1 in 40 with filtered PEG 6000 just prior to analysis
iii. Standard diluent: 9g Sodium chloride, 48g PEG 3350 (Sigma, UK), and 1 g
Sodium azide in 1 litre distilled water.
iv. Standard: Serum SPS01 (Protein Reference Unit, Sheffield)
1.3c Procedure
The method required processed WGLF samples, which were centrifuged at
1500g for 10 minutes. Using a Dilugil dispenser 0.05 ml diluent, standards, and
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test samples were diluted, in duplicate, into two rows of blank and tests with 0.95
ml PEG reagent in 2 ml polysterene tubes (LIP, UK). Turbidity was read at 340
nm after 15 minutes and the standard curve was plotted after blank subtraction.
Quality control used was the same as in IgG ELISA.
1.3d Method validation
Repeat analysis within batch gives a coefficient of variation of 10% for al-
antitrypsin and 8.5% for albumin. Patients results are accepted only if the QC
value is within the 20% range or the 17% range of the expected value accordingly.
Albumin in gut lavage is unstable prior to processing and variable amounts of
10-80% may be lost within 2 hours from the production of the specimen, al-
antitrypsin is stable in lavage for up to two hours.
1.4. WGLF Haemoglobin
1.4a Principle of the method
Haemoglobin is converted to fluorescing porphyrins by the removal of iron.
Total haemoglobin is determined by reaction with heated oxalic acid: FeS04
reagent which converts haem to porphyrin without loss of preformed porphyrins.
A three step purification procedure eliminates other interfering fluorescent
materials that may be present.
1.4b Reagents, standards
All reagents are analar grade and obtained from BDH unless otherwise stated.
i. Oxalic acid reagent: 4.0 g oxalic acid is made up to 10 ml volume with distilled
water at 100°C. 0.31 g FeS04 is then added at 100()C. 0.1 g uric acid and 0.11 g
mannitol are then added with final volume 10ml, at 100°C for 5 minutes
ii. Ethyl acetate/acetic acid 10/1 v/v (Corrosive/inflammable. Store in solvent
cupboard)
iii. 3M Potassium Acetate (294 g/1).
iv. 3M Potassium Acetate in 1M Potassium Hydroxide (56g/l). Label Corrosive
v. N- butanol( Rathburn Chemicals Ltd, Walkeburn). Store in solvent cupboard
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vi. 2M H3PO4/ Acetic acid 9/1 v/v. Dissolve 68 ml of orthophosphoric acid in 300
ml distilled water (fume cupboard). Add 58 ml glacial acetic acid and make up to
500 ml with water . Label Corrosive.
vii. Drabkins Reagent (Sigma , No 525-2): One vial contains 1 g sodium
bicarbonate, 0.2 g potassium ferricyanide, and 0.05 g sodium cyanide. One vial is
reconstituted to 1 litre with PEG 4000 (60 g PEG 3350, 9 g NaCl, 0.2 g sodium
azide in 1 litre distilled water). Label poisonous.
viii. Standard material Cyanomethaemoglobin: 50 mg haemoglobin (Sigma H
7379) in 100 ml Drabkins reagent. Dilute X5
ix. Quality Control: 10 mg of haemoglobin (Sigma H 7379) and dissolve in 100ml
PEG. Add sodium azide to final concentration 0.02g/100ml. Label toxic and store
at -70°C
1.4c Procedure
The method required thawed unfiltered WGLF samples, which were then
centrifuged at 2000 rpm. The supernatant was collected. 0.4 ml of oxalic acid
reagent was added to 0.1 ml of WGLF supernatant, QC, haemoglobin standard,
and blank (PEG) in a 10 ml stoppered quickfit tube. All tubes were heated at
100°C for 30 minutes. Following heating, 1 ml of the 3M potassium acetate
reagent was added and then 3 ml of the ethyl acetate/acetic acid reagent were also
added. The porphyrin analytes were into the upper organic phase. 2 ml of the
upper organic phase were transferred to a 30 ml stoppered quickfit tube. 0.8 ml of
butanol and 6 ml of 3M potassium acetate was added in 1M KOH. This removed
coproporphyrin into the lower alkaline aqueous phase. The next step was to
transfer 1 ml of the upper organic phase to a 10 ml stoppered quickfit centrifuge
tube and add 3 ml phosphoric acid/acetic acid reagent. The top layer that
contained chlorophyll was removed and fluorescence of the lower acid extract was
read.
1.4d Method validation
Between batch coefficient variation is 8% for QC. Other haem containing
proteins have the potential to interfere in this assay: myoglobin in meat,
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peroxidases in vegetables, although neither of those should cause significant
interference in lavage samples, devoid of faecal contaminants.
1.5. WGLF Interleukin -10 (IL-10)
1.5a Principle of the method
A commercial, high sensitivity IL-lp ELISA kit was used on filtered and
processed WGLF samples (Cistron Biotechnology 03-HS96). The microtitration
plate was already coated with a monoclonal antibody to IL-ip. In the first stage
samples or standards were added to the wells and incubated. The unbound IL-ip
was then washed away. In the second stage polyclonal rabbit anti-IL-ip was
added to the wells, so the antibody will bound specifically to the IL-ip bound to
the solid phase. In the third stage, goat anti-rabbit IgG conjugated to horseradish
peroxidase enzyme was added in order to bind any bound rabbit IgG. The fourth
stage included the addition of the enzyme substrate system and by oxidation of the
substrate a colour end product will appear, which was fixed with acid and then
measured at 450nm. A standard curve was constructed and the concentration in
IL-ip of unknown samples was then measured. The lower limit for detection was
4 pg/ml.
1.5b Procedure
lOOpl of each standard and sample (1:2 dilution) were added into the wells
and the plates were incubated for 1 hour at 37°C. The plates were washed three
times and then lOOpl polyclonal IL-ip antiserum was added. The plates were
incubated again at 37°C for 20 minutes. Prior to the addition of 100 ml conjugate,
the plates were further washed three times. The plates were then left at room
temperature for 20 minutes before they were again washed. 100 pi substrate was
added into the wells which were further incubated at room temperature for 20
minutes. The reaction was stopped with 50 pi 4N sulphuric acid and the plate was
read at 450 nm. The standard curve was then constructed.
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1.6. WGLF Interleukin-8 (IL-8)
Similar ELISA method again utilising a commercial available kit (Quantikine,
R&D Minneapolis USA) was used for measurement of IL-8. During the
experiments it was noticed that filtration greatly reduced the amount of IL-8
available to measure. Accordingly non-filtered and processed samples were
assessed. The lower limit of detection was 18 pg/ml.
1.7. WGLF Neutrophil Granulocyte Elastase (GE)
1. 7a Principle of the method
The elastase activity is determined by its amidolytic effect on the substrate
pyroGlu-Pro-Val-pNA. The released pNA is measured photometrically at 405 nm
after the reaction has been stopped with acetic acid
1. 7b Reagents
i. Assay Buffer: 12.1 g Tris with 56.2 g NaCl adjusted with IN HC1 to pH 8.3 and
made with distilled water up to 1 litre
ii. Substrate S-2484 (KabiVitrum AB, Sweden): 25 mg of substrate is dissolved in
7 ml of DMSO. This is further diluted with 3 volumes of distilled water.
iii. Acetic acid 20%
iv. Triton X-100
/. 7c Procedure
Unfiltered unprocessed WGLF samples were used. 1 pi Triton X-100 was
added to an LP6 tube for each sample. Following this, 500 pi of lavage (defrosted
samples) were added and mixed into each tube. Each sample was then sonicated
(X3) at 0° C for 1 minute. 2 LP6 tubes were labeled for each sample (1 test and 1
blank) and 200pl of assay buffer was placed in each tube at 37°C. 200 pi of
sonicated samples were added to all tubes. At this stage, 200 pi of acetic acid was
added to blank tubes. 200 pi of substrate was then added to all tubes and these
were incubated for 3 minutes. The reaction was stopped with 200 pi acetic acid to
282
the test tubes. The result was read on the ELISA reader at 405 nm, and the
amount was calculated as (Average test A405- Average blank A405) X 2.31 ptkat/1.
1.7. d. Method validation
Between batch coefficient variation is 6% for QC. Detection limit of the
method is 39 nkat/1.
1.8.WGLF Neutrophil Polarisation Assay
Details of this assay are presented in chapter 8.
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Appendix II
2.1. Whole Gut Lavage Procedure Monitor Form
The following information is recorded
1. Patient identification
2. Date of lavage
3. Quantity of Klean- Prep® in litres with time start and finish of each litre
4. Time ofbowels first opened
5. Time clear specimen obtained
6. Time specimen received in the laboratory
7. Time specimen stored in freezer
8. Any comments
2.2. Whole Gut Lavage Patient Details Form
The following information is recorded
1. Patient identification
2. Date of lavage
3. Lavage/serum serial number
4. Height and weight of patient










• Hospital and Consultant
• Date of study
• Laboratory Number
• Diagnosis
• Date of Diagnosis
• Past medical History
• Family History
• Extraintestinal manifestations if any
• Preoperative medical treatment prior to colectomy
3.2 Operation Entity
• Date of Colectomy/ restoration/ ileostomy closure if applicable
• Histology resected specimen
• Extent of disease
• Type of pouch
• Stapled or hand shown ileoanal anastomosis
• Mucosectomy or not
• Complications (dehiscence; pelvic sepsis; anastomotic stricture; peritonitis;
perineal sepsis; fistula; outlet obstruction; intestinal obstruction; other)
• Extraintestinal manifestations post operative if any
• Medical treatment post operative
• Preoperative anorectal physiology studies if any
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3.3 Function Entity
• Bowel activity day and night
• Urgency
• Evacuation difficulties
• Soiling day and night
• Use of incontinence pads day and night
• Perianal soreness
• Dietary restrictions if any
• Social handicap if any
• Bleeding
• Medication currently
Calculation of Oresland functional score
3.4 Pouchoscopy & Pouch Biopsy Entity
• Pouchoscopy score (1-6); presence of oedema, granularity, friability, loss of
vascular pattern, mucous exudate, ulceration
• Anal cuff inflammation
• Stenosis at the ileoanal anastomosis
• Investigator's clinical diagnosis at time of lavage/ pouchoscopy
• Previous 'pouchitis' episodes according to patient and their duration
• Histopathology score (Neutrophilia, ulceration, chronic inflammation, villous
atrophy)
® Calculation ofPDAI/ Moskowitz criteria diagnosis
3.5 Test Entity
• Haemoglobin, white cell count, Platelet count
• Erythrocyte Sedimentatiion Rate (ESR)
• C-Reactive Protein












Tests outside the GI Laboratory
As referred in chapter III, the following parameters were recorded:
a. Full Blood Count
b. Erythrocyte Sedimentation rate (ESR)
c. C-reactive protein (CRP)
d. Serum Immunoglobulin plasma levels
The specimens were assayed either in the Western General Hospital or the
Royal Infirmary of Edinburgh Haematology, Clinical Chemistry or Microbiology
laboratories. The Full Blood Count was estimated on a Coulter Counter. The
ESR was read manually. A radioimmune assay was used to measure the CRP.
For serum Immunoglobulins immunoturbimetry was used. Further details are
available from the manuals of the above mentioned laboratories.
♦ ♦♦
